netFormulary
 Report : A-Z of formulary items 03/06/2020 03:16:04
[Back]
 
Section Name Details
01.05.03 Vedolizumab 

See NCL treatment pathways for place in therapy in adults (JFC April 2019). Approved for paediatric use (JFC January 2018).

Provider notes

  • NMUH:
    • Positive NICE TA. This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used  in line with NICE recommendations and/or Local Trust Guidelines.
  • RFL:
    • Restricted to consultant gastrenterologists for NICE approved indications
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • As per NICE TA342 June 2015.
14.04 23-valent pneumococcal polysaccharide vaccine Previously known as Pneumovax® II

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • Non-formulary
14.07 23-valent pneumococcal polysaccharide vaccine Previously known as Pneumovax® II

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Approved as test vaccination to diagnose or exclude antibody deficiency including CVID and SAD (JFC May 2017)

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
    • Diagnose or exclude antibody deficiency including CVID and SAD (UMC March 2017)
  • WH:
    • Non-formulary
13.08.01 5-aminolevulinic acid 78mg/g gel Ameluz®

Approved for first-line treatment in actinic keratosis and superficial basal cell carcinoma (JFC June 2019).

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • First-line treatment of actinic keratosis and basal cell carcinoma
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • First-line treatment of actinic keratosis and basal cell carcinoma
05.03.01 Abacavir 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • HIV medicine only
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • For TB / HIV clinic only
05.03.01 Abacavir + Lamivudine 

Provider notes

  • NMUH:
    • To be prescribed as per BHIVA Guidelines by the HIV team only
  • RFL:
    • HIV medicine only
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • For TB / HIV clinic only
05.03.01 Abacavir + Lamivudine + Zidovudine Trizivir®

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • HIV medicine only
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
10.01.03 Abatacept 

Approved for:

  • Rheumatoid arthritis in line with the NCL RA pathway
  • Juvenile Idiopathic Arthritis (JIA; see NICE TAs)

Provider notes

  • NMUH:
    • This medicine has a positive NICE TA and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines.
    • To be prescribed by Rheumatologists ONLY.
    • Check MHRA Drug Safety Updates.
    • See links below.
  • RFL:
    • Approved for Rheumatoid Arthritis and Juvenile Idiopathic Arthritis, in line with NICE guidance
  • RNOH:
    • Restricted to Rheumatology Consultants ONLY.
  • UCLH:
  • WH:
    • As per NICE TA and above
08.01.05 Abemaciclib tabs 

See NICE TA for eligibility criteria

Provider notes

  • NMUH:
    • This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used  in line with NICE recommendations and/or Local Trust Guidelines.
    • See links below
  • RFL:
    • As per NICE guidance
    • This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system) Additionally for in-patients this drug must be prescribed on an in-patient prescription chart (paper or electronic)
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
08.03.04.02 Abiraterone 

Provider notes

  • NMUH:
    • This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines. To be prescribed as per NICE guidance
    • See links below
  • RFL:
    • As per NICE TAs
    • This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system). Additionally for in-patients this drug must be prescribed on an in-patients prescription chart (paper or electronic)
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary to WH
04.10.01 Acamprosate 

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • No restriction stated
  • RNOH:
    • Requires psychiatrist approval. For use in accordance with NICE CG115.
  • UCLH:
  • WH:
    • Non-formulary
06.01.02.03 Acarbose 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • No restriction stated
10.01.01 Acemetacin 

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Restricted to Rheumatology only.
02.08.02 Acenocoumarol 

Provider notes

  • NMUH:
    • Restricted for patients allergic to Warfain only.
    • Check MHRA Drug Safety Updates
  • RFL:
    • Restricted for patients allergic to warfarin only
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
04.14 Acetazolamide 

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • No restriction stated
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
11.06 Acetazolamide 

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Adjunctive therapy for Open Angle Glaucoma And Ocular Hypertension

Provider notes

  • NMUH:
    • See link below
    • Immedidate release and modified release formulations are both available
  • RFL:
    • Immediate release only
  • RNOH: 
    • Immediate release only
  • UCLH:
  • WH:
    • Immediate release only
11.08.02 Acetylcholine intra-ocular irrigation Miochol-E®, Miphtel®

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
03.07 Acetylcysteine 

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Respiratory consultants only
    • Injection (200mg/ml) can be used orally
    • Tablets 600mg also available
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
07.06 Acetylcysteine 

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
18 Acetylcysteine 

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Provider notes

  • NMUH:
    • See MHRA Drug Safety Update
  • RFL:
    • No restriction stated
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
11.08.01 Acetylcysteine 5% + Hypromellose 0.35% eye drops Ilube®

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
11.08.01 Acetylcysteine eye drops - preservative free 

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Tear deficiency, impaired / abnormal mucus production and restricted to Ophthalmology.
    • 5% (1st line), 10% and 20% eye drops available
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Acetylcysteine 5% preservative-free drops (10mL) is an unlicensed special and restricted to Ophthalmology.
05.03.02.01 Aciclovir 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • No restriction stated
11.03.03 Aciclovir 3% eye ointment 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • 1st line for herpes simplex keratitis and conjunctivitis
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
13.10.03 Aciclovir 5% cream 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • No restriction stated
13.05.02 Acitretin 

Provider notes

  • NMUH:
    • Restricted to Dermatology
  • RFL:
    • Restricted to Dermatology
    • Females of childbearing potential must meet the requirements of the pregnancy prevention programme (PPP) - maximum 30 days supply at at time
    • Acitretin prescriptions should be restricted to a 12 week supply for men and postmenopausal women
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Restricted to Dermatology use only
A5.03.03 Actisorb Silver 220 

Provider notes

  • NMUH:
    • We stock 10.5 cm x 10.5 cm. To be used on the recommendation of the Tissue Viability Nurse only.
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
18 Activated charcoal 

Provider notes

  • NMUH:
    • Carbomix and Charcodote available
  • RFL:
    • Actidose-Aqua Advance, Carbomix, Charcodote available
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
01.05.03 Adalimumab 

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Provider notes

  • NMUH:
    • This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines
    • Red List Medicine – Hospital Only Prescribing PbR (Payment by Results) excluded drug.
    • Restricted to Consultant Gastroenterologists for NICE approved indications.
    • Check MHRA Drug Safety Update
  • RFL:
    • Restricted to Consultant Gastroenterologists for NICE approved indications.
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Restricted to consultant gastroenterologists 
    • NICE TA187 and TA329 applies
    • JFC (Oct 17): Approved for fistulising Crohn's disease in patients not able to receive infliximab.
10.01.03 Adalimumab 

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Approved for:

  • Rheumatoid arthritis in line with the NCL RA pathway
  • Juvenile Idiopathic Arthritis (JIA; see NICE TA)
  • Ankylosing Spondylitis (see NICE TAs)
  • Psoriatic Arthritis (PsA; see NICE TAs)

Provider notes

  • NMUH: 
    • Check MHRA Drug Safety Updates
    • This medicine has a positive NICE TA and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines.
    • Restricted to Consultant Rheumatologists
    • See links below
  • RFL:
    • Approved for use in Psoriatic Arthritis, Rheumatoid Arthritis, Ankylosing Spondylitis and non-radiographic axial spondyloarthritis
  • RNOH:
    • Restricted to Rheumatology Consultants Only
  • UCLH:
  • WH:
    • As per NICE TA and above
11.99.99.99 Adalimumab 

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
13.05.03 Adalimumab 

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Provider notes

  • NMUH:
    • This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines.
    • Restricted to Consultant Dermatologists for NICE approved indications.
    • See links below
    • Check MHRA Drug Safety Updates
  • RFL:
    • Approved for Psoriasis and Hydradenitis Suppurativa (NHSE)
    • Approved for Pyoderma gangrenosum – prior funding approval required
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
13.06.01 Adapalene 0.1% + Benzoyl peroxide 2.5% gel Epiduo®

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Approved for Dermatology for acne vulgaris
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Prescribing by Consultant Dermatologists only for acne
13.06.01 Adapalene 0.1% cream Differin®

Approved for acne (JFC April 2016)

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • Approved for Dermatology for acne vulgaris
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • See indication above
05.03.03.01 Adefovir Dipivoxil 

Provider notes

  • NMUH:
    • This medicine has a positive NICE Technology Appraisal BUT IS NOT LISTED IN THE TRUST FORMULARY AS AN ALTERNATIVE NICE APPROVED MEDICINE IS USED.
  • RFL:
    • Restricted to Hepatology/Virology
    • As per NICE guidance
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
02.03.02 Adenosine 6mg/2mL injection Adenocor®

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • No restriction stated
02.07.03 Adrenaline 1:10,000 (100 mcg/1 ml) injection 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • No restriction stated
03.04.03 Adrenaline 1:10,000 (100 mcg/1 ml) injection 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • Non-formulary
03.04.03 Adrenaline 1:1000 (1 mg/1 ml) injection 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • The use of epinephrine 1 in 1,000 units Min-I-Jet injection is reserved for treatment of anaphylaxis in children < 15 kg in weight.
03.04.03 Adrenaline autoinjector Emerade®

Emerade is preferred to EpiPen for anaphylaxis (JFC August 2015)

Provider notes

  • NMUH:
    • Check for MHRA Drug Safety Updates
  • RFL:
    • No restriction stated
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • No restriction stated
03.04.03 Adrenaline autoinjector Jext®

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • As an alternative if supply problems with EpiPen
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
03.04.03 Adrenaline autoinjector EpiPen®

Emerade is preferred to EpiPen for anaphylaxis (JFC August 2015)

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • No restriction stated
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • Non-formulary
A5.02.07 Advadraw  

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
A5.02.03 Advazorb Border 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
08.01.05 Afatinib 

Provider notes

  • NMUH:
    • This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines.
    • See link below
  • RFL:
    • As per NICE TA
    • This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system).  Additionally for in-patients this drug must be prescribed on an in-patient prescription chart (paper or electronic)
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
08.01.05 Aflibercept infusion Zaltrap®

Provider notes

  • NMUH:
    • Non-formulary
    • See MHRA Drug Safety Update
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
11.08.02 Aflibercept intraocular injection Eylea®

Provider notes

  • NMUH:
    • This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines.
    • To be prescribed by Consultant Ophthalmologists ONLY
    • See links below
  • RFL:
    • As per NICE guidance
    • To be prescribed by consultant opthalmologists only
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
09.08.01 Agalsidase alfa and beta Fabrazyme®

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Restricted to the lysosomal storage disorders unit
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
09.08.01 Agalsidase alfa and beta Replagal®

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Restricted to the lysosomal storage disorders unit
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
02.14 Ajmaline 

Provider notes

  • NMUH:
    • Restricted to Consultant Cardiologists ONLY.
    • Ajmaline 50mg in 10mL injection - available from 'special-order' manufacturers or specialist importing companies.
    • See link below
  • RFL:
    • Approve for diagnosis of Brugada syndrome (August 2016)
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
05.05.01 Albendazole 

Provider notes

  • NMUH:
    • For use for named patients only
  • RFL:
    • No restriction stated
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
09.02.02.02 Albumin Solution 

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Available via the blood bank
  • RNOH:
    • Available from Pathology
  • UCH approvals:
  • WH:
    • No restriction stated
08.01.05 Alectinib tabs 

See NICE TA for eligibility criteria

Provider notes

  • NMUH:
    • This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used  in line with NICE recommendations and/or Local Trust Guidelines.
    • See links below
  • RFL:
    • As per NICE guidance
    • This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system). Additionally for in-patients this drug must be prescribed on an in-patient prescription chart (paper or electronic).
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
08.02.03 Alemtuzumab Lemtrada®

Provider notes

  • NMUH:
    • This medicine has a positive NICE Technology Appraisal but is not listed in the Trust Medicines Formulary as the service is not offered at NMUH.
  • RFL:
    • As per NICE TA
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • Non-formulary
08.04 Alemtuzumab Free-Of-Charge 

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Available for islet cell transplant – contact pharmacy for advice
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
06.06.02 Alendronic Acid 

Provider notes

  • NMUH:
    • Positive NICE TA This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when in line with NICE recommendations and/or Local Trust Guidelines.
    • See links below
  • RFL:
    • No restriction stated
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • No restriction stated
09.06.04 Alfacalcidol One-Alpha®

Provider notes

  • NMUH:
    • See link below
  • RFL:
    • No restriction stated
  • RNOH:
    • Store in refrigerator
  • UCLH:
  • WH:
    • No restriction stated
15.01.04.03 Alfentanil 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • No restriction stated
07.04.01 Alfuzosin immediate release 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
07.04.01 Alfuzosin modified release 

Provider notes

  • NMUH:
    • Restricted to Urology Department, second line use only.
  • RFL:
    • Non-formulary
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • The use of alfuzosin is reserved for the Urology Department only
09.08.01 Alglucosidase Alfa 

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Restricted to the lysosomal storage disorders unit
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
03.04.01 Alimemazine tabs/solution 

Not recommended for any indication - do not prescribe (JFC November 2018)

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Non-formulary
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • Non-formulary
02.12 Alirocumab 

Provider notes

  • NMUH:
    • This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines.
    • To be prescribed on the recommendation of Consultant Cardiologists and Endocrinologists ONLY
    • See links below
  • RFL:
    • As per NICE guidance
    • Restricted to Lipid Clinic
    • Prescriptions are supplied monthly for first 4 months then 3 monthly.  Homecare service also available
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • Non-formulary
13.05.01 Alitretinoin 

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Provider notes

  • NMUH:
    • This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines.
    • Check MHRA Drug Safety updates
  • RFL:
    • For severe chronic hand eczema in line with NICE guidance
    • Females of childbearing potential must meet the requirements of the pregnancy prevention programme (PPP) - maximum 30 days supply at at time
    • Alitretinoin prescriptions should be restricted to a 12 week supply for men and post menopausal women
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
21.01 Alitretinoin 

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Pityriasis rubra pilaris
Evaluation at RFL site only (JFC August 2016). Prior funding approval required.

10.01.04 Allopurinol 

Provider notes

  • NMUH:
    • See link(s) below
  • RFL:
    • No restriction stated
  • RNOH:
    • First choice for long-term control of gout
  • UCLH:
  • WH:
    • No restriction stated
09.06.05 Alpha Tocopheryl Acetate 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • Oral suspension and injection 100mg/2ml kept at the RFH.
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
07.04.05 Alprostadil intracavernous injection Caverject®

GP-RedRed (hospital only prescribing) if used for non-SLS indications

Amber for SLS indications

 

Provider notes

  • NMUH:
    • Red List Medicine – Hospital Only Prescribing
  • RFL:
    • Restricted to Urology and Endocrinology consultants
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • Inj 20 micrograms only
07.04.05 Alprostadil intracavernous injection Viridal® Duo

GP-RedRed (hospital only prescribing) if used for non-SLS indications

Amber for SLS indications

 

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Restricted to Urology and Endocrinology Consultants
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
07.04.05 Alprostadil urethral stick MUSE®

GP-RedRed (hospital only prescribing) if used for non-SLS indications

Amber for SLS indications

 

Provider notes

  • NMUH:

    • Red List Medicine – Hospital Only Prescribing Restricted to Consultants in Urology and Sexual Health (St. Ann's) use only.
  • RFL:
    • Restricted to Urology and Endocrinology Consultants
  • RNOH:

    • Non-formulary
  • UCLH:
  • WH:

    • Non-formulary
01.10 Alteplase 

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Restricted to hepatology only for portal vein thrombosis
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
02.10.02 Alteplase 

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Provider notes

  • NMUH:
    • Positive NICE TA This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines.
    • Restricted for use in Pulmonary Embolism (PE).
  • RFL:
    • Restricted to vascular surgery, MI and for use in the treatment of PE
  • RNOH:
    • Restricted
  • UCLH:
  • WH:
    • For massive PE and PE causing cardiac arrest
02.14 Alteplase 

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Provider notes

  • NMUH:
    • Non-formulary
    • Any suitable patients to be referred to RFH as per guidelines
  • RFL:
    • Approved for:
      • Iliofemoral DVT with (i) May-Thurner syndrome OR extensive clots AND (ii) who have severe symptoms despite 5-7 days anticoagulation OR where a limb is threatened (JFC July 2018)
      • Paget-Schroetter Syndrome
    • Not approved for:
      • Massive or high risk PE (defined as acute PE with sustained hypotension [SBP ≤ 90 mm Hg for at least 15 min or requiring inotropic support, not due to a cause other than PE, such as arrhythmia, hypovolemia, sepsis, or LV dysfunction], pulselessness or persistent profound bradycardia [pulse < 40 bpm], with signs or symptoms of shock) (JFC July 2018)
  • RNOH:
    • Non-formulary
  • UCLH:
    • Approved for:
      • Iliofemoral DVT with (i) May-Thurner syndrome OR extensive clots AND (ii) who have severe symptoms despite 5-7 days anticoagulation OR where a limb is threatened (UMC June 2018)
      • Upper Limb Central Venous Catheter (CVC) Related Thrombosis as last-line therapy (UMC June 2018)
    • Not approved for:
      • Paget-Schroetter Syndrome- Refer patient to RFH (UMC June 2018)
      • Stent rethrombosis (UMC June 2018)
      • Massive or high risk PE (defined as acute PE with sustained hypotension [SBP ≤ 90 mm Hg for at least 15 min or requiring inotropic support, not due to a cause other than PE, such as arrhythmia, hypovolemia, sepsis, or LV dysfunction], pulselessness or persistent profound bradycardia [pulse < 40 bpm], with signs or symptoms of shock) (UMC June 2018)
  • WH:
    • Non-formulary
21.01 Alteplase + dornase alpha intrapleural infusion 

Approved as intrapleural fibrinolytics (alteplase + dornase alfa) for ongoing sepsis in association with a persistent pleural collection, who have not responded to 12-24 hours of antibiotics and simple tube drainage, or there is radiological evidence (either on ultrasound and/or CT) that the effusion is unlikely to drain due to multiple loculation; rather than referring for surgical intervention. Evaluation sites to be approved at DTCs (JFC March 2019)

Notes: The majority of trials use dornase alfa (DNase) 5 mg and alteplase (t-PA) 10 mg administered intrapleurally twice daily for up to 3 days. Administration was followed by clamping of the drain to permit the study drug to remain in the pleural space for 1 hour. One study used dornase alfa (DNase) 5 mg and alteplase (t-PA) 5 mg twice daily. 

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • To be used as per protocol for complex pleural infections (under evaluation)
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
11.99.99.99 Alteplase 25mcg/0.1ml intravitreal injection 

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Restricted for eye procedures
  • RNOH:
    • Non-formulary
  • UCLH:
    • Non-formulary
  • WH:
    • Non-formulary
A2.02.02.03 Altraplen Compact 
  • Bottle (125mL)
  • Banana, hazel-chocolate, strawberry, vanilla
  • Clinically lactose and gluten-free
  • Suitable for vegetarian, Halal and Kosher diets (except strawberry)

Primary care notes

For patients who did not tolerate first-line choices and lower volume is indicated or fluid restricted- see Primary Care Guidance

13.12 Aluminimum chloride 20% Anhydrol Forte®

Provider notes

  • NMUH:
    • Suitable for use in children, adults and the elderly. NOT suitable for use in pregnancy and lactation.
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
13.12 Aluminimum chloride 20% Driclor®

Provider notes

  • NMUH:
    • Suitable for use in pregnancy and lactation.
  • RFL:
    • No restriction stated
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
01.01.01 Aluminium hydroxide + Magnesium hydroxide + Simeticone Maalox Plus®

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Non-formulary
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • Non-formulary
04.09.01 Amantadine 

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • Restricted
  • UCLH:
  • WH:
    • No restriction stated
05.03.04 Amantadine 

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Virology/Microbiology/ID approval only
  • RNOH:
    • Microbiologist approval only
  • UCLH:
  • WH:
    • Microbiologist approval only
14.04 Ambirix® Hepatitis A vaccine with Hepatitis B vaccine

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • No restriction stated
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
02.05.01 Ambrisentan 

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Prior funding approval required. Restricted to the treatment of pulmonary hypertension
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • Non-formulary
11.03.01 Amikacin 0.4mg/0.1mL intravitreal pack 

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Restricted to Opthalmology - seek pharmacy advice
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Intravitreal use - this is an unlicensed special and restricted to Ophthalmology.
11.03.01 Amikacin 1.5% eye drops 

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Restricted to ophthalmology
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Restricted to ophthalmology
24.01 Amikacin 2.5% eye drops 

unlicensedunlicensed

MEH: Bacterial & Mycobacteria keratitis

05.01.04 Amikacin injection 

Provider notes

  • NMUH:
    • Restricted to Microbiology approval only
  • RFL:
    • Refer to amikacin prescribing guidelines in Microguide
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • Microbiology approval only
02.02.03 Amiloride Hydrochloride 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • No restriction stated
03.01.03 Aminophylline Phyllocontin Continus®

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • No restriction stated
03.01.03 Aminophylline IV 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • No restriction stated
05.01.09 Aminosalicylic acid 

Provider notes

  • NMUH:
    • Available from 'special order' manufacturers
  • RFL:
    • Available from 'special order' manufacturers
    • MDR-TB only
    • Restricted to ID / Microbiology
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
02.03.02 Amiodarone 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • No restriction stated
04.02.01 Amisulpride 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • Restricted for initiation until after a discussion with liaison psychiatry team.
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Restricted for initiation by a Consultant Psychiatrist only.
04.03.01 Amitriptyline 

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • Oral solution available as 25 mg/5mL
  • UCLH:
  • WH:
    • No restriction stated
  • CIFT:
    • Approved for depression
  • BEHMT:
    • Approved for depression
04.07.03 Amitriptyline 

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • See link below
    • Oral solution available as 25 mg/5mL 
  • UCLH:
  • WH:
    • No restriction stated
04.07.04.02 Amitriptyline 

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
02.06.02 Amlodipine 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • No restriction stated
13.10.02 Amorolfine 5% nail lacquer 

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • No restriction stated
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
05.01.01.03 Amoxicillin 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • Oral suspension available as 125 mg/5mL and 250 mg/5mL
  • UCLH:
  • WH:
    • No restriction stated
11.03.02 Amphotericin 0.15% eye drops 

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Restricted to Opthalmology for use in candida fungal infections and keratitis
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Restricted to ophthalmology
11.03.02 Amphotericin 5mcg/0.1ml intravitreal injection 

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Eye procedures
  • RNOH:
    • Non-formulary
  • UCLH:
    • Non-formulary
  • WH:
    • Non-formulary
05.02 Amphotericin infusion Fungizone®

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • Not for intravenous use
    • Microbiology/ID approval only
  • RNOH:
    • Non-formulary
  • UCLH:
    • Approved for:
      • Cryptococcosis – treatment (Restricted to Microbiology approval)
      • Serious fungal infections (Restricted to Microbiology approval for intraventricular disease)
  • WH:
    • Non-formulary
05.02 Amphotericin liposomal infusion AmBisome®

Provider notes

  • NMUH:
    • As per Trust Guidelines
  • RFL:
    • Restricted to OLT prophylaxis (2nd transplant/hepatic artery thrombosis)
    • Microbiology/ID approval required for all other indications
  • RNOH:
    • Microbiology approval only
  • UCLH:
  • WH:
    • Microbiology approval only
08.01.05 Anagrelide 

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Approved for Essential Thrombocythaemia
    • This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system)
  • RNOH:
    • Non-formulary
  • UCLH:
    • See links below
  • WH:
    • No restriction stated
10.01.03 Anakinra 

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Approved for adult-onset Stills disease in line with NHSE commissioning policy (JFC October 2018)

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Approved for AOSD in line with NHSE policy (see below)
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
10.04 Anakinra 

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Approved for gout for patients who are hospitalised and refractory to all other treatments. The usual dose is 100 mg daily subcutaneously for 3 days (JFC September 2014) 

Provider notes

  • NMUH:
    • To be prescribed/ recommended by Rheumatology Consultants ONLY
    • Anakinra has been approved for gout. This is an unlicensed indication and the recommended dose is 100mg by subcutaneous injection ONCE a day for 3 days.
    • Check MHRA Drug Safety Updates
  • RFL:
    • Non-formulary
  • RNOH:
    • Restricted to Rheumatology Consultants ONLY.
    • Unlicensed for the treatment of gout, 100mg daily for 3 days
  • UCLH:
  • WH:
    • Restricted to Rheumatology Consultants ONLY
10.04 Anakinra 

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Approved for secondary haemophagocytic lymphohistiocytosis subject to individual funding approval (JFC September 2018). Additional information: Evidence to support SC or IV (local practice is to administer in 100mL sodium chloride 0.9%w/v over 1 hour). 

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Prior funding required
    • Restricted to Rheumatology
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
16.01 Anakinra 

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Approved for Familial Mediterranean Fever, Pericarditis and DIRA (RFL only; JFC May 2016)
    • Prior funding approval required
    • Restricted to use by the Amyloidosis centre only
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
16.01 Anakinra 

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Approval for chronic Granulomatous Disease (January 2013)
    • Prior funding approval required
    • Restricted to use by the Amyloidosis centre only
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
08.03.04.01 Anastrozole 

Provider notes

  • NMUH:
    • Restricted to Oncology department use only.
  • RFL:
    • No restriction stated
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • No restriction stated
05.02.04 Anidulafungin 

Approved for invasive candidiasis, subject to local Antimicrobial Committee approval (JFC February 2019).

Provider notes

  • NMUH:
    • To be used as per Trust antifungal guidelines
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Microbiology approval only
12.03.01 Antacid + Oxetacaine oral suspension 

Approved for oral mucositis post radiotherapy (JFC February 2019).

Provider notes

  • NMUH:
    • For oral mucositis and oesophageal lesions following radiotherapy. 
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
11.04.02 Antazoline 0.5% with Xylometazoline 0.05% Otrivine-Antistin®

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • Allergic conjunctivitis
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
14.05.03 Anti-D (Rh0) Immunoglobulin 

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Provider notes

  • NMUH:
    • This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary.
    • It is available via the blood bank
  • RFL:
    • Not available through pharmacy - obtain from the blood bank
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Available from Haematology (Ext 5035)
02.11 Antithrombin III Kybemin®

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Available through the haemophilia centre
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
08.02.02 Antithymocyte immunoglobulin - rabbit Thymoglobuline®

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Renal transplant: For transplant induction and rejection
    • Liver transplant: For transplant rejection only
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
01.07.02 Anusol-HC® 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • Ointment and suppositories both stocked
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • Ointment containing hydrocortisone 0.25%. Suppositories containing hydrocortisone acetate 10 mg
02.08.02 Apixaban 

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

See NICE TA for eligibity criteria

Provider notes

  • NMUH:
    • Positive NICE TA This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines.
    • See links below
    • Check MHRA Drug Safety Update
    • A referral form must be completed by Authorised Teams/ Haematology team to initiate a DOAC
    • A GP notification form must be completed and sent to the GP for each patient newly started on a DOAC
    • A copy of the above forms (referral form and GP notification form) must be sent to the anticoagulant clinic
  • RFL:
    • As per NICE guidance
    • Follow NCL DOAC prescribing guide
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • 2nd Choice DOAC - For Atrial Fibrillation / Stroke prevention.
02.08.02 Apixaban 

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Approved for (JFC January 2019):

  • Multiple myeloma starting chemotherapy with thalidomide, lenalidomide or pomalidomide who would previously have received LMWH
  • Newly diagnosed multiple myeloma with additional VTE risk factor

Dose is 2.5mg twice-daily.

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • As above
04.09.01 Apomorphine 

Provider notes

  • NMUH:
    • Non-formulary
    • Check MHRA Drug Safety Update
  • RFL:
    • Restricted to neurology only
  • RNOH:
    • Restricted
  • UCLH:
  • WH:
    • Non-formulary
11.08.02 Apraclonidine ophthalmic solution Iopidine®

Provider notes

  • NMUH:
    • Apraclonidine 0.5% used short-term to delay laser treatment or surgery in patients with glaucoma not adequately controlled by another drug
    • See link below   
  • RFL:
    • 1% restricted to Opthalmology - Post-laser, and to low lower IOP in certain circumstances
    • 0.5% restricted to 3rd line for short term reduction of elevated IOP, Horner’s syndrome test  
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Apraclonidine 1% preservative free is restricted to Ophthalmology
10.01.03 Apremilast 

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Approved for:

  • Psoriatic Arthritis (PsA; see NICE TA)

Provider notes

  • NMUH:
    • This medicine has a positive NICE TA and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines.
    • To be prescribed by Rheumatologists ONLY
    • See links below
    • Check MHRA Drug Safety Updates
  • RFL:
    • As per NICE guidance for PsA
  • RNOH:
    • Rheumatology Consultants ONLY
  • UCLH:
  • WH:
    • As per NICE TA and above
13.05.03 Apremilast 

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

 Provider notes

  • NMUH: 
    • This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines.
    • See links below.
    • Check MHRA Drug Safety Updates.
  • RFL:
    • For the treatment of Psoriasis in line with NICE guidance
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
04.06 Aprepitant 

Provider notes

  • NMUH:
    • Restricted to Oncology Consultants only
  • RFL:
    • Restricted to oncology and haematology only
  • RNOH:
    • Restricted for severe emetogenesis.
    • Restricted to Dr Kofi Agyare
  • UCLH:
  • WH:
    • Reserved for the prophylaxis of nausea & vomiting associated with cisplatin (CINV)

 

A5.02.04 Aquacel  

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Hydrocolloid dressing 10 cm * 10 cm (10), 15 cm * 15 cm(5)
13.02.01 Aquadrate® cream Urea 10%

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • No restriction stated
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
13.02.01.01 Aqueous Cream BP 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • No restriction stated
01.06.03 Arachis Oil Enema 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • Non-formulary
  • RNOH:
    • Requires gastroenterologist approval
  • UCLH:
  • WH:
    • Non-formulary
02.08.01 Argatroban 

Anticoagulation in adult patients with heparin-induced thrombocytopenia (HIT) type II who require parenteral antithrombotic therapy and have renal failure (February 2013)

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • As per restrictions above
    • Haemophilia recommendation only
  • RNOH:
    • Requires Haematologist approval. See restriction above.
  • UCLH:
    • Restricted to consultant haematologists. For patients with severe renal impairment (CrCl<30ml/min)
  • WH approval:
    • Non-formulary
09.08.01 Arginine  

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • For peritoneal dialysis patients only (arginine deficiency)
    • Non-formulary for other indications (inc. paediatrics)
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
06.05.02 Argipressin 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • Store in a refrigerator
  • UCLH:
  • WH:
    • Non-formulary
04.02.01 Aripiprazole 

Red (hospital only prescribing) for aripiprazole intramuscular injection

Grey for aripiprazole oral formulations

Approved (7.5mg/1mL IM formulation) for the rapid control of agitation and disturbed behaviours in adult patients with schizophrenia or with manic episodes in Bipolar I Disorder when oral therapy is not appropriate and where IM haloperidol is not recommended (JFC January 2019).

Provider notes

  • NMUH:
    • As per indication stated above
    • To be initiated following psychiatry advice only
  • RFL:
    • Restricted for initiation until after a discussion with liaison psychiatry team
  • RNOH:
    • Initiation with Psychiatry advice only
  • UCLH:
  • WH:
    • Restricted for initiation by a Consultant Psychiatrist only
  • CIFT:
    • Approved for
      • Mania
      • Schizophrenia 
      • Persistent aggression in moderate to severe Alzheimer’s dementia where risk of harm to self & others (off-label)
      • Depression (adjunctive treatment)
      • Challenging behaviour in learning disabilities - 2nd line
  • BEHMT:
    • Approved for
      • Mania
      • Schizophrenia
      • Rapid tranquillisation
04.02.02 Aripiprazole depot injection Abilify Maintena®

Approved for use by Mental Health Trusts only & restricted to patients with schizophrenia already stabilised & responding to oral aripiprazole (JFC February 2015).

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Restricted for initiation until after a discussion with liaison psychiatry team
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
  • CIFT:
    • Restricted formulary - requested via non-form route 
  • BEHMT:
    • Restricted consultant only
    • See 'Prescribing guidelines: Second-generation antipsychotic Long-Acting Injections' below
05.04.01 Artemether + Lumefantrine 

Provider notes

  • NMUH:
    • To be used as per the NMUHT Malaria Guidelines, see links below
  • RFL:
    • No restriction stated
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • First line for uncomplicated falciparum malaria, chloroquine-resistant non-falciparum malaria, and PO step down from IV artesunate
    • See link below
05.04.01 Artesunate 

Approved for severe falciparum malaria (November 2015) 

Provider notes

  • NMUH:
    • To be used on the recommendation of the Infectious Diseases Team or Microbiology according to the NMUHT malaria guidelines.
    • See link below
    • Available from ‘special-order’ manufacturers or specialist importing companies
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
15.02 Articaine hydrochloride + Adrenaline injection 

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • For dental use at BCF only
  • RNOH:
    • Non-formulary
  • UCLH:
    • Non-formulary
  • WH:
    • Non-formulary
07.04.03 Ascorbic Acid Vitamin C

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • Acidification may prevent encrustation of indwelling catheters, excess mucus formation in bladder augmentation and urinary tract infections. Many patients find high dose ascorbic acid unpalatable and may prefer to take cranberry juice drinks that are now widely available in the high street.
09.06.03 Ascorbic Acid Vitamin C

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • Tablets 50mg,100mg, 200mg and 500mg
    • Injection 500mg
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • No restriction stated
A5.03.03 Askina Calgitrol 

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Use restricted to Tissue Viability Nurse (TVN) specialist
02.09 Aspirin 

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • See NCL JFC summary of antiplatelet options in cardiovascular disease for specific indications
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • No restriction stated
04.07.01 Aspirin 

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • Injection: Restricted to neurology for Chronic intractable daily headache, Chronic migraine or Drug withdrawal headache
    • Oral: Mild to moderate pain
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • No restriction stated
05.03.01 Atazanavir 

Provider notes

  • NMUH:
    • To be prescribed as per BHIVA Guidelines by HIV team only
  • RFL:
    • HIV medicine only
  • RNOH:
    • Non-formulary  
  • UCLH:
  • WH:
    • No restriction stated
05.03.01 Atazanavir + cobicistat Evotaz®

Provider notes

  • NMUH:
    • To be initiated by Consultants in HIV Medicine only
  • RFL:
    • HIV Medicine only
  • RNOH:
    • Non-formulary  
  • UCLH:
  • WH:
    • Non-formulary
02.04 Atenolol 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • Atenolol injection restricted to cardiology and ITU only.
  • RNOH:
    • Tablets available. Oral syrup available as 5 mg/mL
  • UCLH:
  • WH:
    • Tabs 50 mg, 100 mg; Syrup 25 mg/5 ml
08.01.05 Atezolizumab  

Provider notes

  • NMUH:
    • This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used  in line with NICE recommendations and/or Local Trust Guidelines.
    • See links below
  • RFL:
    • As per NICE guidance/CDF criteria
    • This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system)
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • As per NICE TA 520
04.04 Atomoxetine 

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Restricted to the Child & Adolescent Mental Health Service only  
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    •  As per NICE TA98 / CG87
  • CIFT
    • Approved for adults with ADHD (off-label)
  • BEHMT
    • Approved for adults with ADHD (off-label)
02.12 Atorvastatin 

Provider notes

  • NMUH:
    • See NCL JFC Statins Guideline
  • RFL:
    • No restriction stated 
  • RNOH:
    • Restricted
  • UCLH:
  • WH:
    • No restriction stated
07.01.03 Atosiban 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • Not a preferred choice agent
    • See ‘Pre-Term Labour’ policy on Freenet
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Atosiban is to be used only in accordance with protocol
05.04.08 Atovaquone 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • Microbiology/ID approval only
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • For Microbiology use only
05.04.01 Atovaquone + Proguanil 

Provider notes

  • NMUH:
    • To be used as per the NMUHT Malaria Guidelines
    • See link below
  • RFL:
    • No restriction stated
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
15.01.05 Atracurium besilate 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • Store in refrigerator 
  • UCLH:
  • WH:
    • No restriction stated
A5.01.01 Atrauman  

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
A5.03.03 Atrauman AG 

Provider notes

  • NMUH:
    • 10cm x 10 cm is available on the recommendation of the Tissue Viability Nurse only.
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
11.05 Atropine eye drops 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • Atropine 0.5% eye drops are not kept.
    • Mydriasis and cycloplegia
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • Eye-drops 0.5% not available
11.05 Atropine eye drops - single use 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • Mydriasis and cycloplegia
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
15.01.03 Atropine injection 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • No restriction stated
15.01.03 Atropine Minijet® injection 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
01.02 Atropine tabs 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
14.04 Avaxim® Hepatitis A vaccine Single Component

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
13.02.01.01 Aveeno® Bath Oil 
  • NOT recommended for dry skin conditions including eczema atopic dermatitis (JFC January 2019)
  • Approved for ichthyosis and epidermolysis bullosa (JFC January 2019)

Secondary care notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Approved for ichthyosis and epidermolysis bullosa
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
13.02.01 Aveeno® cream 

Provider notes

  • NMUH:
    • Non-formulary 
  • RFL: 
    • No restriction stated
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
08.01.05 Avelumab 

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • As per NICE/CDF criteria
    • This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system)
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
07.04.05 Aviptadil + phentolamine Invicorp®

Erectile dysfunction in men who have failed to respond to oral PDE5i (sildenafil and tadalafil) and intracavernosal/urethral alprostadil. Secondary care initiation, primary care continuation (SLS only) (JFC November 2017)

Provider notes

  • NMUH:
    • To be prescribed by Urology Consultants ONLY. To be used as a second line option after treatment failure or intolerance with oral PDE5i (tadalafil or sildenafil) and intracavernosal/ urethral alprostadil.
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Approved by NCL as 2nd line treatment for erectile dysfuntion if alprostadil fails (JFC November 2016)
08.01.05 Axitinib 

See NICE TA for eligibility criteria

Provider notes

  • NMUH:
    • This medicine has a positive NICE Technology Appraisal but is not listed in the Trust Medicines Formulary as the service is not offered at NMUH.
  • RFL:
    • As per NICE TA
    • This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system).  Additionally for in-patients this drug must be prescribed on an in-patients prescription chart (paper or electronic)
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
A2.02.02.01 AYMES Complete 
  • Bottle (200mL)
  • Banana, vanilla, chocolate, strawberry
  • Contains lactose
  • Gluten Free
  • Halal certified (except strawberry)
  • Suitable for Kosher and vegetarians diets (except strawberry)

Provider notes

Non-formulary 

Primary care notes

Second-choice product - for patients who did not tolerate first-line choices - see Primary Care Guidance

A2.02.01.02 AYMES Shake 
  • Sachets - requires a patient to be able to mix with full-fat milk 
  • Vanilla, banana, strawberry, chocolate, neutral
  • Gluten-free
  • Halal certified (except for chicken flavour)
  • Suitable for vegetarians (except for chicken flavour)
  • May not be appropriate in the following patients
    • Patients requiring complete nutrition e.g. reliant entirely on supplements, patients requiring enteral feeding
    • Renal patients (CKD stage 4 and 5)
    • Vegans and patients with lactose intolerance

Provider notes

Non-formulary 

Primary care notes

First-choice product - see Primary Care Guidance

A2.02.02.03 AYMES Shake Compact 
  • Sachets - requires a patient to be able to mix with full-fat milk 
  • Vanilla, banana, strawberry, chocolate, neutral
  • Gluten-free
  • Halal certified (except strawberry)
  • Suitable for vegetarians (except strawberry)
  • May not be appropriate in the following patients
    • Patients requiring complete nutrition e.g. reliant entirely on supplements, patients requiring enteral feeding
    • Renal patients (CKD stage 4 and 5)
    • Vegans and patients with lactose intolerance

Provider notes

Non-formulary 

Primary care notes

First-choice product for patients who cannot tolerate 200mL presentation - see Primary Care Guidance

08.01.03 Azacitidine 

See NICE TA for eligibility criteria

Provider notes

  • NMUH:
    • This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines.
    • See links below
  • RFL:
    • Approved for Haematology for MDS, CMML and AML in line with NICE TA
    • This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system)
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
01.05.03 Azathioprine 

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Azathioprine should be initiated only by the Gastroenterology team for difficult cases. FBC and LFT monitoring is required.
01.05.03 Azathioprine 

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Approved for autoimmune hepatitis (JFC February 2018)

Provider notes

  • NMUH:
  • RFL:
    • See indication above
  • RNOH:
  • UCLH:
  • WH:
    • Specialist initiation, continuation in primary care
08.02.01 Azathioprine 

GP-RedRed (hospital only prescribing) for renal transplant

Grey for other indications

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Regular monitoring of FBC and LFTs is required.
10.01.03 Azathioprine 

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • Restricted to Rheumatology Consultants ONLY
    • See links below
  • UCLH:
  • WH:
    • No restriction stated
13.05.03 Azathioprine 

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
13.05.03 Azathioprine 

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Approved for Pemphigus Vulgaris (PV), Mucous membrane pemphigoid (MMP), Recurrent apthous stomatitis (RAS), Oral lichen planus (OLP), Oral Crohn’s disease (OCD) (JFC June 2017)

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • See above
  • RNOH:
    • Non-formulary
  • UCLH:
    • See indication above
  • WH:
    • Non-formulary
13.06.01 Azelaic acid 15% gel Finacea®

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Restricted to Dermatology
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
13.06.01 Azelaic acid 20% cream Skinoren®

 Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • Restricted to Dermatology
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
12.02.01 Azelastine + Fluticasone nasal spray Dymista®

Approved for allergic rhinitis when 1st line betamethasone monotherapy and 2nd line fluticasone monotherapy have failed (JFC September 2015)

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Approved for the indication outlined above
11.04.02 Azelastine 0.5 mg/ml eye drops 

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Restricted to allergy clinic only
  • RNOH:
    • Non-formulary
  • UCLH:
    • Non-formulary
  • WH:
    • Non-formulary
12.02.01 Azelastine nasal spray Rhinolast®

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Restricted to the allergy clinic only
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • The use of azelastine hydrochloride nasal spray is restricted to ENT department only
11.03.01 Azithromycin 15 mg/g eye drops 

Provider notes

  • RFL:
    • Restricted to Opthalmology.
    • Approved for use in ocular chlamydia infections, blepharitis, paediatrics and adults.
    • Azithromycin 1.5% single use eye drops                                                
05.01.05 Azithromycin tabs/caps/suspension 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • Refer to Microguide for agreed indications, all other indications require microbiology approval
    • Used for prophylaxis and treatment of Mycobacterium avium intracellulare in HIV
  • RNOH:
    • Oral suspension available as 200 mg/5mL
  • UCLH:
  • WH:
    • Suspension is reserved for Paediatric and Neonatal use only
24.01 Azithromyin 1.5% single use eye drops 

MEH: Ocular Chlamydia infections; blepharitis

05.01.02.03 Aztreonam 

Provider notes

  • NMUH:
    • Consultant Microbiologist recommendation only
  • RFL:
    • Microbiology approval only
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
10.02.02 Baclofen intrathecal 

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Non-formulary
  • RNOH:
    • Unlicensed - Intrathecal baclofen 1000 micrograms/mL, 2000 micorgrams/mL and 3000 micrograms/mL are unlicensed products
  • UCLH:
  • WH:
    • Non-formulary
10.02.02 Baclofen oral 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • Oral liquid available as 5 mg/5mL
  • UCLH:
  • WH:
    • No restriction stated
13.02.01.01 Balneum® bath oil 
  • NOT recommended for dry skin conditions including eczema atopic dermatitis (JFC January 2019)
  • Approved for ichthyosis and epidermolysis bullosa (JFC January 2019)

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Only approved for above indications
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • Non-formulary
13.02.01 Balneum® cream Urea 5%

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Non-formulary
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • Non-formulary
13.02.01.01 Balneum® Plus bath oil 

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Approved for ichthyosis and epidermolysis bullosa only (JFC January 2019)
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Restricted to Dermatology use ONLY
13.02.01 Balneum® Plus cream Urea 5%

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Preferred urea containing emollient
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
10.01.03 Baricitinib 

Approved for:

  • Rheumatoid arthritis (see NICE TA)

Provider notes

  • NMUH:
    • This medicine has a positive NICE TA and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines - TO AWAIT UPDATED NCL JFC PATHWAY PRIOR TO PRESCRIBING
    • See link below
  • RFL:
    • As per NICE guidance for the treatment of RA
  • RNOH:
    • Rheumatology Consultants Only
  • UCLH:
  • WH:
    • As per NICE TA and above
08.02.02 Basiliximab 

See NICE TA for eligibility criteria

Provider notes

  • NMUH:
    • This medicine has a positive NICE Technology Appraisal but service is not offered at NMUH.
    • Check MHRA Drug Safety Alerts
  • RFL:
    • Prior funding required for treatment of lymphoma with radiolabelled basiliximab.
    • Approved for Renal (as per TA) and Liver (contact Pharmacy) for transplant patients.
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
08.02.04 BCG bladder instillation OncoTICE®

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • No restriction stated
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
08.02.04 BCG bladder instillation ImmuCyst®

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
14.04 BCG diagnostic agent - Intradermal injection 

Provider notes

  • NMUH:
    • Tuberculin Purified Protein Derivative (PPD)
  • RFL:
    • No restriction stated
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • Tuberculin PPD SSI is an unlicensed product
14.04 BCG vaccine - Intradermal injection 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • BCG Vaccine SSI is an unlicensed product
12.02.01 Beclometasone dipropionate 50mcg/spray nasal spray 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • No restriction stated
03.02 Beclometasone dipropionate inhaler (pMDI) Clenil Modulite®

Provider notes

  • NMUH:
    • See links below
  • RFL:
    • Clenil Modulite® is not interchangeable with other CFC-free beclometasone dipropionate inhalers and should be prescribed by brand name
  • RNOH:
    • Clenil Modulite® is not interchangeable with other CFC-free beclometasone dipropionate inhalers and should be prescribed by brand name
  • UCLH:
  • WH:
    • First choice
    • CFC-free beclometasone inhalers are not equipotent and should be prescribed by brand name
    • Inhaler 50 micrograms, 100 micrograms, 200 micrograms, 250 micrograms/metered inhalation ONLY
03.02 Beclometasone dipropionate inhaler (pMDI) Qvar®

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Qvar® is not interchangeable with other CFC-free beclometasone dipropionate inhalers and should be prescribed by brand name
    • MDI, Autohaler and Easi-Breathe available
  • RNOH:
    • Restricted for continuation of treatment. Qvar® is not interchangeable with other CFC-free beclometasone dipropionate inhalers and should be prescribed by brand name
  • UCLH:
  • WH:
    • Turbohalers, Accuhalers and Autohalers are reserved for unable to tolerate an MDI with a spacing device.
    • Inhaler CFC-Free 50 micrograms, 100 micrograms/metered inhalation (Qvar) & Qvar Autohaler 50 micrograms, 100 micrograms, /metered inhalation ONLY
03.02 Beclometasone diproponate + Formoterol + Glycopyrronium inhaler (pMDI) Trimbow®

Approved for COPD when ICS + LAMA + LABA inhalation therapy is indicated, as per NICE guidance (JFC September 2019)

Provider notes

  • NMUH:
    • As per recommendations stated above
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
    • Non-formulary
  • WH:
    • As above
03.02 Beclometasone diproponate + Formoterol inhaler (pMDI) Fostair®

Provider notes

  • NMUH:
    • See links below
  • RFL:
    • No restriction stated
  • RNOH:
    • For continuation of therapy only
  • UCLH:
  • WH:
    • Fostair should only be supplied when prescribed by, or on the recommendation of, the Respiratory Team. This is to ensure that it is prescribed appropriately.
05.01.09 Bedaquiline 

Approved for XDR-TB and MDR-TB in line with the NHS England Clinical Commissioning Policy F04/P/a (JFC April 2017)

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Approved for XDR-TB and MDR-TB in line with NHSE policy
    • Restricted to ID team only
  • RNOH:
    • Non-formulary  
  • UCLH:
    • Pulmonary multidrug-resistant tuberculosis in line with NHS England policy, restricted to TB team
  • WH:
    • As above
03.04.02 Bee and Wasp Allergen Extracts Pharmalgen®

Provider notes

  • NMUH:
    • Non-formulary.
    • This medicine has a positive NICE Technology Appraisal, however, VENOM IMMUNOTHERAPY SERVICE IS NOT PROVIDED AT NMUH. 
  • RFL:
    • Non-formulary
  • RNOH:
    • Restricted Item Restricted
  • UCLH:
  • WH:
    • No restriction stated
10.01 Belimumab 

Provider notes

  • NMUH:
    • This medicine has a positive NICE Technology Appraisal but is not listed in the Trust Medicines Formulary as the service is not offered at NMUH - for intiation at specialist centres.
    • See MHRA Drug Safety Update.
  • RFL:
    • Approved for use in the treatment of SLE in line with NICE guidance
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • As per NICE technology appraisal.
    • See link below.
08.01.01 Bendamustine 

See NICE TA for eligibility criteria

Provider notes

  • NMUH:
    • Positive NICE TA This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines.
    • See links below
  • RFL:
    • Approved for relapsed low grade NHL and MM (3rd line) as per CDF criteria
    • Approved for use as per NICE TA216
    • This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system)
  • RNOH:
    • Non-formulary
  • UCLH:
    • For relapsed multiple myeloma in line with Cancer Drugs Fund only
  • WH:
    • As per NICE TA(s)
02.02.01 Bendroflumethiazide 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • No restriction stated
04.02.01 Benperidol 

Provider notes

  • NMUH:
    • Non-formulary  
  • RFL:
    • Restricted for initiation until after a discussion with liaison psychiatry team.
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
03.04.02 Benralizumab injection  

See NICE TA for eligibility criteria

Provider notes

  • NMUH:
    • Non-formulary
    • This medicine has a positive NICE Technology Appraisal, however, the service is not provided at NMUH.
  • RFL:
    • In line with NICE TA only, restricted to respiratory
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
13.09 Benzalkonium chloride 0.5% shampoo Dermax®

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Restricted to dermatology
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
05.01.01.01 Benzathine benzylpenicillin 

Provider notes

  • NMUH:
    • Used in the treatment of early syphilis and late latent syphilis
    • Benzathine Benzylpenicillin 2.4 mega unit injection, available from ‘special-order’ manufacturers or specialist importing companies
  • RFL:
    • Used in the treatment of early syphilis and late latent syphilis
    • Benzathine Benzylpenicillin 2.4 mega unit injection, available from ‘special-order’ manufacturers or specialist importing companies
      RNOH approvals
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
10.04 Benzbromarone 

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Rheumatology and Renal initiation only – hospital only prescribing
  • RNOH:
    • Non-formulary
  • UCLH:
    • Non-formulary
  • WH:
    • Non-formulary
13.10.02 Benzoic Acid Ointment, Compound BP Whitfield's ointment

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
13.06.01 Benzoyl peroxide - Topical PanOxyl®

Provider notes

  • NMUH:
    • Formulary options:
      • Aquagel 2.5% & 10%
      • Gel 5%
    • NON-FORMULARY
      • Aquagel 5% 
      • Cream 5% 
      • Gel 10%
      • Panoxyl wash
  • RFL:
    • 2.5% and 5% gel available
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • Non-formulary
13.06.01 Benzoyl peroxide 5% + Clindamycin 1% gel Duac® Once Daily

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • Restricted to Dermatology
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Duac gel is restricted to Dermatology
12.03.01 Benzydamine 0.15% spray or mouthwash 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • Mouthwash and Spray available
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
13.10.04 Benzyl Benzoate Application BP 25% 

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
05.01.01.01 Benzylpenicillin 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • No restriction stated
04.06 Betahistine Dihydrochloride 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • No restriction stated
10.01.02.02 Betamethasone  

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • Non-formulary  
  • UCLH:
  • WH:
    • No restriction stated
13.04 Betamethasone dipropionate 0.05% - Topical Diprosone®

Provider notes

  • NMUH:
    • Diprosone cream and Diprosone ointment are FORMULARY.
    • Diprosone lotion is NON-FORMULARY.
  • RFL:
    • Diprosone cream and Diprosone ointment are FORMULARY
    • Diprosone lotion is NON-FORMULARY
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
13.04 Betamethasone dipropionate 0.05% + Salicylic acid 3% - Topical Diprosalic®

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • Ointment and Scalp Application available
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
13.04 Betamethasone dipropionate 0.064% + Clotrimazole 1% - Topical Lotriderm®

Provider notes

  • NMUH:
    • Restricted to Dermatology department use ONLY
  • RFL:
    • Dermatology use only
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
11.04.01 Betamethasone sodium phosphate 0.1% + Neomycin 0.5% drops 

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Restricted to Ophthalmology
12.01.01 Betamethasone sodium phosphate 0.1% + Neomycin 0.5% drops 

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
12.02.03 Betamethasone sodium phosphate 0.1% + Neomycin 0.5% drops 

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
12.01.01 Betamethasone sodium phosphate 0.1% drops 

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • Not applicable 
  • UCLH:
  • WH:
    • No restriction stated
12.02.01 Betamethasone sodium phosphate 0.1% drops 

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

 Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
11.04.01 Betamethasone sodium phosphate 0.1% drops, 0.1% ointment 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • No restriction stated
12.03.01 Betamethasone soluble tablets 

Approved for oral mucosal inflammatory disease (JFC March 2018)

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • As above
06.03.02 Betamethasone systemic injection 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Inj 4 mg/1 ml ONLY
06.03.02 Betamethasone tablets 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
13.04 Betamethasone valerate 0.025% - Topical 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • cream and ointment available
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • No restriction stated
13.04 Betamethasone valerate 0.1% - Topical 

Provider notes

  • NMUH: 
    • When Betnovate cream or ointment are requested/prescribed, the non-proprietary version, betamethasone valerate 0.1% cream or ointment will be supplied.
    • When Betnovate scalp application is prescribed/requested, Betacap (betametasone valerate 0.1%) scalp application will be supplied.
    • Bettamousse® is NON-FORMULARY
  • RFL:
    • Cream, Ointment, Scalp application and Foam available
  • RNOH:
    • No restriction stated
    • Bettamousse® is not available
  • UCLH:
  • WH:
    • No restriction stated
    • Betacap® and Bettamousse® are not available
13.04 Betamethasone valerate 0.1% + Clioquinol 3% - Topical 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • Cream and Ointment available
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
13.04 Betamethasone valerate 0.1% + Fucidic acid 2% - Topical 

 Provider notes

  • NMUH:
    • Fucibet cream is FORMULARY
    • Fucibet lipid cream is NON-FORMULARY
  • RFL:
    • Cream available
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • Restricted to Dermatology use ONLY
    • Cream ONLY available
13.04 Betamethasone valerate 0.1% + Neomycin 0.5% - Topical 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • Cream available
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
11.06 Betaxolol 0.5% solution eye drops 

See NCL guideline for place in therapy.

Provider notes

  • NMUH:
    • See link below
    • Check MHRA Drug Safety Update
  • RFL:
    • Open angle glaucoma and ocular hypertension
    • 0.25% eye drops stocked as well.
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
08.01.05 Bevacizumab 

Provider notes

  • NMUH:
    • This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used  in line with NICE recommendations and/or Local Trust Guidelines.
    • See links below
  • RFL:
    • This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system)
    • Discuss with cancer pharmacy team before prescribing
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
11.08.02 Bevacizumab intravitreal injection 

Approved for:

  • Neovascular glaucoma (single-dose intravitreal) as an adjunct to panretinal photocoagulation (January 2017)
  • Pre-operative adjunct to diabetic vitrectomy (MEH only; April 2017)
  • Coats' disease and Familial exudative vitreoretinopathy (FEVR) (November 2015)

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Approved for use in neovascular glaucoma as an adjunct to panretinal photocoagulation
  • RNOH:
    • Non-formulary
  • UCLH:
    • Non-formulary
  • WH:
    • Non-formulary
14.04 Bexsero® Meningococcal group B Vaccine

Approved in line with Public Health England Men B immunisation programme  (JFC August 2015) 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • Restricted to paediatrics, patients with asplenia or splenic dysfunction, complement deficiencies including complement inhibitor therapy and patients receiving eculizumab
  • RNOH:
    • Non-formulary
  • UCLH:
    • No restriction stated
  • WH:
    • Non-formulary
01.10 Bezafibrate 

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Approved for Primary Biliary Cholangitis as second-line therapy after ursodeoxycholic acid if intolerant to obeticholic acid. Notes: daily dose of 400 mg modified-release once-daily (JFC January 2019)

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • See indication above
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
02.12 Bezafibrate 

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Provider notes

  • NMUH:
    • Immediate and modified release
    • No restriction stated
  • RFL:
    • Immediate and modified release
    • Restricted to Lipid Clinic
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
08.03.04.02 Bicalutamide 

Provider notes

  • NMUH:
    • Restricted to Consultant Oncologist and Urologist use only.
  • RFL:
    • No restriction stated
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Bicalutamide 150mg is reserved for the treatment of locally advanced prostate cancer where it is important to maintain sexual potency.
11.06 Bimatoprost 0.01% eye drops 

See NCL guideline for place in therapy.

Provider notes

  • NMUH:
    • See link below
  • RFL:
    • No restriction stated
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • No restriction stated
11.06 Bimatoprost 0.03% + Timolol 0.1% eye drops Ganfort®

Combination therapies to be used when compliance / cost issues arise. See NCL guideline for place in therapy.

Provider notes

  • NMUH:
    • See link below
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
11.06 Bimatoprost 0.03% + Timolol 0.1% eye drops - preservative free Ganfort®

Restricted to patients with true preservative allergy and/or evidence of epithelial toxicity from preservatives and/or severe dry eyes. See NCL guideline for place in therapy.

Combination therapies to be used when compliance/cost issues arise. See NCL guideline for place in therapy.

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Open angle glaucoma and ocular hypertension
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
11.06 Bimatoprost 0.03% eye drops- single use 

See NCL guideline for place in therapy.

Provider notes

  • NMUH:
    • Restricted to patients with true preservative allergy and/or evidence of epithelial toxicity from preservatives and/or severe dry eyes
    • See link below
  • RFL:
    • Open angle glaucoma and ocular hypertension
  • RNOH:
  • UCLH:
  • WH:
    • No restriction stated
08.01.05 Binimetinib tabs 

See NICE TA for eligibility criteria

Provider notes

  • NMUH:
    • Non-formulary
    • This medicine has a positive NICE Technology Appraisal but is not listed in the Trust Medicines Formulary as the service is not offered at NMUH.
  • RFL:
    • As per NICE guidance
    • This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system) Additionally for in-patients this drug must be prescribed on an in-patient prescription chart (paper or electronic)
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
09.08.01 Biotin  

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Restricted to paediatrics and neonates
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
12.03.05 BioXtra® oral gel 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • Non-formulary
06.01.01.02 Biphasic Insulin Aspart NovoMix® 30

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • No restriction stated
06.01.01.02 Biphasic Insulin Lispro Humalog® Mix25, Humalog® Mix50

Approved for:

  • First choice biphasic analogue insulin in Type 2 diabetes. See NCL guideline for insulin in Type 2 diabetes guideline.
  • Type 1 diabetes


Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • No restriction stated
06.01.01.02 Biphasic Isophane Insulin Humulin® M3

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • No restriction stated
06.01.01.02 Biphasic Isophane Insulin Insuman® Comb 25, Insuman® Comb 50

First choice biphasic human insulin. See NCL guideline for insulin in Type 2 diabetes guideline.

Insuman® Comb 15 removed from the market (January 2020)

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Non-formulary
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • Non-formulary
01.06.02 Bisacodyl 

Provider notes

  • NMUH:
    • See link below
  • RFL:
    • No restriction stated
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • Please note: Suppositories 10 mg, Paediatric suppositories 5 mg only
01.03.03 Bismuth subsalicylate Pepto-Bismol®

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Approved for eradication of  H.Pylori, after first-line treatment and previous exposure to levofloxacin (JFC April 2019).

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • See indication above
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
02.04 Bisoprolol 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • No restriction stated
02.08.01 Bivalirudin 

Provider notes

  • NMUH:
    • This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary but may NOT be routinely stocked in pharmacy. This medicine will be ordered if use is as per local Trust Guideline or is approved by the Trust Medicines Management Committee. Contact pharmacy medicines information on ext 2417 for further information
  • RFL:
    • Non-formulary
  • RNOH:
    • Restricted
  • UCLH:
  • WH:
    • NICE TA230 applies. Not routinely stocked at WH.
08.01.02 Bleomycin 

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system)
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
14.04 Boostrix-IPV 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
  • UCLH:
  • WH:
    • No restriction stated
08.01.05 Bortezomib injection 

See NICE TA for eligibility criteria

Provider notes

  • NMUH:
    • This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines.
    • To be prescribed by the Haematology Team ONLY
    • See links below
  • RFL:
    • As per NICE guidance/CDF criteria
    • This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system)
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
02.05.01 Bosentan 

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Approved for digital ulceration in systemic sclerosis in line with NHSE Clinical Commissioning Policy A13/P/e (May 2015)

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • In line with NHSE clinical comissioning policy
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
02.05.01 Bosentan 

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Prior funding approval required
    • Restricted to the treatment of pulmonary hypertension
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
08.01.05 Bosutinib 

See NICE TA for eligibility criteria

Provider notes

  • NMUH:
    • This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used  in line with NICE recommendations and/or Local Trust Guidelines.
    • See links below
  • RFL:
    • As per NICE guidance
    • This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system).  Additionally for in-patients this drug must be prescribed on an in-patient prescription chart (paper or electronic)
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
01.07.04 Botulinum toxin type A Botox®, Dysport®, Xeomin®

NOTE: There is more than one monograph for Botulinum toxin type A, click here to search for formulary status and its use for other indications. 

Provider notes

  • NMUH:
    • Xeomin brand only
  • RFL:
    • Botox brand only - restricted to Colorectal team
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
01.10 Botulinum toxin Type A Botox®, Dysport®, Xeomin®

NOTE: There is more than one monograph for Botulinum toxin type A, click here to search for formulary status and its use for other indications. 

Approved for Sphincter of Oddi Dysfunction  (JFC January 2013)

Provider notes

  • NMUH:
    • Xeomin is formulary when used in the treatment of achalasia (other brands and indications are non-formulary)
  • RFL:
    • Botox brand for Sphincter of Oddi Dysfunction, achalasia and gastroparesis
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
04.07.04.02 Botulinum Toxin Type A Botox®

NOTE: There is more than one monograph for Botulinum toxin type A, click here to search for formulary status and its use for other indications. 

Provider notes

  • NMUH:
    • Positive NICE TA but service not offered at NMUH.
  • RFL:
    • As per NICE TA260
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
04.09.03 Botulinum Toxin Type A Botox®, Dysport®, Xeomin®

NOTE: There is more than one monograph for Botulinum toxin type A, click here to search for formulary status and its use for other indications. 

Provider notes

  • NMUH:
    • Non-formulary 
  • RFL:
    • Dysport: Restricted to Spasticity clinic only
    • Botox: Restricted to blepharospasm, facial palsy, hand spasticity patients with scleroderma (restricted to named Plastic Surgeon consultant)
  • RNOH:
    • Dysport is first-line
  • UCLH:
  • WH:
    • Non-formulary
07.04.02 Botulinum toxin Type A Botox®

NOTE: There is more than one monograph for Botulinum toxin type A, click here to search for formulary status and its use for other indications. 

Approved for neurogenic bladder dysfunction for patients refractory to oral therapies (JFC January 2013)

Provider notes

  • NMUH:
    • Botox brand only
    • Restricted to consultants Dr Yoong, Mr Nair and Mr Godbole for use in Overactive Bladder (OAB) only
  • RFL:
    • Restricted to urology only
  • RNOH:
    • Restricted to Consultant Urologists only for neurogenic detrusor overactivity
  • UCLH:
  • WH:
    • See Botulinum Toxin Management Algorithm Diagram for direction of use
07.04.02 Botulinum toxin Type A Botox®

NOTE: There is more than one monograph for Botulinum toxin type A, click here to search for formulary status and its use for other indications. 

Not approved for urinary retention due to a disorder of the urethral sphincter (JFC October 2019)

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Restricted to urology only
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
13.12 Botulinum toxin type A  

NOTE: There is more than one monograph for Botulinum toxin type A, click here to search for formulary status and its use for other indications. 

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Approved for use in dermatology for the treatment of hyperhidrosis
    • Botox brand used
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
04.09.03 Botulinum Toxin Type B NeuroBloc®

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Non-formulary
  • RNOH:
    • Restricted  
  • UCLH:
  • WH:
    • Non-formulary
08.01.05 Brentuximab vedotin 

See NICE TA for eligibility criteria

Provider notes

  • NMUH:
    • This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines.
    • See links below
    • TA477 does not apply at NMUH as service is not offered
  • RFL:
    • This drug for the treatment of malignant disease must be prescribed on chemocare (RFL elecctronic chemotherapy prescribing system)
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • As per NICE TA
08.01.05 Brigatinib tabs 

See NICE TA for eligibility criteria

Provider notes

  • NMUH:
    • This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used  in line with NICE recommendations and/or Local Trust Guidelines. 
    • See link below
  • RFL:
    • As per NICE guidance
    • This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system) Additionally for in-patients this drug must be prescribed on an in-patient prescription chart (paper or electronic)
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
11.06 Brimonidine 0.2% + Timolol 0.5% eye drops Combigan®

Combination therapies to be used when compliance / cost issues arise. See NCL guideline for place in therapy.

Provider notes

  • NMUH:
    • See link below
  • RFL:
    • Open angle glaucoma and ocular hypertension
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • See link below
11.06 Brimonidine 0.2% eye drops 

See NCL guideline for place in therapy.

Provider notes

  • NMUH:
    • See link below
  • RFL:
    • Open angle glaucoma and ocular hypertension (3rd line)
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Not to be used for first-line treatment - see link below
13.06.01 Brimonidine 3 mg/g gel 

Approved for moderate to severe rosacea causing psychological distress or reduced quality of life - initiation by secondary care Dermatologist and continuation in primary care (JFC September 2014)

Provider notes

  • NMUH:
    • Check MHRA Drug Safety Update
  • RFL:
    • See indication above
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
11.06 Brinzolamide 0.1% eye drops 

See NCL guideline for place in therapy.

Provider notes

  • NMUH:
    • See link below
  • RFL:
    • Open angle glaucoma and ocular hypertension (2nd line)
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Use in line with NCL guideline below
11.06 Brinzolamide 1% + Timolol 0.5% eye drops Azarga®

Combination therapies to be used when compliance / cost issues arise. See NCL guideline for place in therapy.

Provider notes

  • NMUH:
    • See link below
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
04.08.01 Brivaracetam 

Approved as an adjunct for refractory partial onset seizures epilepsy who have not responded to levetiracetam, and had to stop due to off-target effects before effectiveness could be established. All initiations require individual patient applications to be considered by JFC Support to ensure adherence to criteria (JFC October 2018). Restricted to epilepsy specialist services at UCLH/NHNN and RFL.

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Individual patient approval via JFC Support, see above
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
13.05.03 Brodalumab 

Provider notes

  • NMUH:
    • This medicine has a positive NICE TA and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines - TO AWAIT UPDATED NCL JFC PATHWAY PRIOR TO PRESCRIBING
    • See links below
  • RFL:
    • As per NICE guidance
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
04.09.01 Bromocriptine 

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • Restricted
  • UCLH:
  • WH:
    • No restriction stated
06.07.01 Bromocriptine 

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • Restricted to Endocrinology and Gynaecology
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • 1st Choice
01.05.02 Budesonide Entocort®

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Capsules: Restricted to left-sided ulcerative colitis
    • Enema: 2nd line when prednisolone enema not tolerated
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
01.05.02 Budesonide Budenofalk®

Budenofalk® 2mg/dose rectal foam approved for active ulcerative colitis limited to the rectum and sigmoid colon as second-line (prednisolone retention enema is the first-line choice) (JFC October 2018).

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • Tablets: Non-formulary
    • Enema: See indication above
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • As above
03.02 Budesonide + Formoterol inhaler (DPI) Symbicort® Turbohaler, DuoResp Spiromax®

Not approved as the sole inhaler for asthma (SMART), may be used twice daily for asthma (JFC September 2015).

Provider notes

  • NMUH:
    • To be prescribed as per JFC Asthma / COPD guidelines
    • See links below
  • RFL:
    • No restriction stated
  • RNOH:
    • Symbicort only
  • UCLH:
  • WH:
    • Non-formulary
12.02.01 Budesonide 64mcg/spray nasal spray 

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • No restriction stated
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
03.02 Budesonide inhaler (DPI) Pulmicort® Turbohaler

Provider notes

  • NMUH:
    • See links below
  • RFL:
    • No restriction stated
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • No restriction stated
01.10 Budesonide nebuliser suspension 

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Approved as second-line choice (after fluticasone inhaler) for eosinophilic oesophagitis in both adults and children. Dose should be dispersed in viscous suspending agent (e.g. Splenda slurry). Starting dose is 1 mg twice-daily for adults and children > 10 years old, 1 mg once-daily for children < 10 years old; down titrate dose for maintenance dosing (JFC February 2018)

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • See local policy for information on use
  • RNOH:
    • Non-formulary
  • UCLH:
    • Non-formulary
  • WH:
    • As above
03.02 Budesonide nebuliser suspension 

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Nebulised budesonide should only be prescribed on the advice of a Consultant Paediatrician or a Respiratory Consultant.
02.02.02 Bumetanide 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • No restriction stated
15.02 Bupivacaine  

Approved for post-operative pain management following limb amputation for peripheral arterial disease to reduce post-operative opioid requirement (0.125% infusion via perineural stump catheter) (JFC September 2019). 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • Inj 0.25% (25mg/10mL); 0.5% (50mg/10mL) only
15.02 Bupivacaine + Adrenaline 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • No restriction stated
15.02 Bupivacaine + Fentanyl 

Provider notes

  • NMUH:
    • A ready-mixed bag of Fentanyl + Bupivicaine is available from Pharmacy
  • RFL:
    • Theatres: Bupivacaine 0.125% + Fentanyl 4micrograms/mL in NaCl 0.9% 480mL epidural bag
    • Labour: Bupivacaine 0.1% + Fentanyl 2micrograms/mL in NaCl 0.9% 15mL epidural syringe
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
15.02 Bupivacaine + Glucose Marcain Heavy®

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • No restriction stated
04.07.02 Buprenorphine patch '35', '52.5','70'  

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Restricted to Pain team initiation
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
04.07.02 Buprenorphine patch '5', '10', '15' and '20' 

Buprenorphine patch ‘5’ and ‘10’ patches approved for patients unable to take oral opioids due to swallowing difficulties / short bowel AND requiring a lower dose transdermal opioid dose than the 12 micrograms fentanyl patch (JFC March 2015).

Provider notes

  • NMUH:
    • See restriction above (5 and 10mcg/hr patches only)
  • RFL:
    • No restriction stated
  • RNOH:
    • See restriction above (5 and 10mcg/hr patches only)
  • UCLH:
  • WH:
    • See restriction above (5 and 10mcg/hr patches only)
04.07.02 Buprenorphine sublingual tablets 

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • No restriction stated
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
04.10.03 Buprenorphine sublingual tablets  

Provider notes

  • NMUH:
    • Positive NICE TA This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary - see link below
    • For continuation ONLY
  • RFL:
    • In line with ‘Opioid dependence guideline’ on Freenet
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • Non-formulary
04.10.02 Bupropion 

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • No restriction stated
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
  • CIFT:
    • Approved for major depression where NICE recommended options are ineffective or not tolerated (off-label)
  • BEHMT approvals:
    • Non-formulary
06.07.02 Buserelin 

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
06.07.02 Buserelin 

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
08.03.04.02 Buserelin 

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
04.01.02 Buspirone 

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Restricted for initiation until after a discussion with liaison psychiatry team
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
  • CIFT:
    • Approved as anxiolytic
  • BEHMT:
    • Approved as anxiolytic
08.01.01 Busulfan infusion 

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
    • Approved for conditioning prior to haematopoietic progenitor cell transplantation
  • WH:
    • No restriction stated
08.01.01 Busulfan tablets 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
    • This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system). Additionally for in-patients this drug must be prescribed on an in-patient prescription chart (paper or electronic)
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
03.04.03 C1 Esterase Inhibitor Cinryze®

Approved for prophylaxis and treatment of hereditary angioedema in line with NHS Commissioning Policies (JFC October 2018).

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • For hereditary angioedema in line with NHSE commissioning policy
    • Restricted to immunology
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
03.04.03 C1 Esterase Inhibitor Berinert®

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • For hereditary angioedema in line with NHSE commissioning policy
    • Restricted to immunology
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
08.01.05 Cabazitaxel 

See NICE TA for eligibility criteria

Provider notes

  • NMUH:
    • This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines.
    • See links below
  • RFL:
    • As per NICE TA
    • This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system)
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary to WH
04.09.01 Cabergoline 

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • No restriction stated
  • RNOH:
    • Restricted
  • UCLH:
  • WH:
    • Non-formulary
06.07.01 Cabergoline 

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Provider notes

  • NMUH:
    • Restricted to Obs & Gynae Consultant use only
  • RFL:
    • Restricted to Endocrinology and Gynaecology / Obstetrics
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Cabergoline is reserved for use by Dr Moult and for suppression of lactation
08.01.05 Cabozantinib caps Cometriq®

See NICE TA for eligibility criteria

Provider notes

  • NMUH:
    • Non-formulary
    • This medicine has a positive NICE Technology Appraisal but is not listed in the Trust Medicines Formulary as the service is not offered at NMUH.
  • RFL:
    • As per NICE guidance for the treatment of medullary thyroid cancer
    • This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system).  Additionally for in-patients this drug must be prescribed on an in-patient prescription chart (paper or electronic)
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
08.01.05 Cabozantinib tabs Cabometyx®

See NICE TA for eligibility criteria

Provider notes

  • NMUH:
    • This medicine has a positive NICE Technology Appraisal but is not listed in the Trust Medicines Formulary as the service is not offered at NMUH.
  • RFL:
    • As per NICE guidance for the treatment of renal cell carcinoma
    • This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system).  Additionally for in-patients this drug must be prescribed on an in-patient prescription chart (paper or electronic)
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary to WH
21.01 Cacicol 

Non-healing corneal ulcers/ persistent epithelial defects. 
Under evaluation at MEH only (restricted to corneal eye disease service only, April 2017)

13.03 Calamine lotion 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • Non-formulary
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • Lotion BP 100 ml only
13.05.02 Calcipotriol 50mcg/g - Topical 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • Ointment and Scalp solution available
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Calcipotriol scalp application is restricted to Dermatology use only
13.05.02 Calcipotriol 50micrograms/g + Betamethasone dipropionate 0.05% - Topical 

Provider notes

  • NMUH:
    • Restricted to consultant Dermatologists ONLY
  • RFL:
    • Ointment and Gel available
    • Restricted to Dermatology ONLY
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • For patients who fail separate topical steroid + vitamin D2 (e.g. calcipotriol)
    • Dovobet ointment restricted to Dermatology use ONLY
13.05.02 Calcipotriol 50micrograms/g + Betamethasone dipropionate 0.05% - Topical foam Enstilar®

Approved after failure of combined topical steroid + vitamin D2 (e.g. Dovobet ointment) (JFC May 2017)

Provider notes

  • NMUH:
    • For Trunk & Limb psoriasis in patients who fail combined topical steroid + vitamin D2 (e.g. Dovobet ointment)
    • Restricted to dermatology use only
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • For patients who fail combined topical steroid + vitamin D2 (e.g. Dovobet ointment)
    • Restricted to dermatology use only
06.06.01 Calcitonin (salmon) 

Provider notes

  • NMUH:
    • See link below
    • Check MHRA Drug Safety Updates
  • RFL:
    • No restriction stated
  • RNOH:
    • Restricted
    • Store in a refrigerator
    • Allow to reach room temperature before subcutaneous or intramuscular use.
  • UCLH:
  • WH:
    • No restriction stated
13.05.02 Calcitriol 3mcg/g - Topical Silkis®

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Dermatology use only
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Calcitriol ointment is restricted to Dermatology use only
09.05.01.02 Calcitriol injection 

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Approved for percutaneous injection into the parathyroid gland for hyperparathyroidism if intolerant or unresponsive to oral therapy (November 2013)
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
09.06.04 Calcitriol oral 

Provider notes

  • NMUH:
    • See link below
  • RFL:
    • No restriction stated
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
09.05.02.02 Calcium acetate + Magnesium carbonate tabs Osvaren®

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Restricted to renal patients only
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
09.05.02.02 Calcium acetate tabs Phosex®

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Restricted to renal patients only
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
09.06.04 Calcium and Ergocalciferol 

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • No restriction stated
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • Non-formulary
09.05.01.01 Calcium carbonate Cacit®

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  •  WH:
    • Non-formulary
09.05.01.01 Calcium carbonate Calcichew®

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • No restriction stated
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
09.05.01.01 Calcium Carbonate Adcal®

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • No restriction stated
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • No restriction stated
09.05.02.02 Calcium carbonate Calcichew®

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Provider notes

  • NMUH:
    • Calcichew is available on the Formulary for the management of hyperphosphotaemia in renal patients
  • RFL:
    • No restriction stated
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
09.05.02.02 Calcium carbonate Adcal®

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Non-formulary
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • No restriction stated
09.05.01.01 Calcium Chloride injection 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • No restriction stated
08.01 Calcium Folinate 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • No restriction stated
09.05.01.01 Calcium Gluconate 10% injection 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • No restriction stated
09.05.01.01 Calcium Gluconate effervescent tablets 

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • BCF: No restriction (historical)
    • RFH: Non-formulary
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • Non-formulary
13.02.01 Calmurid® cream Urea 10%

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • No restriction stated
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
A2.04.01.02 Calogen 

Provider notes

  • NMUH:
    • For disease-related malnutrition, malabsorption states or other conditions requiring fortification with a high-fat supplement with or without fluid and electrolyte restrictions Fat supplement without any electrolytes. Used for when protein, fluid or electrolytes restricted. Tolerating low volume of food. Can be used as a “medicinal dose” in combination with another supplement which is providing protein and calories
  • RFL:
    • No restriction stated
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
06.01.02.03 Canagliflozin 

Provider notes

  • NMUH:
    • This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines.
    • See links below
    • Only on the recommendation of the Diabetes Team.
    • Check MHRA Drug Safety Alerts
  • RFL:
    • Restricted to Endocrinology
    • See links below
  • RNOH:
    • Requires initiation by a Diabetes Specialist
    • Check MHRA Drug Safety Updates
  • UCLH:
  • WH:
    • No restriction stated
    • Check MHRA Drug Safety Updates
10.01.04 Canakinumab 

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Restricted to the Amyloidosis centre
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
02.05.05.02 Candesartan 

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • Restricted
  • UCLH:
  • WH:
    • 1st choice A2RA/ARB for heart failure
02.09 Cangrelor 

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Primary percutaneous coronary intervention (PPCI) who are intubated and cannot tolerate oral antiplatelets (JFC October 2017)
  • RNOH:
    • Non-formulary
  • UCLH:
    • Non-formulary
  • WH:
    • Non-formulary
21.02 Cannabidiol oral solution (free of charge) Epidiolex®

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
    • Approved for the reduction of seizures in Dravet Syndrome and Lennox-Gastaut syndrome in patients aged two years or more (UCLH and GOSH only; JFC January 2019).
  • WH:
    • Non-formulary
08.01.03 Capecitabine 

See NICE TA for eligibility criteria

Provider notes

  • NMUH:
    • This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines.
    • Check MHRA Drug Safety Update
  • RFL:
    • This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system).  Additionally for in-patients this drug must be prescribed on an in-patient prescription chart (paper or electronic)
    • See NICE TA and NHSE Commissioning Policy
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
05.01.09 Capreomycin 

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Microbiology/ ID approval only (TB treatment)
  • RNOH:
    • Non-formulary  
  • UCLH:
  • WH:
    • Restricted to TB clinic or as per Microbiology advice
10.03.02 Capsaicin cream  

Provider notes

  • NMUH: 
    • 0.025% NON FORMULARY
    • 0.075% restricted to pain clinic use ONLY
  • RFL: 
    • 0.075% strength kept for neuropathic pain
    • 0.025% is non-formulary
  • RNOH:
    • 0.025% restricted for use in accordance with the NICE guideline for osteoarthritis
    • See link(s) below
    • 0.075% NON FORMULARY
  • UCLH:
  • WH:
    • 0.025% restricted to the Rheumatology team. This strength of capsaicin cream is indicated for osteoarthritis only.
    • 0.075% restricted to pain clinic ONLY
10.03.02 Capsaicin patch 

JFC approved for neuropathic pain (January 2013)

Provider notes

  • NMUH:
    • Non-formulary  
  • RFL:
    • Non-formulary
  • RNOH:
    • Restricted to named Consultants within the Chronic Pain team (Dr Roxy Zarnegar and Dr Tacson Fernandez) ONLY in accordance with DTC approval
  • UCLH:
  • WH:
    • Non-formulary
02.05.05.01 Captopril 

Provider notes

  • NMUH:
    • Only used for test dose
  • RFL:
    • No restriction stated
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • The use of Captopril is reserved for situations where a short- acting preparation is necessary.
04.02.03 Carbamazepine 

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Restricted for initiation until after a discussion with liaison psychiatry team
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
04.07.03 Carbamazepine 

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Provider notes

  • NMUH:
    • See link below
  • RFL:
    • No restriction stated
  • RNOH:
    • Oral liquid available as 100 mg/5mL 
  • UCLH:
  • WH:
    • No restriction stated
04.08.01 Carbamazepine 

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Prescribe by brand when used for epilepsy.

Immediate release and modified release.

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • Oral liquid available as 100 mg/5mL
  • UCLH:
  • WH:
    • No restriction stated
07.01.01 Carbetocin 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Prevention of postpartum haemorrhage due to uterine atony following C-section
06.02.02 Carbimazole 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • No restriction stated
03.07 Carbocisteine 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • Restricted. Capsules available. Oral syrup available as 250 mg/5mL
  • UCLH:
  • WH:
    • Carbocisteine to be initiated by respiratory team only
    • Liquid only available for patients with swallowing difficulties or for enteral feeding tube administration
11.08.01 Carbomers eye gel Viscotears®, GelTears® and others

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • Dry eyes, unstable tear film
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • No restriction stated
08.01.05 Carboplatin 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system)
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
08.01.05 Carboplatin + paclitaxel  

Approved as first-line treatment for advanced squamous cell carcinoma of anus  (JFC March 2019). 

Note: Carboplatin AUC5 day 1 of 28 day cycles + paclitaxel 80 mg/m2 on day 1, day 8 and day 15 of 28 day cycles. 6 cycles (each cycle 28 days) 

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • As above
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
08.01.05 Carboplatin + paclitaxel (CROSS) 

Approved as neo-adjuvant treatment before surgery for adenocarcinoma of the oesophagus or the gastro-oesophageal junction (JFC November 2017)

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • As above
  • RNOH:
    • Non-formulary
  • UCLH:
    • As above
  • WH:
    • Non-formulary
07.01.01 Carboprost 

Provider notes

  • NMUH:
    • Restricted to Obs and Gynae only. 
    • See link below
  • RFL:
    • Restricted to Obs and Gynae only
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • No restriction stated
08.01.05 Carfilzomib 

See NICE TA for eligibility criteria

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • As per NICE TA
    • This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system)
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • As per NICE TA 457
12.03.01 Carmellose and gelatin oramucosal paste Orabase®

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
11.08.01 Carmellose eye drops - single use 

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • No restriction stated
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Restricted to Ophthalmology
01.10 Carvedilol 

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Approved for primary and secondary prevention of variceal bleeding for patients who do not respond to or cannot tolerate propranolol (August 2015)

Provider notes

  • NMUH:
    • See restrictions on use
  • RFL:
    • See restrictions on use
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • See restrictions on use
02.04 Carvedilol 

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • No restriction stated
05.02.04 Caspofungin 

Provider notes

  • NMUH:
    • Microbiology consultant approval only
  • RFL:
    • See Microguide for agreed indications
    • Restricted to Haematology / Oncology as per policy
    • Microbiology approval required for all other indications.
  • RNOH:
    • Microbiology approval only
    • Store in a fridge
  • UCLH:
  • WH:
    • Reserved for prescribing by paediatric consultants only
A5.02.05 Cavi-Care 

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
05.01.02.01 Cefalexin 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • See Microguide for approved indications
    • Microbiology/ID approval required for all other indications
  • RNOH:
    • Oral suspension available as 250 mg/5mL
  • UCLH:
  • WH:
    • No restriction stated
05.01.02.01 Cefazolin 

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Approved for surgical prophylaxis
    • Microbiology/ID approval required for all other indications
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
05.01.02.01 Cefixime 

Provider notes

  • NMUH:
    • Restricted to Consultants in GU Medicine.
  • RFL:
    • Restricted to GUM
    • Microbiology/ID approval required for all other indications
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
05.01.02.01 Cefotaxime 

Provider notes

  • NMUH:
    • Restricted to Microbiology approval only
  • RFL:
    • See Microguide for approved indications. Approved for Neonatal unit
    • Microbiology/ID approval required for all other indications
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • Restricted to Paediatrics and Neonatal use only
05.01.02.01 Ceftazidime 

Provider notes

  • NMUH:
    • Restricted to Microbiology approval only
  • RFL:
    • Microbiology/ID approval only
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • For restricted indications as per Trust guidelines or Microbiology advice
05.01.02.01 Ceftazidime + Avibactam  

Approved for the treatment of infections caused by non-MBL carbapenemase-producing aerobic Gram-negative organisms, that have proven susceptibly to ceftazidime-avibactam and where the only alternative active agents, if any, are limited to colistin, tigecycline and fosfomycin, which cannot be used due to resistance or intolerance - Microbiology recommendation only (JFC August 2017)

Provider notes

  • NMUH:
    • Microbiology approval only
  • RFL:
    • Consultant Microbiology/ID approval only
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Restricted antibiotics. Microbiology approval only
11.03.01 Ceftazidime 5% eye drops 

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Restricted to Opthalmology. Approved for use in bacterial keratitis / ulcers
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Restricted to ophthalmology
05.01.02.01 Ceftolozane + tazobactam 

Approved for multi-resistant Gram-negative organisms that have proven susceptibly to ceftolozane-tazobactam and where the only alternative active agents, if any, are limited to colistin, tigecycline and fosfomycin (JFC September 2016)

Provider notes

  • NMUH:
    • Microbiology recommendation ONLY
  • RFL:
    • Consultant Microbiology/ID approval only
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Restricted antibiotics. Microbiology approval only
05.01.02.01 Ceftriaxone 

Provider notes

  • NMUH:
    • Restricted to use in paediatrics for sepsis and meningitis
  • RFL:
    • See Microguide for agreed indications
    • Microbiology/ID approval required for all other indications
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • For restricted indications as per Trust guidelines or Microbiology advice
05.01.02.01 Cefuroxime 

Provider notes

  • NMUH:
    • Restricted to Microbiology approval only
    • Injection is formulary
    • Tablets are non-formulary
  • RFL:
    • See Microguide for approved indications
    • Microbiology/ID approval required for all other indications
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • Non-formulary
11.03.01 Cefuroxime 5% eye drops 

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Restricted to Opthalmology. Approved for use in bacterial keratitis / ulcers
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Restricted to ophthalmology
11.03.01 Cefuroxime intracameral injection Aprokam®

Approved for prophylaxis post-cataract surgery (June 2013)

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Restricted to Opthalmology
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
10.01.01 Celecoxib 

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • For Rheumatology use only
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
02.14 Celiprolol 

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Approved for vascular Ehlers-Danlos syndrome (JFC April 2016)

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
08.01.05 Cemiplimab infusion 

See NICE TA for eligibility criteria

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • As per TA592
    • This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system)
  • RNOH:
    • Non-formulary
  • UCLH:
    • Non-formulary
  • WH:
    • Non-formulary
08.01.05 Ceritinib 

Provider notes

  • NMUH:
    • This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used  in line with NICE recommendations and/or Local Trust Guidelines. 
    • See link below
  • RFL:
    • As per NICE guidance
    • This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system).  Additionally for in-patients this drug must be prescribed on an in-patient prescription chart (paper or electronic)
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • As per NICE TA
10.01.03 Certolizumab pegol 

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Approved for:

  • Rheumatoid arthritis in line with the NCL RA pathway
  • Ankylosing Spondylitis (see NICE TAs)
  • Psoriatic arthritis (PsA; see NICE TAs)

Provider notes

  • NMUH:
    • This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines (see links below).
    • Restricted to Consultant Rheumatologists
    • See MHRA Drug Safety Update.
    • See links below.
  • RFL:
    • Approved for Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis and non-radiographic axial spondyloarthritis in line with NICE guidance.
  • RNOH:
    • Restricted for Rheumatology Consultants ONLY.
    • See links below.
  • UCLH:
  • WH:
    • As per NICE TA and above
13.05.03 Certolizumab pegol 

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

See NICE TA for eligibility criteria

Provider notes

  • NMUH:
    • This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines. 
    • See links below
  • RFL:
    • As per NICE guidance
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
03.04.01 Cetirizine 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
    • High doses may be used in dermatology
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • No restriction stated
13.02.01.01 Cetraben® bath additive 
  • NOT recommended for dry skin conditions including eczema atopic dermatitis (JFC January 2019)
  • Approved for ichthyosis and epidermolysis bullosa (JFC January 2019)

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Restricted to Dermatology use ONLY
13.02.01 Cetraben® cream 

Cetraben cream, Enopen cream, ExCetra cream, Exmaben cream and Soffen cream all contain Liquid paraffin light 105 mg/g + White soft paraffin 132 mg/g.

Provider notes

  • NMUH:
    • Restricted for prescribing in Paediatrics and by Dermatologists
    • Preferred preparation is Enopen Cream
  • RFL:
    • No restriction stated
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Cream 50g, 500g ONLY
13.09 Cetrimide 10% + Undecenoic acid 1% shampoo Ceanel Concentrate®

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Restricted to dermatology
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
08.01.05 Cetuximab 

See NICE TA for eligibility criteria

Provider notes

  • NMUH:
    • This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines.
    • Check MHRA Drug Safety Updates
    • See links below
  • RFL:
    • As per NICE guidance
    • This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system)
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
04.01.01 Chloral Hydrate 

Provider notes

  • NMUH:
    • Chloral Mixture, BP 2000, 500mg/5mL (Unlicensed)
  • RFL:
    • No restriction stated
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Restricted to Paediatrics only
    • Chloral hydrate suppositories 25mg & 100mg available
  • CIFT:
    • Non-formulary
  • BEHMT:
    • Non-formulary
08.01.01 Chlorambucil 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
    • This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system). Additionally for in-patients this drug must be prescribed on an in-patient prescription chart (paper or electronic)
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
05.01.07 Chloramphenicol 

Provider notes

  • NMUH:
    • Chloramphenicol capsules are non-formulary
    • To be used as per the Trust guidelines for Management of Acute Bacterial Meningitis 
  • RFL:
    • As per agreed indications on microguide
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • Microbiology approval only
11.03.01 Chloramphenicol 0.5% eye drops - Single use drops 

 Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
11.03.01 Chloramphenicol 0.5% eye drops, 1% eye ointment 

 Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • Eye drops 0.5% preservative free 10mL (Moorfields special) also available
12.01.01 Chloramphenicol 5% ear drops 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • No restriction stated
04.01.02 Chlordiazepoxide 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • Restricted to in-patient use for alcohol detoxification and anxiety.
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • No restriction stated
  • CIFT:
    • Approved for
      • Anxiolytic
      • Alcohol withdrawal
      • Acute phase of mania (off-label)
  • BEHMT:
    • Approved for  
      • Anxiolytic
      • Alcohol withdrawal
11.03.01 Chlorhexidine 

Provider notes

  • RFL:
    • Chlorhexidine Digluconate 0.02% eye drops (preservative free)
    • Restricted to Opthalmology for use in acanthamoeba keratitis and as an antiseptic in povidone iodine allergy
13.11.02 Chlorhexidine + Alcohol wipes Clinell Alcoholic 2% Chlorhexidine Wipes®

Provider notes

  • NMUH:
    • This product is available as individual sachets of 105x105mm in size and comes in boxes of 200.
    • Uses:
      1. Skin antisepsis prior to insertion of peripheral cannulae, or taking blood cultures.
      2. Skin antisepsis prior to taking blood cultures.
      3. Line care: Disinfection of catheter hubs/ports of all IV lines prior to access.
      4. Post insertion line care  (ChloraPrep to be used for skin antisepsis prior to insertion of central line cannulae)
  • RFL:
    • No restriction stated
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
13.11.02 Chlorhexidine 0.015% + Cetrimide 0.15% skin cleaner Tisept®

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • No restriction stated
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
12.02.03 Chlorhexidine 0.1% + Neomycin 0.5% cream Naseptin®

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • MRSA decolonisation procedure - see Microguide
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • No restriction stated
12.03.04 Chlorhexidine 0.2% mouthwash 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • MRSA screening procedure
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • No restriction stated
12.03.04 Chlorhexidine 0.2% oral spray 

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • No restriction stated
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Restricted to community clinic only
12.03.04 Chlorhexidine 1% dental gel 

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • No restriction stated
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
07.04.04 Chlorhexidine acetate 0.02% catheter maintenance solution 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
13.11.02 Chlorhexidine skin cleaners 

Provider notes

  • NMUH:
    • The following products are available:
      • ChloraPrep®, Hibiscrub® (see link below for MRSA eradication protocol), Hibitane Obstetric® (restricted to obstetrics), Hydrex®, Unisept®
  • RFL:
    • The following products are avaialble:
      • ChloraPrep®, Hibiscrub®, Hibitane Obstetric®, Hydrex®, Unisept®
  • RNOH:
    • Available products:
      • ChloraPrep®, Hibiscrub®
  • UCLH:
  • WH:
    • Available products:
      • Chlorhexidine 0.05%CX Antiseptic Dusting Powder®, Hibiscrub®, Hibitane Obstetric®, Hydrex®
12.01.03 Chlorobutanol 5% + Arachis (peanut) oil ear drops Cerumol®

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
15.02 Chloroprocaine 

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
05.04.01 Chloroquine 

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Provider notes

  • NMUH:
    • To be used as per the NMUHT Malaria Guidelines, see links below
  • RFL:
    • No restriction stated
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
10.01.03 Chloroquine 

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
02.14 Chlorothiazide 

Provider notes

  • NMUH:
    • For the treatment of chronic hypoglycaemia, heart failure, hypertension and ascites, in children.
    • See the BNF for children for further prescribing information.
    • Chlorothiazide suspension 250mg/5ml, available from ‘special-order’ manufacturers or specialist importing companies
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Chlorothiazide Suspension 250 mg/5 ml (unlicensed product)
03.04.01 Chlorphenamine 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • Tablets and injection available, Oral syrup available as 2 mg/5mL
  • UCLH:
  • WH:
    • No restriction stated
04.02.01 Chlorpromazine 

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • Restricted for initiation until after a discussion with liaison psychiatry team.
    • Suppositories are not stocked
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Tabs 25 mg, 50 mg, 100 mg. Syrup 25 mg/5ml, 100 mg/5 ml. Injection 50 mg/2ml. Only
04.06 Chlorpromazine 

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Provider notes

  • NMUH:
    • No restriction stated  
  • RFL:
    • Tablets, oral solution and injection: No restriction stated
    • Suppository: Non-formulary
  • RNOH:
    • Oral solution available as 25 mg/5mL
  • UCLH:
  • WH:
    • No restriction stated
12.03.01 Choline Salicylate 8.7% oral gel Bonjela® Adult, Teejel®

Provider notes

  • NMUH:
    • Teejel stocked
  • RFL:
    • No restriction stated
  • RNOH:
    • For patients 16 years and above
  • UCLH:
  • WH:
    • No restriction stated
06.05.01 Chorionic Gonadotrophin Choragon®, Pregnyl®

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • Restricted to Endocrinology
    • Emergency use of Gonasi® (unlicensed) whilst Pregnyl® and Choragon® are unavailable, but new starters must be referred to tertiary care centres
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
03.02 Ciclesonide inhaler (pMDI) Alvesco®

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • No restriction stated
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
01.05.03 Ciclosporin 

NOTE: There is more than one monograph for Ciclosporin, click here to search for formulary status and its use for other indications. 

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:

    • Ciclosporin is restricted to Consultant Gastroenterologists only
    • FBC, LFT & drug level monitoring required
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:

    • Ciclosporin is restricted to Consultant Gastroenterologists only
    • FBC, LFT & drug level monitoring required
08.02.02 Ciclosporin Deximune®

GP-RedRed (hospital only prescribing) for renal transplant

Grey for other transplants

NOTE: There is more than one monograph for Ciclosporin, click here to search for formulary status and its use for other indications. 

 

Provider notes

  • NMUH:

    • No restriction stated
  • RFL:

    • Liver transplant: Preferred brand for new patients
    • Renal transplant: Not for new patients
    • Transplant patients must be maintained on the same brand
  • RNOH:

    • Non-formulary
  • UCLH:
  • WH:

    • Non-formulary
08.02.02 Ciclosporin Capsorin®

GP-RedRed (hospital only prescribing) for renal transplant

Grey for other transplants

NOTE: There is more than one monograph for Ciclosporin, click here to search for formulary status and its use for other indications. 

 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
08.02.02 Ciclosporin Neoral®

GP-RedRed (hospital only prescribing) for renal transplant

Grey for other transplants

NOTE: There is more than one monograph for Ciclosporin, click here to search for formulary status and its use for other indications. 

 

Provider notes

  • NMUH:

    • Restricted to Consultant use only.
  • RFL:

    • Liver transplant: Not for new patients unless liquid formulation required
    • Renal transplant: Preferred brand for renal transplant
    • Transplant patients must be maintained on the same brand
  • RNOH:

    • Non-formulary
  • UCLH:
  • WH:

    • Non-formulary
08.02.02 Ciclosporin Capimune®

GP-RedRed (hospital only prescribing) for renal transplant

Grey for other transplants

NOTE: There is more than one monograph for Ciclosporin, click here to search for formulary status and its use for other indications. 

 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
08.02.02 Ciclosporin Sandimmun®

GP-RedRed (hospital only prescribing) for renal transplant

Grey for other transplants

NOTE: There is more than one monograph for Ciclosporin, click here to search for formulary status and its use for other indications. 

 

Provider notes

  • NMUH:

    • No restriction stated
  • RFL:

    • Liver transplant: Not for new patients
    • Renal transplant: Not for new patients
    • Transplant patients must be maintained on the same brand
  • RNOH:

    • Non-formulary
  • UCLH:
  • WH:

    • Non-formulary
10.01.03 Ciclosporin 

NOTE: There is more than one monograph for Ciclosporin, click here to search for formulary status and its use for other indications. 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • Deximune® is the preferred brand
  • RNOH:
    • Restricted to Rheumatology Consultants ONLY
    • See links below
  • UCLH:
  • WH:
    • No restriction stated
13.05.03 Ciclosporin 

NOTE: There is more than one monograph for Ciclosporin, click here to search for formulary status and its use for other indications. 

Approved for:

  • chronic refractory idiopathic urticaria (JFC - January 2015)
  • severe atopic dermatitis (DMARD fact sheet)
  • severe psoriasis (DMARD fact sheet)

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • Preferred brand is Deximune
    • No restriction stated
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
11.99.99.99 Ciclosporin 0.06% eye drops 

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Severe allergic eyes disease, severe dry eyes, corneal erosions
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
11.99.99.99 Ciclosporin 0.1% eye drops Ikervis®

Approved for ocular inflammatory conditions. See NCL fact sheet. 

Provider notes

  • NMUH:
    • This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines.
    • To be prescribed Consultant Ophthamologist ONLY
    • See links below
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
    • For initiation by corneal specialists only
  • WH:
    • Restricted to ophthalmology
11.99.99.99 Ciclosporin 0.2% eye ointment 

Approved for ocular inflammatory conditions. See NCL fact sheet. 

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Severe allergic eyes disease, severe dry eyes, corneal erosions
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
11.99.99.99 Ciclosporin 2% eye drops 

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Severe allergic eyes disease, severe dry eyes, corneal erosions
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
13.07 Cidofovir in Unguentum M 

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Restricted to Dermatology and HIV team only for treatment-resistant herpes
    • Prior funding approval required before dispensing.
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
05.03.02.02 Cidofovir infusion 

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • HIV/Virology approval required
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
01.03.01 Cimetidine 

 Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Alternative to ranitidine. Tabs 200 mg, 400 mg.
09.05.01.02 Cinacalcet 

Approved for complex primary hyperparathyroidism in adults in line with NHSE clinical commissioning policy (JFC April 2018)

Provider notes

  • NMUH:
    • This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines.
    • For continuation of supply for those renal patients that have been initiated on treatment by Royal Free Hospital.
    • Formulary for treatment of Hypercalcaemia of primary hyperparathyroidism or parathyroid carcinoma - see link below
  • RFL:
    • Restricted to ‘cinacalcet gatekeeper’ approval only for secondary hyperparathyroidism – see NICE TA.
    • Restricted to endocrinology for complex primary hyperparathyroidism – see NHSE commissioning policy
  • RNOH:
    • Non-formulary
  • WH:
    • For primary hyperparathyroidism in line with NHSE policy 16034/P
    • For secondary hyperparathyroidism in line with NICE TA 117
04.06 Cinnarizine 

 Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
02.12 Ciprofibrate 

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Restricted to Lipid Clinic
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
05.01.12 Ciprofloxacin 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • See microguide for agreed indications
    • Microbiology approval required for all other indications
  • RNOH:
    • Oral suspension available as 250 mg/5mL
  • UCLH:
  • WH:
    • For restricted indications as per Trust guidelines or Microbiology advice
11.03.01 Ciprofloxacin 0.3% eye drops/ointment 

 Provider notes

  • NMUH:
    • Restricted to Ophthalmology department use ONLY.
  • RFL:
    • Restricted to Opthalmology
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
15.01.05 Cisatracurium 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • The use of cisatracurium is restricted to theatres only.
08.01.05 Cisplatin 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
    • This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system)
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
04.03.03 Citalopram 

Provider notes

  • NMUH:
    • See links below
    • Check MHRA Drug Safety Updates
  • RFL:
    • No restriction stated
  • RNOH:
    • Tablets available. Oral drops available as 40 mg/mL
  • UCLH:
  • WH:
    • No restriction stated
  • CIFT:
    • Approved for
      • Depression
      • Generalized Anxiety Disorder (GAD) and panic disorder - 1st/2nd line
      • Social Anxiety Disorder (SAD) - 1st/2nd line
  • BEHMT:
    • Approved for
      • Depression
      • Panic disorder 
08.01.03 Cladribine injection 

Provider notes

  • NMUH:
    • To be prescribed by the Haematology Team ONLY.
    • Refer to BCSH Guidelines on Hairy Cell Leukaemia
  • RFL:
    • No restriction stated
    • This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system)
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
08.02.04 Cladribine tablets Mavenclad®

See NICE TA for eligibility criteria

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • As per NICE TA
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
05.01.05 Clarithromycin 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • Microbiologist approval only
    • Oral suspension available as 250 mg/5mL
  • UCLH:
  • WH:
    • No restriction stated
05.01.06 Clindamycin 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • As per RFL policy on microguide
    • Microbiology approval required for all other indications
    • Used for prophylaxis and treatment of Mycobacterium avium intracellulare in HIV
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • Microbiology approval only
13.06.01 Clindamycin 1% topical solution Dalacin T®

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • Restricted to Dermatology only
  • RNOH:
    • Restricted
  • UCLH:
  • WH:
    • Non-formulary
07.02.02 Clindamycin 2% vaginal cream Dalacin®

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
04.08.01 Clobazam 

Provider notes

  • NMUH:
    • Clobazam oral suspension is non-formulary
  • RFL:
    • Blacklist restriction except in epilepsy
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • Should only be commenced on the recommendation of a Neurologist
13.04 Clobetasol propionate 0.05% - Topical 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • Cream, Ointment and Scalp application (lotion) available
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • No restriction stated
13.04 Clobetasol propionate 0.05% + Neomycin + Nystatin - Topical 

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Cream and ointment available
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
13.04 Clobetasol propionate 0.05% shampoo Etrivex®

Provider notes

  • NMUH:
    • For use SECOND LINE in topical treatment of MODERATE SCALP PSORIASIS in adults who have failed treatment with Dermovate 0.05% Scalp Application.
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
13.14 Clobetasol propionate 1 in 4 in White Soft Paraffin 

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Restricted to dermatology, as per Special BAD list
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Clobetasol propionate 1 in 4 in White Soft Paraffin 100 g (unlicensed product)
13.04 Clobetasone butyrate 0.05% - Topical Eumovate®

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • No restriction stated
13.04 Clobetasone butyrate 0.05% + Oxytetracyline 3% + Nystatin - Topical Trimovate®

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • No restriction stated
  • UCLH:
    • Approved for Pruritus ani; Dermatitis - seborrhoeic - infected; Nappy rash; Infected intertrigo; Eczema - infected
  • WH:
    • No restriction stated
05.01.10 Clofazimine 

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Microbiology/ID approval only
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Microbiology approval only
04.01.01 Clomethiazole 

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • No restriction stated (capsules only)
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
  • CIFT:
    • Non-formulary
  • BEHMT:
    • Non-formulary
06.05.01 Clomifene 

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

GP-Red Red (hospital only prescribing) if used for IVF

GP-Grey Red for other indications

 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
04.03.01 Clomipramine Antidepressant

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
  • CIFT:
    • Approved for depression 
  • BEHMT:
    • Approved for depression 
04.02.03 Clonazepam 

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Restricted for initiation until after a discussion with liaison psychiatry team
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • Non-formulary
  • CIFT:
    • Approved for
      • Anxiety (off-label)
      • Acute phase of mania (off-label)
  • BEHMT:
    • Approved for 
      • Anxiety (off-label)
      • Mania (off-label)
04.07.03 Clonazepam 

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • No restriction stated
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Specialist use only
04.08.01 Clonazepam 

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • Suspension 2 mg/5ml. Suspension should not be administered via PEG tubes as it is incompatible with the polystyrene fittings
02.05.02 Clonidine 

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • Only 25 microgram tablets and the injection kept at the RFH
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • No restriction stated
04.07.04.02 Clonidine 

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
04.14 Clonidine 

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Provider notes

  • NMUH:Non-formulary
  • RFL:
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
02.09 Clopidogrel 

See NICE TA for eligibility

Provider notes

  • NMUH:
    • To be prescribed as per NICE guidelines - see links below for further details
  • RFL:
    • To be prescribed in line with NICE
    • See NCL summary for information on preferred choices for specific indications
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • No restriction stated
07.02.02 Clotrimazole 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • Only 1% cream, 200mg Pessaries and 500mg Pessaries stocked
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • Pessaries available as 200 mg & 500 mg
13.10.02 Clotrimazole 1% - Topical 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • Cream 1% only
  • UCLH:
  • WH:
    • Cream 1% 20g, Solution 1% 20mL and Dusting Powder 1% 30g ONLY
12.01.01 Clotrimazole 1% ear drops 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
11.03.02 Clotrimazole 1% eye drops 

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Restricted approved for use in fungal infections
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
04.02.01 Clozapine Clozaril®

Provider notes

  • NMUH:
    • Restricted to Consultant Psychiatrist use only
    • Monitoring required
    • See links below
  • RFL:
    • Restricted for initiation until after a discussion with liaison psychiatry team
    • If a patient is admitted on this therapy please ensure that the pharmacy mental health team are aware.
    • Patients being treated in the UK will be registered with CPMS (Clozaril Patient Monitoring Service)
    • See links below
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Restricted for initiation by a Consultant Psychiatrist only
21.01 Co‐careldopa 

Rotigotine or co‐careldopa for Hemispatial neglect that is interfering with progress of neurorehabilitation - UCLH only
Approval was subject to Dr Swayne working with Dr Sofat and JFC support to agree the datacollection form and the duration of the pilot study. Duration of audit TBC (November 2016).

13.09 Coal tar 1% + Coconut oil 1% + Salicylic acid 0.5% shampoo Capasal®

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • Restricted to dermatology patients only
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
13.05.02 Coal tar 12% + Salicylic acid 2% + Precipitated sulfur 4% scalp ointment Cocois®

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
13.05.02 Coal tar 12% + Salicylic acid 2% + Precipitated sulfur 4% scalp ointment Sebco®

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • No restriction stated
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
13.05.02 Coal tar and salicylic acid ointment, BP 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • There are non-proprietary preparations available at the Royal Free Hospital but not listed in the eBNF, contact Pharmacy for details.
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
13.09 Coal tar extract 5% alcoholic shampoo Alphosyl 2 in 1®

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • Restricted to Dermatology only
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
13.14 Coal tar in Betamethasone ointment 

Provider notes

  • NMUH:
    • To be prescribed by Consultant Dermatologists for the treatment of Psoriasis.
    • Coal Tar 10% in Betamethasone 0.025%; Ointment Coal Tar 5% in Betamethasone 0.025% Ointment
    • The above preparations are available from ‘special-order’ manufacturers or specialist importing companies
  • RFL:
    • Restricted to dermatology. As per specials list.
      • 5% coal tar in 0.25% betamethasone ointment
      • 10% coal tar in 0.25% betamethasone ointment
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
13.05.02 Coal tar lotion 5% Exorex®

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Restricted to dermatology
    • Lotion (cutaneous emulsion) and Shampoo available
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
02.02.04 Co-amilofruse  

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • No restriction stated
02.02.04 Co-amilozide 

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Non-formulary
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • Non-formulary
05.01.01.03 Co-Amoxiclav 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • Oral suspension available as 125/31.25 mg/5mL and 250/62.5 mg/5mL
  • UCLH:
  • WH:
    • No restriction stated
04.09.01 Co-Beneldopa immediate release 

Provider notes

  • NMUH:
    • Use only on the recommendation of consultant neurologists and Dr Woothipoom in accordance with the NCL JFC Parkinson's Disease Pathway (see below)
  • RFL:
    • No restriction stated
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • No restriction stated
04.09.01 Co-Beneldopa modified release 

Provider notes

  • NMUH:
    • Use only on the recommendation of consultant neurologists and Dr Woothipoom in accordance with the NCL JFC Parkinson's Disease Pathway (see below)
  • RFL:
    • No restriction stated
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • No restriction stated
05.03.01 Cobicistat 

Second line protease inhibitor booster for HIV for confirmed ritonavir intolerance (March 2016)

Provider notes

  • NMUH:
    • To be initiated by Consultants in HIV Medicine only
    • See MHRA Drug Safety Updates
  • RFL:
    • HIV medicine only
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
11.07 Cocaine 10% eye drops 

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Ophthalmology surgery only
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
11.07 Cocaine 4% eye drops 

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • This is an unlicensed special and restricted to Ophthalmology
    • This is a controlled drug
15.02 Cocaine oromucosal solution 

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • 5% and 10% mouthwash available
  • RNOH:
    • Restricted - 10% available
  • UCLH:
    • Non-formulary
  • WH:
    • Non-formulary
04.09.01 Co-Careldopa + Entacapone 

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • No restriction stated
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
04.09.01 Co-Careldopa immediate release 

Provider notes

  • NMUH:
    • Use only on the recommendation of consultant neurologists and Dr Woothipoom in accordance with the NCL JFC Parkinson's Disease Pathway (see below)
  • RFL:
    • No restriction stated
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • No restriction stated
04.09.01 Co-Careldopa intestinal gel Duodopa®

Approved for Parkinson's disease in line with NHSE clinical commissioning policy D04/P/e (JFC November 2019).

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Restricted to neurology only; prior funding approval required
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
04.09.01 Co-Careldopa modified release 

Provider notes

  • NMUH:
    • Use only on the recommendation of consultant neurologists and Dr Woothipoom in accordance with the NCL JFC Parkinson's Disease Pathway (see below)
  • RFL:
    • No restriction stated
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • No restriction stated
04.07.01 Co-codamol 30/500 Paracetamol + Codeine

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • Non-formulary
04.07.01 Co-codamol 8/500 Paracetamol + Codeine

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • No restriction stated
13.06.02 Co-Cyprindiol 2000/35 (cyproterone 2mg / ethinylestradiol 35micrograms) Dianette®

Provider notes

  • NMUH:
    • Check MHRA Drug Safety Updates
  • RFL:
    • No restriction stated
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
01.06.02 Co-danthramer 

Provider notes

  • NMUH:
    • Restricted to terminally ill patients only
  • RFL:
    • Restricted to oncologist and geriatricians
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • Because of a potential carcinogenic risk, danthron containing laxatives are indicated only for constipation in the terminally ill. Co-danthramer may cause irritation and excoriation in incontinent patients and may colour the urine red. Please note: Capsules not available. Suspension only.
01.06.02 Co-danthrusate 

Provider notes

  • NMUH:
    • Restricted to terminally ill patients only
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
    • Non-formulary 
  • WH:
    • Non-formulary
01.04.02 Codeine 

NOTE: There is more than one monograph for codeine, click here to search for formulary status and its use for other indications. 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • No restriction stated
04.07.02 Codeine 

NOTE: There is more than one monograph for codeine, click here to search for formulary status and its use for other indications. 

Provider notes

  • NMUH:
    • Check MHRA Drug Safety Updates
  • RFL:
    • No restriction stated
  • RNOH:
    • Restricted for patients admitted on codeine, requiring further supply.
    • Oral solution available as 15 mg/5mL
  • UCLH:
  • WH:
    • No restriction stated
03.09.01 Codeine Linctus BP 

NOTE: There is more than one monograph for codeine, click here to search for formulary status and its use for other indications. 

Provider notes

  • NMUH:
    • Check for MHRA Drug Safety Updates
  • RFL:
    • No restriction stated
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • No restriction stated
04.07.01 Co-dydramol 10/500 Paracetamol + Dihydrocodeine

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
10.01.04 Colchicine 

Provider notes

  • NMUH:
    • See link(s) below
  • RFL:
    • No restriction stated
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • No restriction stated
12.04 Colchicine  

Approved for oral mucosal inflammatory disease in particular ‘Recurrent apthous stomatitis (RAS)’ and ‘Oral ulceration in Behcet’s disease’ (JFC April 2018).

Additional information: Transfer of care to GPs after stabilisation in secondary care. Monitoring requirements to be communicated to the GP via letter. Monitoring requirements are FBC, U&E and LFTs at 3 months, 6 months and then annually, CK only if myalgia.

Provider notes

  • NMUH:
    • As above. Unlicensed form must be completed prior to use.
  • RFL:
    • Approved for Behcet's (see Bart's protocol)
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • As above
09.06.04 Colecalciferol + Calcium carbonate Adcal-D3®

Provider notes

  • NMUH:
    • See links below
  • RFL:
    • No restriction stated
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • No restriction stated
09.06.04 Colecalciferol caps/liquid 

Provider notes

  • NMUH:
    • See links below
  • RFL:
    • No restriction stated
  • RNOH:
    • Oral liquid available as 3000 units/mL
  • UCLH:
  • WH:
    • No restriction stated
02.12 Colesevelam Cholestagel®

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Non-formulary for hypercholesterolaemia 
    • Available for partial biliary obstruction, primary biliary cirrhosis and diarrhoea if colestyramine and colestipol is unavailable (off-label)
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • Non-formulary
02.12 Colestipol Colestid®

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Restricted to Lipid clinic for hypercholesterolaemia 
    • Restricted to Hepatology / Gastroenterology for partial biliary obstruction, primary biliary cirrhosis and diarrhoea if colestyramine is unavailable (off-label)
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
01.09.02 Colestyramine 

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • Sugar-free formulations preferred
    • Current shortage - colestipol is the recommended alternative
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • No restriction stated
02.12 Colestyramine 

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • Sugar-free formulation preferred
    • Restricted to Lipid Clinid for hypercholesterolaemia 
    • Current shortage - colestipol is the recommended alternative
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
05.01.07 Colistimethate for nebulisation 

Provider notes

  • NMUH:
    • Microbiology recommendation only
  • RFL:
    • Consultant Microbiology/ID approval only
  • RNOH:
    • Microbiologist approval only
  • UCLH:
  • WH:
    • Check with Microbiology
05.01.07 Colistimethate injection 

Provider notes

  • NMUH:
    • Microbiology recommendation only
  • RFL:
    • Consultant Microbiology/ID approval only
  •  RNOH:
    • Microbiologist approval only
  • UCLH:
  • WH:
    • Check with Microbiology
13.10.05 Collodion Flexible BP 

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • No restriction stated
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
01.01.01 Co-magaldrox 

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Only Mucogel kept
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • Suspension (Maalox) containing magnesium hydroxide 195mg, dried aluminium hydroxide 220mg/5ml. Na+ content 0.24mmol/5ml
09.02.02.01 Compound Sodium Lactate (Hartmann's) Intravenous Infusion 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • 500 mL and 1000 mL
  • UCLH:
  • WH:
    • No restriction stated
03.04.03 Conestat Alfa 

Approved for prophylaxis and treatment of hereditary angioedema in line with NHS Commissioning Policies (JFC October 2018)

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • For hereditary angioedema in line with NHSE comissioning policy
    • Restricted to immunology
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
06.04.01.01 Conjugated oestrogen Premarin®

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated (0.625mg and 1.25mg only)
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
06.04.01.01 Conjugated oestrogen with Medroxyprogesterone Premique®

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Tabs containing conjugated oestrogens 625 micrograms and medroxyprogesterone acetate 5 mg ONLY
01.04.02 Co-Phenotrope 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
02.04 Co-tenidone 

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • No restriction stated
  • RNOH:
    • Non-formulary
  • UCLH:
    • Non-formulary
  • WH:
    • Non-formulary
05.01.08 Co-trimoxazole 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • See Microguide for agreed indications
    • Approved for treatment and prevention of PCP infection; see Chemotherapy protocols
    • Microbiology or ID approval required for other indications
  • RNOH:
    • Oral suspension available as 40/200 mg/5mL and 80/400 mg/5mL
  • UCLH:
  • WH:
    • Microbiology approval only
A2.03.01 Cow and Gate Pepti-Junior 

Provider notes

  • NMUH:
    • Suitable for infants from birth for:
      • protracted diarrhoea
      • food intolerance
      • short bowel
      • cystic fibrosis
      • inflammatory bowel disease
      • malnutrition
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
08.01.05 Crisantaspase 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
08.01.05 Crizotinib 

See NICE TA for eligibility criteria

Provider notes

  • NMUH:
    • This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines.
    • See links below
    • Check MHRA drug safety alerts
    • See London Cancer Guidelines for the Treatment of Lung Cancer
  • RFL:
    • As per NICE TA
    • This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system).  Additonally for in-patients this drug must be prescribed on an in-patient prescription chart (paper or electronic)
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
13.03 Crotamiton 10% cream Eurax®

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • Non-formulary
09.01.02 Cyanocobalamin 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • Non-formulary
04.06 Cyclizine 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • No restriction stated
  • UCLH:
    • Tablets approved for:
      • Nausea
      • Vomiting
      • Labyrinthine disorders
      • Motion sickness
      • Vertigo
      • Prevention/treatment of post-operative nausea and vomiting
      • Nausea or vomiting associated with radiotherapy
      • Nausea and vomiting associated with narcotic analgesics
    • Injection approved for:
      • Nausea
      • Vomiting
      • Labyrinthine disorders
      • Motion sickness
      • Vertigo
      • Prevention/treatment of post-operative nausea and vomiting
      • Pre-op. emergency surgery: Reduce regurgitation/aspiration gastric contents
      • Nausea or vomiting associated with radiotherapy
      • Nausea and vomiting associated with narcotic analgesics
  • WH:
    • No restriction stated
11.05 Cyclopentolate eye drops 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • Mydriasis and cycloplegia
  • RNOH:
  • UCLH:
  • WH:
    • No restriction stated
11.05 Cyclopentolate eye drops - single use 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • Mydriasis and cycloplegia
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
08.01.01 Cyclophosphamide 

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
    • This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system). Additionally for in-patients this drug must be prescribed on an in-patient prescription chart (paper or electronic)
    • For immune system disorders refer to local protocols
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
10.01.03 Cyclophosphamide 

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Approved for use in Scleroderma (lung fibrosis), Vasculitis, SLE and Sarcoid
  • RNOH:
    • Non-formulary
  • UCLH:
    • Non-formulary
  • WH:
    • Non-formulary
05.01.09 Cycloserine 

Provider notes

  • NMUH:
    • Restricted for the use in combination with other drugs for Tuberculosis resistant to first line drugs only
  • RFL:
    • Microbiology/ ID approval only
  • RNOH:
    • Non-formulary  
  • UCLH:
  • WH:
    • Restricted to TB clinic or as per Microbiology advice
03.04.01 Cyproheptadine 

Provider notes

  • NMUH:
    • Stocked in the Emergency Drug Cupboard ONLY as an antidote for serotonin syndrome.
  • RFL:
    • No restriction stated
    • Approved for cold urticaria - Dermatology use only
    • Approved for carcinoid (NET) diarrhoea
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
06.04.02 Cyproterone 

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • Restricted to Endocrinology
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • In view of hepatotoxicity associated with long-term daily doses of 300 mg daily, the CSM recommend the use of cyproterone in prostatic cancer should be restricted to:
      • Short courses to cover testosterone flare associated with LHRH agonists.
      • Treatment of hot flushes after orchidectomy or LHRH agonists.
      • Patients who do not respond to, or are intolerant of other treatments.
    • Tabs 50 mg, 100 mg
08.03.04.02 Cyproterone 

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
08.01.03 Cytarabine 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
    • This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system)
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
02.08.02 Dabigatran 

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

See NICE TA for eligibity criteria

Provider notes

  • NMUH:
    • Positive NICE TA This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines.
    • Restricted for thromboprophylaxis post elective total hip or knee replacement surgery and emergency hip fracture surgery, as per Trust guidelines.
    • See links below
    • Check MHRA Drug Safety Updates
    • A referral form must be completed by Authorised Teams/ Haematology team to initiate a DOAC
    • A GP notification form must be completed and faxed to the GP for each patient newly started on a DOAC
    • A copy of the above forms (referral form and GP notification form) must be sent to the anticoagulant clinic
  • RFL:
    • As per NICE guidance
    • Follow NCL DOAC prescribing guide
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Restricted for use as thromboprophylaxis after elective hip and knee surgery
08.01.05 Dabrafenib caps 

See NICE TA for eligibility criteria

Provider notes

  • NMUH:
    • This medicine has a positive NICE Technology Appraisal but is not listed in the Trust Medicines Formulary as the service is not offered at NMUH.
  • RFL:
    • As per NICE guidance
    • This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system).  Additionally for in-patients this drug must be prescribed on an in-patient prescription chart (paper or electronic)
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
08.01.05 Dacarbazine 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
    • This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system)
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
08.01.05 Dacomitinib tabs 

See NICE TA for eligibility criteria

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • As per TA595
    • This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system)
  • RNOH:
    • Non-formulary
  • UCLH:
    • Non-formulary
  • WH:
    • Non-formulary
08.01.02 Dactinomycin 

Not approved for Relapsed/refractory acute myeloid leukaemia (AML) (JFC October 2016)

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
05.01.07 Dalbavancin infusion 

Approved if recommended by Microbiology for skin and soft tissue infections in patients only if (JFC April 2017):

  • unable to receive oral therapy and
  • available treatment pathways for repeated IV antibiotics are unsuitable e.g. chaotic lifestyle, immobility, poor venous access

Provider notes

  • NMUH:
    • On microbiology recommendation only
  • RFL:
    • Restricted to Microbiology Consultant only
  • RNOH:
    • Non-formulary
  • UCLH:
    • Skin and soft tissue infections in patients unable to receive oral therapy- Restricted to Microbiology recommendation (JFC April 2017)
  • WH:
    • As above (restricted to Microbiology)
02.08.01 Danaparoid 

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • As per local protocol only
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
03.04.03 Danazol 

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Approved for prophylaxis of C1 esterase inhibitor deficiency and other bradykinin-mediated angioedema (JFC October 2018).

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • As per JFC recommendations. Restricted to immunology
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
06.07.02 Danazol 

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
10.02.02 Dantrolene sodium 

Provider notes

  • NMUH:
    • Check MHRA Drug Safety Update
  • RFL:
    • No restriction stated
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • No restriction stated
15.01.08 Dantrolene sodium injection 

Provider notes

  • NMUH:
    • Check MHRA Drug Safety Update
  • RFL:
    • Stock kept in theatres on Malignant Hyperthermia trolley
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Dantrolene Injection is kept in the following locations: Main Theatres, Obstetrics Theatre
06.01.02.03 Dapagliflozin 

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Provider notes

  • NMUH:
    • This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines.
    • See links below
    • Only on the recommendation of the Diabetes Team.
    • Check MHRA Drug Safety Alerts
  • RFL:
    • Restricted to Endocrinology
    • See links below
  • RNOH:
    • Requires initiation by a Diabetes Specialist
    • Check MHRA Drug Safety Updates
  • UCLH:
  • WH:
    • No restriction stated
    • Check MHRA Drug Safety Updates
06.01.02.03 Dapagliflozin 

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

See NICE TA for eligibility criteria

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
    • Non-formulary
  • WH:
    • As above
05.01.10 Dapsone 

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • Microbiology/ID approval only
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
12.04 Dapsone 

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Approved for oral mucosal inflammatory conditions: mucous membrane pemphigoid (MMP), recurrent aphthous stomatitis (RAS) and linear IgA bullous dermatosis (JFC April 2018)

Additional information: Transfer of care to GPs after stabilisation in secondary care. Monitoring requirements to be communicated to the GP via letter. Monitoring requirements are FBC and reticulocyte count weekly for four weeks, monthly for 6 months, then every 3 months thereafter. LFTs should be monitored monthly for 3 months, then every 3 months thereafter for duration of therapy.

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Approved for Behcet's (see Bart's protocol)
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • As above
05.01.07 Daptomycin 

Store in a refrigerator

Provider notes

  • NMUH:
    • Consultant Microbiologist approval only
  • RFL:
    • Microbiology/ID approval only
  • RNOH:
    • Microbiology approval only
  • UCLH:
  • WH:
    • Microbiology approval only
08.02.04 Daratumumab injection 

See NICE TA for eligibility criteria

Provider notes

  • NMUH:
    • This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines. 
    • See links below
  • RFL:
    • As per NICE TA
    • This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system)
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • As per NICE TA
09.01.03 Darbepoetin alfa Aranesp®

Provider notes

  • NMUH:
    • For continuation of supply for those renal patients that have been initiated on treatment by Royal Free Hospital.
  • RFL:
    • Restricted to Renal team – preferred brand of erythropoietin
    • Restricted to Haematology for MDS
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • As per NICE TA 323
05.03.01 Darunavir 

Provider notes

  • NMUH:
    • To be prescribed as per BHIVA Guidelines by the HIV team only
  • RFL:
    • HIV medicine only
  • RNOH:
    • Non-formulary  
  • UCLH:
  • WH:
    • For TB / HIV clinic only
05.03.01 Darunavir + Cobicistat Rezolsta®

Provider notes

  • NMUH:
    • To be initiated by Consultants in HIV Medicine only
  • RFL:
    • HIV medicine only
  • RNOH:
    • Non-formulary  
  • UCLH:
  • WH:
    • Non-formulary
05.03.01 Darunavir + Cobicistat + Emtricitabine + Tenofovir alafenamide Symtuza®

Approved for HIV infection in line with NHSE commissioning policy F03/P/b (JFC January 2019)

 Provider notes

  • NMUH:
    • To be prescribed by the HIV team only, as per the clinical commissioning policy - see link below.
  • RFL:
    • HIV medicine only
  • RNOH:
    • Non-formulary  
  • UCLH:
  • WH:
    • Non-formulary
05.03.03.02 Dasabuvir 

Provider notes

  • NMUH:
    • To be prescribed by Consultants Andrew Millar, Dimitra Doufexi and Jonathan Ainsworth only for Hepatitis C
    • See links below
    • Check MHRA Drug Safety Updates
  • RFL:
    • For use by Hepatology in the treatment of Hepatitis C in line with NICE guidance
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
08.01.05 Dasatinib 

Provider notes

  • NMUH:
    • This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used  in line with NICE recommendations and/or Local Trust Guidelines.
    • See links below
  • RFL:
    • As per NICE guidance
    • This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system).  Additionally for in-patient this drug must be prescribed on an in-patient prescription chart (paper or electronic)
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
08.01.02 Daunorubicin 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
    • This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system)
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
08.01.02 Daunorubicin liposomal DaunoXome®

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • No restriction stated
    • This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system)
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
09.01.03 Deferasirox 

Provider notes

  • NMUH:
    • See links below
  • RFL:
    • Commissioned as per NHS England policy for haemoglobinopathies.
    • Confirm with the commissioning team regarding other indications.
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
09.01.03 Deferiprone 

Provider notes

  • NMUH:
    •  To be prescribed by the Haematology Team ONLY.
    • See links below
  • RFL:
    • Commissioned as per NHS England policy for haemoglobinopathies.
    • Confirm with the commissioning team regarding other indications.
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Tabs 500 mg ONLY
06.03.02 Deflazacort 

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Restricted to Rheumatology and Endocrinology only.
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
08.03.04.02 Degarelix 

Provider notes

  • NMUH:
    • This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines
    • See link below
  • RFL:
    • As per NICE TA
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
05.01.09 Delamanid 

Approved for XDR-TB and MDR-TB in line with the NHS England Clinical Commissioning Policy F04/P/a (JFC April 2017)

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • As per NHSE policy for XDR-TB and MDR-TB
  • RNOH:
    • Non-formulary  
  • UCLH:
    • Pulmonary multidrug-resistant tuberculosis in line with NHS England policy, restricted to TB team
  • WH:
    • TB clinic only
05.01.03 Demeclocycline 

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
    • ???
  • WH:
    • Microbiology approval only
06.05.02 Demeclocycline 

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Provider notes

  • NMUH:
    • For treatment of SIADH
  • RFL:
    • For treatment of SIADH
  • RNOH:
    • Treatment of hyponatraemia resulting from inappropriate secretion of antidiuretic hormone, if fluid restriction alone does not restore sodium concentration or is not tolerable. Initially 0.9–1.2 g is given daily in divided doses, reduced to 600–900 mg daily for maintenance.
  • UCLH:
  • WH:
    • ???
06.06.02 Denosumab XGEVA®

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Approved for hypercalcaemia of malignancy who are either refractory to bisphosphonates or have creatinine clearance <30mL/min in whom bisphosphonates are contraindicated (JFC August 2018).

Only on the advice of oncology or palliative care consultants.

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • As per above agreed indication
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • As above
06.06.02 Denosumab XGEVA®

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Approved for preventing skeletal related events for oncology patients subject to service redevelopment (November 2015)

Provider notes

  • NMUH:
    • This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines.
    • See links below
    • To be prescribed by the Oncology team ONLY.
    • Check MHRA Drugs Safety Updates
  • RFL:
    • As per NICE TA265.

      • This drug must be prescribed on chemocare (RFL electronic chemotherapy prescribing system)
  • RNOH:
    • Giant cell tumour of bone
  • UCLH:
  • WH:
    • No restriction stated
06.06.02 Denosumab Prolia®

Red (hospital only prescribing) for osteoporotic men or women with renal impairment

Grey for osteoporotic women when used in line with NICE TA

 

Approved for osteoporosis in women (see NICE TA) and men unable to take oral bisphosphonates (either due to intolerance or unable to comply with administration instructions) and unable to receive IV zoledronic acid due to renal dysfunction (JFC October 2017)

Provider notes

  • NMUH:
    • This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines.
    • See links below
    • To be prescribed by Rheumatology and Care of the Elderly Consultants ONLY.
    • Check MHRA Drugs Safety Updates
  • RFL:
    • Approved for osteoporosis treatment in line with NICE TA by Endocrinology and Rheumatology
    • See links below
  • RNOH:
    • Store in a refrigerator
  • UCLH:
  • WH:
    • Also approved for osteoporosis in men unable to take oral bisphosphonates and unable to receive IV zoledronic acid due to renal dysfunction (November 2017)
07.02.02 Dequalinium chloride vaginal tablets 

Approved for bacterial vaginosis as a second-line alternative to clindamycin 2% intravaginal cream in patients who have not tolerated or failed metronidazole treatment (JFC August 2018).

Provider notes

  • NMUH:
    • Restricted to GU medicine ONLY
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • As above
13.02.02 Derma-S® barrier preparation 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
13.02.01 Dermatonics Once Heel Balm® Urea 25%

JFC approved for primary and secondary care for treatment of anhidrotic, fissured, calloused and hard foot skin in diabetic patients at high risk of ulceration (March 2018)

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • See indication above.
    • Restricted to podiatry use ONLY
13.02.01 Dermol® 500 lotion 

Provider notes

  • NMUH:
    • Restricted to the Dermatology team
  • RFL:
    • No restriction stated
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • Restricted to the Dermatology team
13.02.01.01 Dermol® bath/shower additive 

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Dermol 200 shower gel and 600 bath emollient available
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
13.02.01 Dermol® cream 

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • No restriction stated
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
09.01.03 Desferrioxamine Mesilate 

Provider notes

  • NMUH:
    • To be prescribed by the Haematology Team ONLY.
    • See links below
  • RFL:
    • Commissioned as per NHS England policy for haemoglobinopathies.
    • Confirm with the commissioning team regarding other indications.
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
18 Desferrioxamine Mesilate 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
15.01.02 Desflurane 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • No restriction stated
03.04.01 Desloratadine 

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • The use of desloratadine is reserved for consultant ENT surgeons only
    • Tabs 5mg ONLY
06.05.02 Desmopressin 

Provider notes

  • NMUH:
    • DDAVP: On formulary
    • DesmoMelt: Formulary for use as a first line agent in the treatment of primary nocturnal enuresis
  • RFL:
    • DDAVP: Restricted to child health; sublingual tablets available (120micrograms and 240micrograms)
    • Desmotabs: Restricted to child health
    • Desmospray: On formulary
    • Octim: On formulary
    • Injection: 4micrograms in 1mL available
  • RNOH:
    • Tablets, Injection, Nasal spray (for continuation of treatment), Oral lyophilisates (for continuation of treatment)
  • UCLH:
  • WH:
    • DDAVP: Intranasal solution 100 micrograms/1 ml & Inj 4 micrograms/1 ml ONLY
    • DesmoMelt: The use of Desmomelt tablets is restricted to Paediatrics only
    • Desmotabs: The use of desmopressin tablets is restricted to Dr Rossi only
    • Desmospray: On Formulary
07.03.02.01 Desogestrel 75mcg pill generic, Cerazette®, Cerelle®, other brands available

Provider notes

  • NMUH:
    • Preferred brand = generic
    • Restricted to Consultants in GU Medicine ONLY
  • RFL:
    • Preferred brand = generic
    • Approved for Sexual Health and Family
    • Approved for Gynaecology
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Cerelle or generic
10.01.02.02 Dexamethasone 

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • No restriction stated
  • RNOH:
    • No restriction stated  
  • UCLH:
  • WH:
    • No restriction stated
11.04.01 Dexamethasone + Framycetin + Gramicidin drops Sofradex®

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
12.01.01 Dexamethasone + Framycetin + Gramicidin drops Sofradex®

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • Non-formulary
12.01.01 Dexamethasone + Neomycin + Glacial Acetic Acid ear spray  Otomize®

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • Restricted to ENT department use only
11.04.01 Dexamethasone + Neomycin + Polymyxin B drops, ointment Maxitrol®

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • No restriction stated
12.01.01 Dexamethasone 0.1% + Ciprofloxacin 0.3% ear drops Cilodex®

Approved for treatment of acute otitis externa with perforated/damaged tympanic membrane (JFC March 2018)

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • As above
11.04.01 Dexamethasone 0.1% eye drops 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • No restriction stated
11.04.01 Dexamethasone 0.1% eye drops - preservative free 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Dexamethasone eye drops 0.1% preservative-free (Moorfields)
11.04.01 Dexamethasone intravitreal implant Ozurdex®

Provider notes

  • NMUH:
    • This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines. 
    • To be prescribed by Consultant Ophthalmologists ONLY for the treatment of Macular Oedema Secondary to Retinal Vein Occlusion as per NICE guidance.
    • See links below
  • RFL:

    • Macular oedema following RVO, Specialist use in line with NICE TA 

  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
06.03.02 Dexamethasone oral and systemic injection 

Provider notes

  • NMUH:
    • See MHRA Drugs Safety Updates
  • RFL:
    • No restriction stated
  • RNOH:
    • Oral solution available as 2 mg/5mL
  • UCLH:
  • WH:
    • The use of dexamethasone inj 24mg/ml is restricted to theatres only
04.04 Dexamfetamine 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • Restricted to the Sleep Clinic for narcolepsy
    • Restricted to CAMS for ADHD in children and adolescents  
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    •  As per NICE TA98 / CG87
  • CIFT
    • Approved for adults with ADHD (off-label) - 3rd line after methylphenidate and lisdexamphetamine
  • BEHMT
    • Approved for adults with ADHD (off-label)
15.01.04.04 Dexmedetomidine injection 

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Approved for light sedation (RASS 0 to -3) in mechanically ventilated adult patients with CAM ICU positive agitated delirium where agitation precludes weaning and extubation only after standard sedative agents (including propofol, clonidine or a benzodiazepine) had been trialled for 48 hours. (JFC January 2019).

Provider notes

  • NMUH:
    • As per indication above
  • RFL:
    • see above indication
    • Refer to local protocol for use
  • RNOH: As per indication above
  • UCLH:
  • WH:
    • As above.
04.07.02 Diamorphine 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • No restriction stated
04.01.02 Diazepam 

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • Stored and supplied as a controlled drug on ITU, CHDU, Philip Newman ward and Ian Munroe ward
    • Oral solution available as 2 mg/5mL
  • UCLH:
  • WH:
    • Tablets 2 mg, 5 mg, 10 mg.
    • Oral solution 2 mg/5 ml, 5mg/5 ml 
    • Injection (emulsion) 10 mg/2 ml - Diazemuls
  • CIFT:
    • Approved for
      • Anxiolytic
      • Alcohol withdrawal
      • Acute phase of mania (off-label)
      • Benzodiazepine dependence (off-label)
  • BEHMT:
    • Approved for
      • Anxiolytic
      • Alcohol withdrawal
      • Acute phase of mania (off-label)
      • Benzodiazepine dependence (off-label)
04.08.02 Diazepam 

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • Only diazepam injection (emulsion) and rectal solution stocked
  • RNOH:
    • Stored and supplied as a controlled drug on ITU, CHDU, Philip Newman ward and Ian Munroe ward
    • Oral solution available as 2 mg/5mL
  • UCLH:
  • WH:
    • ‘Diazemuls’ are preferred to plain diazepam injection as they are less likely to cause thrombophlebitis
10.02.02 Diazepam 

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • Stored and supplied as a controlled drug on ITU, CHDU, Philip Newman ward and Ian Munroe ward
    • Oral solution available as 2 mg/5mL
  • UCLH:
  • WH:
    • No restriction stated
15.01.04.01 Diazepam 

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
06.01.04 Diazoxide 

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • 50mg tablets only
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Restricted to children < 1year
06.06.02 Dibotermin Alfa, rhBMP-2 Inductos®

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Non-formulary
  • RNOH:
    • Complex spinal fusion surgeries in line with NHSE commissioning policy
    • This product is currently unavailable in the UK
  • UCLH:
  • WH:
    • Non-formulary
11.03.01 Dibromopropamidine 0.15% eye ointment 

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Restricted approved for use in acanthamoeba keratitis
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
04.14 Dichlorphenamide 

 

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
    • Approved for
      • Periodic paralysis – second line for patients who have not responded to acetazolamide (UCLH only; JFC February 2019)
  • WH:
    • Non-formulary
13.08.01 Diclofenac 3% gel Solaraze®

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • Restricted to Dermatologists
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
10.01.01 Diclofenac sodium  

Provider notes

  • NMUH:
    • See MHRA Drug Safety Update
  • RFL:
    • Restricted to Rheumatology, Obstetricians / Gynaecology and Paediatrics (suppositories or injection)
    • Injection, Suppositories 12.5mg/25mg/100mg, EC tablets 25mg/50mg 
  • RNOH:
    • Restricted: Diclofenac treatment should only be initiated after careful consideration for patients with significant risk factors for cardiovascular events (eg, hypertension, hyperlipidaemia, diabetes mellitus, smoking).
  • UCLH:
  • WH:
    • See MHRA Drug Safety Update
10.01.01 Diclofenac sodium + Misoprostol 

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • No restriction stated
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Must not be given to women of child-bearing potential
11.08.02 Diclofenac sodium 0.1% eye drops - single use Voltarol® Ophtha

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Restricted to Opthalmology.
    • Cataract surgery, post-op inflammation , ocular symptoms in allergic conjunctivitis
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
10.01.01 Diclofenac sodium modified release 

Provider notes

  • NMUH:
    • Non-formulary
    • Check MHRA Drug Safety Updates 
  • RFL:
    • Restricted to only Rheumatology and Obs / Gynae
    • M/R tablets 75mg and 100mg available
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • See MHRA Drug Safety Update
18 Dicobalt edetate 

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • No restriction stated
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
01.02 Dicycloverine 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • Non-formulary
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • Non-formulary
08.03.01 Diethylstilbestrol 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
13.04 Diflucortolone valerat 0.3% - Topical Nerisone Forte®

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Oily cream and ointment available
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Oily Cream ONLY
13.04 Diflucortolone valerate 0.1% - Topical Nerisone®

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Cream, oily cream and ointment are available 
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
02.01.01 Digoxin 

Provider notes

  • NMUH:
    • NB. The Digoxin 100 micrograms/mL (Paediatric) is unlicensed and NON-FORMULARY. 
  • RFL:
    • No restriction stated
  • RNOH:
    • Tablets available. Oral elixir available as 50 micrograms/mL
  • UCLH:
  • WH:
    • No restriction stated
02.01.01 Digoxin specific antibody fragments Digifab®

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
04.07.02 Dihydrocodeine 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • Oral elixir available as 10 mg/5mL
  • UCLH:
  • WH:
    • No restriction stated
04.07.02 Dihydrocodeine modified release  

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
04.07.04.03 Dihydroergotamine inj 

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Restricted to neurology for migraine and cluster headache
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
21.01 Diltiazem cream 

Diltiazem cream for transrectal ultrasound guided prostate biopsy
Twelve-month evaluation at UCLH site only (March 2015)

01.07.04 Diltiazem Cream 2% 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • For anal fissures only - restricted to Colorectal team
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • No restriction stated
02.06.02 Diltiazem immediate release 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • No restriction stated
02.06.02 Diltiazem modified release 

Prescribe by brand name: modified-release preparations have different release characteristics and are not interchangeable.

Provider notes

  • NMUH:
    • Adizem-SR, Adizem-XL, Tildiem LA, Tildiem Retard available
  • RFL:
    • Tildiem LA, Tildiem Retard and Slozem and the preferred brands
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • Tildiem LA, Tildiem Retard available
08.02.04 Dimethyl fumarate Tecfidera®

DO NOT CONFUSE Tecfidera® AND Skilarence® AS THEY ARE LICENSED FOR DIFFERENT INDICATIONS

Provider notes

  • NMUH:
    • This medicine has a positive NICE Technology Appraisal but is not listed in the Trust Medicines Formulary as the service is not offered at NMUH.
    • Check MHRA Drugs Safety Updates
  • RFL:
    • As per NICE TA
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
13.05.03 Dimethyl fumarate Skilarence®

DO NOT CONFUSE Tecfidera® AND Skilarence® AS THEY ARE LICENSED FOR DIFFERENT INDICATIONS

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • As per NICE guidance
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
13.10.04 Dimeticone 4% lotion Hedrin®

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • No restriction stated 
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
07.01.01 Dinoprostone Prostin E2®

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • See ‘Induction of Labour’ policy on Freenet
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Vaginal gel 1 mg/2.5 ml (Prostin E2), Vaginal gel 2 mg/2.5 ml (Prostin E2) Inj 5 mg/0.5 ml extra amniotic
07.01.01 Dinoprostone Propess®

Provider notes

  • NMUH:
    • Restricted to Obstetrics and Gynaecology Consultants only for induction and Augmentation of Labour
  • RFL:
    • See ‘Induction of Labour’ policy on Freenet
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
14.04 Diphtheria antitoxin 

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Unlicensed product
13.02.01 Diprobase® cream 

Provider notes

  • NMUH:
    • Restricted to Dermatology team
  • RFL:
    • No restriction stated
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • 50g, 500g only
02.09 Dipyridamole 

See NICE TA for eligibility

Provider notes

  • NMUH:
    • This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used  in line with NICE recommendations and/or Local Trust Guidelines.
  • RFL:
    • See NCL JFC summary of antiplatelet options in cardiovascular disease for advice on specific indications
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • No restriction stated
11.99.99.99 Disodium Edetate 0.37% eye drops 

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Allergic and inflammatory eye conditions and collagenase inhibitor
  • RNOH:
    • Non-formulary
  • UCLH:
    • Non-formulary
  • WH:
    • Non-formulary
02.03.02 Disopyramide immediate release 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • Cardiology only
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • No restriction stated
02.03.02 Disopyramide modified release 

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Cardiology only
  • RNOH:
    • Non-formulary
  • UCLH:
    • Non-formulary
  • WH:
    • Non-formulary
04.10.01 Disulfiram 

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • No restriction stated
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
13.05.02 Dithranol cream Dithrocream®

Provider notes

  • NMUH:
    • Dithrocream 0.25% and Dithrocream 0.5% are FORMULARY, for irritation on trunk and limbs.
    • Dithrocream 0.1%, Dithrocream 1% and Dithrocream 2% are NON-FORMULARY.
  • RFL:
    • Dithrocream 0.1%, 0.25%, 0.5%, 1% and 2% available
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
13.05.02 Dithranol Paste, BP 

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • There are non-proprietary preparations available at the Royal Free Hospital but not listed in the eBNF, contact Pharmacy for details.
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
02.07.01 Dobutamine 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • No restriction stated
08.01.05 Docetaxel 

See NICE TA for eligibility criteria

Provider notes

  • NMUH:
    • Positive NICE TA This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines.
  • RFL:
    • No restrictions stated
    • This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system)
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Breast and lung cancer
08.01.05 Docetaxel + oxaliplatin + disodium folinate + fluorouracil (FLOT) 

Approved gastric or gastro-oesophageal junction adenocarcinoma (JFC November 2017)

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • As above
  • RNOH:
    • Non-formulary
  • UCLH:
    • As above
  • WH:
    • Non-formulary
01.06.02 Docusate sodium 

Provider notes

  • NMUH:
    • See link below
  • RFL:
    • No restriction stated
  • RNOH:
    • Caps 100mg. Oral solution 50 mg/5 ml. Paediatric oral solution 12.5 mg/5 ml
  • UCLH:
  • WH:
    • Caps 100 mg. Oral solution 50 mg/5 ml. Paediatric oral solution 12.5 mg/5 ml
05.03.01 Dolutegravir 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • HIV medicine only
  • RNOH:
    • Non-formulary  
  • UCLH:
  • WH:
    • Non-formulary
05.03.01 Dolutegravir + Abacavir + Lamivudine Triumeq®

Approved for HIV in line with NHSE Commissioning Policy B06/P/a.

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • HIV medicine only
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
01.02 Domperidone 

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • See MHRA safety alert
  • RNOH:
    • Tablets availabe. Oral suspension available as 1 mg/mL.
  • UCLH:
    • Non-formulary
  • WH:
    • See MHRA safety alert
04.06 Domperidone 

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Provider notes

  • NMUH:
    • Check MHRA Safety Drug Updates
  • RFL:
    • No restriction stated
  • RNOH:
    • Oral suspension available as 1 mg/mL 
  • UCLH:
  • WH:
    • Risk of cardiac side effects - to be used at the lowest effective dose for the shortest period of time
04.11 Donepezil 

Provider notes

  • NMUH:
    • This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines
    • See link below
  • RFL:
    • No restriction stated
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • Restricted to Care of the Elderly consultants only
    • Tabs 5mg only
02.07.01 Dopamine 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • No restriction stated
11.06 Dorzolamide 2% + Timolol 0.5% eye drops Cosopt®

Combination therapies to be used when compliance / cost issues arise. See NCL guideline for place in therapy.

Provider notes

  • NMUH:
    • See link below
  • RFL:

    • Open angle glaucoma and ocular hypertension

  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • No restriction stated
11.06 Dorzolamide 2% + Timolol 0.5% eye drops - unit dose Cosopt®

Restricted to patients with true preservative allergy and/or evidence of epithelial toxicity from preservatives and/or severe dry eyes. Combination therapies to be used when compliance / cost issues arise. See NCL guideline for place in therapy. See NCL guideline for place in therapy.

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
  • RNOH:
  • UCLH:
  • WH:
    • Restricted to Ophthalmology 
11.06 Dorzolamide 2% eye drops 

See NCL guideline for place in therapy.

Provider notes

  • NMUH:
    • See link below
  • RFL:
    • No restriction stated
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Not to be used as first-line treatment - see link below
11.06 Dorzolamide 2% eye drops - unit dose 

Restricted to patients with true preservative allergy and/or evidence of epithelial toxicity from preservatives and/or severe dry eyes. See NCL guideline for place in therapy.

Provider notes

  • NMUH:
  • RFL:
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
04.03.01 Dosulepin 

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Not approved for any indication in line with NHS England 'Items which should not routinely be prescribed in primary care' guidance (JFC January 2020)

Provider notes

  • NMUH:
    • For continuation ONLY
    • Non-formulary for initiation in all indications
  • RFL:
    • No restriction stated
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
  • CIFT:
    • Non-formulary
  • BEHMT:
    • Non-formulary
04.07.04.02 Dosulepin 

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Not approved for any indication in line with NHS England 'Items which should not routinely be prescribed in primary care' guidance (JFC January 2020)

Provider notes

  • NMUH:
    • For contiuation of treatment ONLY
    • Non-formulary for iniation in all indications
  • RFL:
    • No restriction stated
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
13.02.01 Doublebase® gel 

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • No restriction stated
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • Non-formulary
03.05.01 Doxapram 

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • No restriction stated
15.01.07 Doxapram 

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • No restriction stated
  • RNOH:
    • Non-formulary
  • UCLH:
    • Non-formulary
  • WH:
    • Non-formulary
02.05.04 Doxazosin 

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • Immediate release preparations only
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • Immediate release preparations only.
    • Prolonged release preparations not recommended for routine use by NHSE (Dec 2017)
07.04.01 Doxazosin 

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Provider notes

  • NMUH:
    • Modified release preparations are non-formulary
  • RFL:
    • Modified release preparations are non-formulary
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • Modified release praparations are non-formulary
08.01.02 Doxorubicin 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
    • This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system)
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Inj 50 mg ONLY
08.01.02 Doxorubicin pegylated liposomal Caelyx®

See NICE TA for eligibility criteria

Provider notes

  • NMUH:
    • This medicine has a positive NICE Technology Appraisal but is not listed in the Trust Medicines Formulary as the service is not offered at NMUH.
  • RFL:
    • No restriction stated
    • This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system)
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
05.01.03 Doxycycline 

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • Oral: See Microguide for approved indications
    • IV: Seek Microbiology, ID or Pharmacy advice before prescribing
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • No restriction stated
05.04.01 Doxycycline 

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Provider notes

  • NMUH:
    • See link below
  • RFL:
    • No restriction stated
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
02.03.02 Dronedarone 

Provider notes

  • NMUH:
    • NOT 1ST LINE DRUG - REQUIRES CARDIOLOGIST APPROVAL.
    • This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used  in line with NICE recommendations and/or Local Trust Guidelines.
  • RFL:
    • Cardiology initiation only – use as per NICE TA
  • RNOH:
    • Requires CARDIOLOGIST approval
  • UCLH:
  • WH:
    • For use in the treatment of Non‐Permanent Atrial Fibrillation (AF) where it is not the first‐line option; this is use is limited to an SpR or a Consultant cardiologist who has seen the patient.
06.01.02.03 Dulaglutide 

Semaglutide is the preferred GLP-1 receptor agonist for type 2 diabetes, when used in line with the NCL Fact sheet (JFC August 2019).

Dulaglutide should only be initiated for patients (JFC August 2019):

  • who are needle-phobic and cannot use the semaglutide pen device.
  • with impaired manual dexterity (e.g. due to severe arthritis) and cannot use the semaglutide pen device.
  • with learning difficulty or mental health issues and require GLP-1 receptor agonist administration by a third-party as the dulaglutide device minimises the risk of needle-stick injury

Provider notes

  • NMUH:
    • Non-formulary but see link below
  • RFL:
    • Restricted to initiation by endocrinology only for Type 2 diabetes
    • See above for detailed eligibility criteria
  • RNOH:
    • Requires initiation by a Diabetes Specialist
  • UCLH:
  • WH:
    • As above
04.03.04 Duloxetine Cymbalta®

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Non-formulary
  • RNOH:
    • Restricted
  • UCLH:
  • WH:
    • Non-formulary
04.07.03 Duloxetine Cymbalta®

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Approved for neuropathic pain in patients who cannot tolerate, or have an inadequate response to, both amitriptyline and gabapentin (JFC November 2013).

Provider notes

  • NMUH:
    • Restricted for patients who cannot tolerate, or have an inadequate response to, both amitriptyline and gabapentin
  • RFL:
    • Restricted for patients who cannot tolerate, or have an inadequate response to, both amitriptyline and gabapentin
  • RNOH:
    • Restricted for patients who cannot tolerate, or have an inadequate response to, both amitriptyline and gabapentin
  • UCLH:
  • WH:
    • Restricted for patients who cannot tolerate, or have an inadequate response to, both amitriptyline and gabapentin
07.04.02 Duloxetine Yentreve®

Provider notes

  • NMUH:
    • Duloxetine (Yentreve) is FORMULARY for use in women with moderate to severe urinary stress incontinence. Duloxetine (Yentreve) should be used as a second line option for urinary stress incontinence, as an alternative to surgical treatment, as per NICE guidance.
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
A5.02.04 DuoDERM Extra Thin 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
13.05.01 Dupilumab injection 

See NICE TA for eligibility criteria

Provider notes

  • NMUH:
    • This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines.
  • RFL:
    • For the treatment of Atopic Dermatitis in line with NICE guidance
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
A5.01.02 Durafiber 

Absorbent Cellulose dressing with gel matrix 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
A5.03.03 Durafiber Ag 

Provider notes

  • NMUH:
    • To be used on the recommendation of the Tissue Viability Nurse only.
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
08.01.05 Durvalumab 

See NICE TA for eligibility criteria

Provider notes

  • NMUH:
    • Non-formulary
    • This medicine has a positive NICE Technology Appraisal but is not listed in the Trust Medicines Formulary as the service is not offered at NMUH.
  • RFL:
    • As per NICE/CDF criteria
    • This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system)
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
13.14 Dutasteride 

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Approved for use by Dermatology for frontal fibrosing alopecia (third line drug. Off label use)
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
13.02.01 E45® cream 

Provider notes

  • NMUH:
    • E45 cream is NON-FORMULARY.
    • Cetomacrogel A cream (500g) is used at NMUHT.
  • RFL:
    • Non-formulary
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • Non-formulary
A5.02.03 Eclypse Adherent 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
11.03.02 Econazole 1% eye drops 

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • This is an unlicensed special and restricted to Ophthalmology
09.01.03 Eculizumab 

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • As per NICE
  • RNOH:
    • Non-formulary
  • UCLH:
    • See links below
  • WH:
    • Non-formulary
09.09 Eculizumab 

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Approved for 2nd line management of Delayed Haemolytic Transfusion Reactions [DHTRs] hyperhaemolysis in adult Sickle Cell and β-thalassaemia patients who have not responded to IVIG and steroids (pending internal funding approval; JFC July 2019)

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
    • Restricted to haematology. UMC to be informed of each patient. Funding agreed for 1 patient per annum. 
  • WH:
    • Non-formulary
02.08.02 Edoxaban 

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

See NICE TA for eligibity criteria

Provider notes

  • NMUH:
    • Positive NICE TA - This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines.
    • A referral form must be completed by Authorised Teams/ Haematology team to initiate a DOAC
    • A GP notification form must be completed and sent to the GP for each patient newly started on a DOAC
    • A copy of the above forms (referral form and GP notification form) must be sent to the anticoagulant clinic
  • RFL:
    • As per NICE guidance
    • Follow NCL DOAC prescribing guide
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • Not to be used for initiation of therapy.
05.03.01 Efavirenz 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • HIV medicine only
  • RNOH:
    • Non-formulary  
  • UCLH:
  • WH:
    • No restriction stated
13.09 Eflornithine 11.5% cream Vaniqa®

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • Restricted to dermatology and endocrinology only
    • Initiate in secondary care only and transfer to primary care after 4 months if effective
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
05.03.03.02 Elbasvir + Grazoprevir 

Provider notes

  • NMUH:
    • This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines.
    • See links below
    • To be prescribed by Consultants Andrew Millar, Dimitra Doufexi and Jonathan Ainsworth ONLY for Hepatitis C.
  • RFL:
    • Approved for use by Hepatology in the treatment of Hepatitis C in line with NICE guidance
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
A2.01.01.02 Elemental 028 ® Extra 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
09.08.01 Eliglustat 

See NICE HST for eligibility criteria

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Gaucher disease in line with NICE HST
  • RNOH:
    • Non-formulary
  • UCLH:
    • Gaucher disease in line with NICE HST
  • WH:
    • Non-formulary
09.08.01 Elosulfase alfa 

See NICE HST for eligibility criteria

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Morquio A Syndrome in line with NICE HST
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
09.01.04 Eltrombopag 

Provider notes

  • NMUH:
    • Positive NICE TA This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines see link below.
  • RFL:
    • As per NICE guidance and CCG policy
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • See links below
01.04.02 Eluxadoline 

Provider notes

  • NMUH:
    • This medicine has a positive NICE TA and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • NICE TA471 applies
02.11 Emicizumab 

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Approved for congenital haemophilia A with factor VIII inhibitors in line with NHSE clinical commissioning policy 170067/P (RFL only; JFC November 2018)
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
06.01.02.03 Empagliflozin 

Provider notes

  • NMUH:
    • This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines.
    • See links below
    • Only on the recommendation of the Diabetes Team.
    • Check MHRA Drug Safety Alerts
  • RFL:
    • Restricted to Endocrinology
    • See links below
  • RNOH:
    • Requires initiation by a Diabetes Specialist
    • Check MHRA Drug Safety Updates
  • UCLH:
  • WH:
    • No restriction stated
    • Check MHRA Drug Safety Updates
05.03.01 Emtricitabine 

Provider notes

  • NMUH:
    • To be prescribed as per BHIVA Guidelines by the HIV team only
    • Patients currently benefiting from FTC in their combination therapy, who either accessed FTC in studies or move to London with FTC as part of their existing regimen, should continue to receive FTC without interruption
    • For patients who have previously not received 3TC, the decision to prescribe 3TC or FTC to be made by the clinician and patient after discussion and consideration of relevant factors
  • RFL:
    • HIV medicine only
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • For TB / HIV clinic only
05.03.01 Emtricitabine + Rilpivirine + Tenofovir disoproxil Eviplera®

Provider notes

  • NMUH:
    • NHSE approval required
    • Initiation restricted to Consultants HIV Medicine
  • RFL:
    • HIV medicine only
  • RNOH:
    • Non-formulary  
  • UCLH:
  • WH:
    • Non-formulary
05.03.01 Emtricitabine + Tenofovir alafenamide Descovy®

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • HIV medicine only
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
13.02.01.01 Emulsiderm® liquid emulsion 

Provider notes

  • NMUH:
    • Restricted to Dermatology team
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
13.02.01 Emulsifying Ointment, BP 

Provider notes

  • NMUH:
    • Stock 500g tub
    • Emulsifying ointment can be used as a soap substitute
    • Check MHRA Drug Safety Updates
  • RFL:
    • No restriction stated
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • No restriction stated
02.05.05.01 Enalapril  

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • No restriction stated
08.01.05 Encorafenib caps 

See NICE TA for eligibility criteria

Provider notes

  • NMUH:
    • Non-formulary
    • This medicine has a positive NICE Technology Appraisal but is not listed in the Trust Medicines Formulary as the service is not offered at NMUH.
  • RFL:
    • As per NICE TA
    • This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system).  Additionally for in-patients this drug must be prescribed on an in-patient prescription chart (paper or electronic)
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
05.03.01 Enfuvirtide 

Provider notes

  • NMUH:
    • To be used in accordance with the London HIV consortium BHIVA guidelines
    • For HIV team only
    • Patients currently benefiting from enfuvirtide in their combination therapy should continue to receive enfuvirtide without interruption. Current benefit is defined as patients whose viral load is either undetectable or remaining below their pre-enfuvirtide baseline level. Patients whose current viral load has substantially rebounded or returned to their baseline level when their first used enfuvirtide and who have a strong CD4 count, are likely to have developed or be developing resistance to enfuvirtide. Enfuvirtide is also unlikely to be having antiretroviral activity, and these patients should consider stopping the enfuvirtide in their combination, with close monitoring BHIVA Guidelines - Treatment of HIV-1 infected adults with antiretroviral therapy
  • RFL:
    • HIV medicine only
  • RNOH:
    • Non-formulary  
  • UCLH:
  • WH:
    • Non-formulary
14.04 Engerix B® Hepatitis B vaccine Single Component

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • No restriction stated
02.08.01 Enoxaparin 

Red (hospital only prescribing) for defined course thromboprophylaxis and patients requiring treatment doses in line with NCL guidance (see Section 3.1)

Amber for long-term thromboprophylaxis and patients requiring treatment doses in line with NCL guidance (see Section 3.3)

 

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Prophylaxis - only whilst tinzaparin shortage
    • Treatment - haemophilia recommendation only
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
02.01.02 Enoximone 

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • No restriction stated
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
A2.04.01.02 Enshake 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
A2.02.02.03 Ensure Compact 
  • Bottle (125mL)
  • Vanilla, banana, strawberry, café latte
  • Contains lactose
  • Gluten free
  • Halal certified (except strawberry)
  • Banana and vanilla flavours Kosher certified
  • Suitable for vegetarian diet (except strawberry)

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary

Primary care notes

Second-choice product - for patients who did not tolerate first-line choices and lower volume is indicated or fluid restricted - see Primary Care Guidance

A2.02.02.01 Ensure Plus Advance 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
A2.02.02.01 Ensure Plus Fibre 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
A2.02.01.02 Ensure Plus Juce 
  • Bottle (220mL)
  • Apple, orange, fruit punch, peach, lemon and lime, strawberry
  • Clinically lactose and gluten-free
  • Halal certified (except lemon and lime)
  • Kosher certified (except strawberry)
  • Suitable for vegetarian diets (except strawberry)

Provider notes

  • NMUH:
    • Taste aberrations/aversions to milky supplements, fat intolerance/steatorrhoea, Cancer cachexia, poor wound healing, anorexia, Disease-related malnutrition, short bowel syndrome, Intractable malabsorption, pre-operative preparation for those who are malnourished. Proven inflammatory bowel disease, total gastrectomy, bowel fistulae, dysphagia Non-milk tasting. For patients who dislike milk. Used to meet nutritional requirements in addition to oral intake
  • RFL:
    • No restriction stated
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary

Primary care notes

Second-choice product - for patients who did not tolerate first-line choices and cannot tolerate milk-based supplements- see Primary Care Guidance

A2.02.02.01 Ensure Plus Milkshake style 
  • Bottle (200mL)
  • Vanilla, strawberry, chocolate, coffee, fruits of the forest, neutral, orange, peach, raspberry and banana
  • Clinically lactose and gluten free Halal certified (except vanilla)
  • Kosher certified and suitable for vegetarian diet (except strawberry, fruits of the forest, peach, raspberry)

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary

Primary care notes

Second-choice product - for patients who did not tolerate first-line choices - see Primary Care Guidance

A2.02.02.01 Ensure Plus Yoghurt style 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
A2.01.02.03 Ensure Twocal 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
04.09.01 Entacapone 

Provider notes

  • NMUH:
    • Use only on the recommendation of consultant neurologists and Dr Woothipoom in accordance with the NCL JFC Parkinson's Disease Pathway (see link)
  • RFL:
    • No restriction stated
  • RNOH:
    • No restriction stated
  • UCLH:
    • Parkinson's disease - adjunct to levodopa + dopa-decarboxylase inhibitor
  • WH:
    • Entacapone is available for use by Care of the Elderly and Neurology Consultants only
05.03.03.01 Entecavir 

Provider notes

  • NMUH:
    • Positive NICE TA This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines.
    • See link below
  • RFL:
    • See NICE TA for eligibility criteria
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
08.03.04.02 Enzalutamide 

Provider notes

  • NMUH:
    • This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and Local Trust Guidelines.
    • See links below
  • RFL:
    • As per NICE TAs
    • This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system). Additionally for in-patients this drug must be prescribed on an in-patients prescription chart (paper or electronic)
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary to WH
14.04 Enzira® Influenza vaccine

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Non-formulary
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • Non-formulary
13.02.01 Epaderm® cream/ointment 

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • No restriction stated
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Epaderm ointment only - restricted to paediatric trial of emollients
02.07.02 Ephedrine 

Provider notes

  • NMUH:
    • Restricted for use in Theatres only.
  • RFL:
    • No restriction stated
  • RNOH:
    • In idiopathic orthostatic hypotension in spinally injured patients
  • UCLH:
  • WH:
    • Ephedrine inj is available for use by anaesthetists only.
12.02.02 Ephedrine 0.5% nasal drops 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • No restriction stated
07.06 Ephedrine tablets 

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Provider notes

  • NMUH:
    • Approved for use for priapism (unlicensed use).
    • See links below
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
08.01.02 Epirubicin 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
    • This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system)
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
02.02.03 Eplerenone 

Approved for heart failure in patients unable to tolerate spironolactone due to gynaecomastia (JFC April 2017)

Provider notes

  • NMUH:
    • Check for MHRA Drug Safety Updates
    • Restricted for patients who are unable to tolerate spironolactone due to gynaecomastia
  • RFL:
    • Restricted to cardiology for:
      • Heart failure in patients unable to tolerate spironolactone due to gynaecomastia
      • Ejection Fraction <40% post STEMI
  • RNOH:
    • Requires CARDIOLOGIST approval
  • UCLH:
    • Restricted to patients intolerant of spironolactone due to gynacomastia
  • WH:
    • Eplerenone is reserved for the use of Consultant Cardiologists only for those who develop gynecomastia with spironolactone
09.01.03 Epoetin alfa Eprex®

Provider notes

  • NMUH:
    • For anaemia associated with chronic renal failure only.
    • Restricted to renal consultants signature and Dr. Tindall signature only.
    • Please note that the CSM has advised that the subcutaneous route is contraindicated in chronic renal failure. Please use the IV route instead. The dialysis unit has changed over to NeoRecormon which is an IV preparation.
  • RFL:
    • Restricted to Renal team - for patients who cannot tolerate darbepoetin or established patients only
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Epoetin is available for treatment anaemia of renal disease only
09.01.03 Epoetin beta NeoRecormon®

Provider notes

  • NMUH:
    • Positive NICE TA This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used  in line with NICE recommendations and/or Local Trust Guidelines.
    • Restricted to Renal and Haematology Consultants.
    • See MHRA drug safety updates 
  • RFL:
    • Restricted to Renal team - for patients who cannot tolerate darbepoetin or established patients only
    • Restricted to Haematology for MDS
  • RNOH:
    • Store in a refrigerator
  • UCLH:
  • WH:
    • Epoetin is available for treatment anaemia of renal disease only
    • Pre-filled syringe 2,000 units, 3,000 units, 4,000 units, 6,000 units, 10,000 units ONLY
02.08.01 Epoprostenol 

Approved for pulmonary hypertension (November 2013)

Provider notes

  • NMUH:
    • Restricted for ICU use only.
    • Check MHRA for Drug Safety Updates
  • RFL:
    • Restricted to ITU and pulmonary hypertension
  • RNOH:
    • Non-formulary
  • UCLH:
    • Approved for primary pulmonary hypertension: functional grades III + IV
    • Approved for Inhibition of platelet aggregation during renal dialysis
  • WH approvals:
    • No restriction stated
02.09 Eptifibatide Integrilin®

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
09.06.04 Ergocalciferol 

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • 300,000 units intramuscular injection only
  • RNOH:
    • Restricted
  • UCLH:
  • WH:
    • Inj 7.5 mg (300,000 units)/1 ml only
07.01.01 Ergometrine maleate 

Provider notes

  • NMUH:
    • Restricted to Obstetrics Only 
  • RFL:
    • No restriction stated
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
07.01.01 Ergometrine maleate + Oxytocin Syntometrine®

Provider notes

  • NMUH:
    • Restricted to Obstetrics ONLY
  • RFL:
    • See Maternity Unit Guideline on Massive Obstetric Haemorrhage
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
04.07.04.01 Ergotamine Tartrate 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
08.01.05 Eribulin 

See NICE TA for eligibility criteria

Provider notes

  • NMUH:
    • This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines.
    • See links below
  • RFL:
    • As per NICE guidance
    • This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system)
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
08.01.05 Erlotinib 

Provider notes

  • NMUH:
    • This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when use in line with NICE recommendations and/or Local Trust Guidelines.
    • To be prescribed by the Oncology team ONLY.
    • See links below
  • RFL:
    • AS per NICE guidance
    • This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system).  Additionally for in-patients this drug must be prescribed on an in-patient prescription chart (paper or electronic)
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
05.01.02.02 Ertapenem 

Provider notes

  • NMUH:
    • Microbiology approval only
  • RFL:
    • Microbiology approval only (except ITU, microbiology approval required within 48 hours)
  • RNOH:
    • Microbiologist approval only
  • UCLH:
  • WH:
    • Restricted antibiotic - Microbiology approval only
06.01.02.03 Ertugliflozin tabs 

Provider notes

  • NMUH:
    • This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used  in line with NICE recommendations and/or Local Trust Guidelines. 
    • See link below
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • As per NICE TA
01.02 Erythromycin 

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Provider notes

  • NMUH:
    • Non-formulary
  • RFL: 
    • Off-label use
  • RNOH: 
    • Off-label use
  • UCLH:
  • WH:
    • Off-label use
05.01.05 Erythromycin 

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Provider notes

  • NMUH:
    • Injection is reserved for the use of Paediatrics only
  • RFL:
    • No restriction stated
  • RNOH:
    • Oral suspension available as 125 mg/5mL and 250 mg/5mL
  • UCLH:
  • WH:
    • Restricted to Maternity use or as prokinetic
11.03.01 Erythromycin 0.5% eye ointment 

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • This is unlicensed special and restricted to Ophthalmology
13.06.01 Erythromycin 40mg + Zinc acetate 12mg/mL topical solution Zineryt®

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • Restricted to Dermatology
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
04.03.03 Escitalopram 

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
  • CIFT approvals:
    • Social Anxiety Disorder - if other SSRIs are not appropriate
    • Depression
  • BEHMT approvals:
    • Non-formulary
02.04 Esmolol 

Provider notes

  • NMUH:
    • Only 100mg/10ml vials are kept at NMUHT.
  • RFL:
    • Restricted to ITU, cardiology and theatres only.
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • No restriction stated
01.03.05 Esomeprazole 

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • RFH: Non-formulary
    • BCF: No restriction stated (historical use)
  • RNOH:
    • Non-formulary
  • UCLH:
    • Non-formulary
  • WH:
    • Non-formulary
06.04.01.01 Estradiol Zumenon®

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
06.04.01.01 Estradiol Elleste-Solo®

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
07.02.01 Estradiol 10mcg vaginal tablet Vagifem®

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • No restriction stated
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
07.02.01 Estradiol 7.5mcg /24hrs 7.5 microgram/24 hours vaginal delivery system Estring®

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
06.04.01.01 Estradiol gel Oestrogel®

Approved as hormone replacement therapy for oestrogen deficiency symptoms in postmenopausal women (JFC September 2018).

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Restricted to the menopause clinic only
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • As above
06.04.01.01 Estradiol patch Evorel®, FemSeven®, Estradot®, Estraderm MX®, Progynova TS®

Provider notes

  • NMUH:
    • FemSeven available
  • RFL:
    • Evorel available, use other brands if shortage of Evorel
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Evorel 50 micrograms/24 hours,100 micrograms/24 hours ONLY. For patients requiring 25 micrograms of estradiol per day, the Evorel 50 micrograms patch may be cut in half.
06.04.01.01 Estradiol with Dydrogesterone Femoston-Conti®

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • Femoston-Conti 1/5 available
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Femoston-conti available
06.04.01.01 Estradiol with Dydrogesterone Femoston®

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • Femoston 1/10 and 2/10 available
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Femoston 1/10 tablets available
06.04.01.01 Estradiol with Levonorgestrel patch FemSeven® Conti

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
06.04.01.01 Estradiol with Levonorgestrel patch FemSeven® Sequi

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
06.04.01.01 Estradiol with Norethisterone Climesse®

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
06.04.01.01 Estradiol with Norethisterone Kliofem®

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
06.04.01.01 Estradiol with Norethisterone Kliovance®

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
06.04.01.01 Estradiol with Norethisterone patch Evorel® Sequi

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
06.04.01.01 Estradiol with Norethisterone patch Evorel® Conti

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
07.02.01 Estriol 0.01% vaginal cream Gynest®

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • For Gynae (HRT) and Paediatrics (labial adhesions) only 
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
07.02.01 Estriol 1mg/1g vaginal cream Ovestin®

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • No restriction stated
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
10.01.03 Etanercept 

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

JFC approved Benepali as the brand of choice.

Approved for:

  • Rheumatoid arthritis in line with the NCL RA pathway
  • Juvenile Idiopathic Arthritis (JIA; see NICE TAs below)
  • Ankylosing spondylitis (see NICE TAs below)
  • Psoriatic Arthritis (PsA; see NICE TAs below)

Provider notes

  • NMUH:
    • This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines
    • Restricted to Consultant Rheumatologists
    • See MHRA Drug Safety Update
    • See links below
  • RFL:
    • Approved for use in Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis and non-radiographic axial spondyloarthritis in line with NICE guidance
  • RNOH:
    • Rheumatology Consultants ONLY
    • Please prescribe by brand name Benepali or Enbrel - patients requiring 50 mg should be prescribed Benepali and patients requiring 25 mg should be prescribed Enbrel
    • See links below
  • UCLH:
  • WH:
    • As per NICE TA and above
13.05.03 Etanercept 

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

JFC approved Benepali as the brand of choice.

Provider notes

  • NMUH:
    • This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines.
    • Restricted to Consultant Dermatologists
    • Check MHRA safety updates.
    • See links below.
  • RFL:
    • Approved for use in the treatment of Psoriasis in line with NICE guidance
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
16.01 Etanercept 

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

JFC approved Benepali as the brand of choice.

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:

    • Restricted to National Amyloidosis Centre
  • RNOH:
    • Non-formulary
  • UCLH:
    • Non-formulary
  • WH:
09.05.01.02 Etelcalcetide  

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Restricted to ‘etelcalcetide gatekeeper’ approval only for secondary hyperparathyroidism – see NICE TA
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
05.01.09 Ethambutol  

Provider notes

  • NMUH:
    • No restriction stated (suspension 400mg/5ml [unlicensed] is available for the treatment of tuberculosis in children)
  • RFL:
    • For treatment of tuberculosis only
  • RNOH:
    • Microbiologist approval only
  • UCLH:
  • WH:
    • No restriction stated
06.04.01.01 Ethinylestradiol 

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • No restriction stated
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
08.03.01 Ethinylestradiol 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
07.03.01 Ethinylestradiol / levonorgestrel phased pill 21-days TriRegol®, Logynon®

Provider notes

  • NMUH:
    • Preferred brand = Logynon
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
07.03.01 Ethinylestradiol / levonorgestrel phased pill 28-days Logynon ED®

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
07.03.01 Ethinylestradiol 20 mcg / norethisterone 1mg pill 21-days Loestrin 20®

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
07.03.01 Ethinylestradiol 20mcg / desogestrel 150mcg pill 21-days Bimizza®, Gedarel 20/150®, Mercilon®, Munalea 20/150®

Provider notes

  • NMUH:
    • Restricted to Consultants in GU Medicine ONLY = Gedarel 20/150
    • Preferred brand for Obs & Gynae = Mercilon
  • RFL:
    • Preferred brand = Munalea
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Preferred brand = Mercilon
    • The CSM has advised that combined contraceptives containing gestodene or desogestrel should not be used by women with risk factors for venous thromboembolism (for further information see BNF). For other women a levonorgestrel or norethisterone-containing product is also generally the initial choice. But the statement by the Department of Health on 7 April, 1999 acknowledges the tiny difference in VTE risk between theses and those containing desogestrel. “Women must be fully informed of these very small risks. The type of pill provided is for the women together with her doctor or other family planning professionals jointly to decide in the light of her individual medical history.”
07.03.01 Ethinylestradiol 20mcg / gestodene 75 mcg pill 21-days Aidulan 20/75®, Femodette®, Millinette 20/75®, Sunya®

Provider notes

  • NMUH:
    • Preferred brand = Millinette 20/75
    • Millinette 20/75 is restricted to Consultants in GU Medicine ONLY
  • RFL:
    • Preferred brand = Aidulan
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
07.03.01 Ethinylestradiol 30 mcg / drospirenone 3 mg pill 21-days Lucette®, Yasmin®, Yiznell®, other brands available

Not approved for oral contraception (JFC, February 2016)

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Preferred brands = Lucette®, Yiznell® and Yasmin®
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
07.03.01 Ethinylestradiol 30 mcg / norethisterone 1.5mg pill 21-days Loestrin 30®

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • No restriction stated
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
07.03.01 Ethinylestradiol 30mcg / desogestrel 150mcg pill 21-days Gedarel 30/150®, Marvelon®, Munalea 30/150®, other brands available

Provider notes

  • NMUH:
    • Restricted to Consultants in GU Medicine ONLY = Gedarel 30/150
    • Preferred brand for Obs & Gynae = Marvelon
  • RFL:
    • No restriction stated
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Preferred brand = Marvelon
    • The CSM has advised that combined contraceptives containing gestodene or desogestrel should not be used by women with risk factors for venous thromboembolism (for further information see BNF). For other women a levonorgestrel or norethisterone-containing product is also generally the initial choice. But the statement by the Department of Health on 7 April, 1999 acknowledges the tiny difference in VTE risk between theses and those containing desogestrel. “Women must be fully informed of these very small risks. The type of pill provided is for the women together with her doctor or other family planning professionals jointly to decide in the light of her individual medical history.”
07.03.01 Ethinylestradiol 30mcg / gestodene 75 mcg pill 21-days Aidulan 30/75®, Femodene®, Katya®, other brands available

Provider notes

  • NMUH:
    • Restricted to Consultants in GU Medicine ONLY = Millinette 30/75
    • Preferred brand for Obs & Gynae = Femodene
  • RFL:
    • Preferred brand = Aidulan
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Preferred brands = Femodene
    • Millinette 30/75= for Community Clinics ONLY
    • The CSM has advised that combined contraceptives containing gestodene or desogestrel should not be used by women with risk factors for venous thromboembolism (for further information see BNF). For other women a levonorgestrel or norethisterone-containing product is also generally the initial choice. But the statement by the Department of Health on 7 April, 1999 acknowledges the tiny difference in VTE risk between theses and those containing desogestrel. “Women must be fully informed of these very small risks. The type of pill provided is for the women together with her doctor or other family planning professionals jointly to decide in the light of her individual medical history.”
07.03.01 Ethinylestradiol 30mcg / levonorgestrel 150mcg pill 21-days Microgynon 30®, Rigevidon®, Maexeni®, other brands available

Provider notes

  • NMUH:
    • Restricted to GU Medicine ONLY = Rigevidon
    • For Obs & Gynae = Microgynon 30
  • RFL:
    • Preferred brands = Maexeni, Rigevidon, Microgynon 30
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Preferred brand = Microgynon 30
    • Rigevidon= Formulary item for Community Trust
07.03.01 Ethinylestradiol 30mcg / levonorgestrel 150mcg pill 28-days Microgynon 30 ED®

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • No restriction stated
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
07.03.01 Ethinylestradiol 35 mcg / norgestimate 250 mcg pill 21-day Cilique®, Cilest®, Lizinna®

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • Preferred brand = Cilest
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • There is insufficient information to know if there is an increased risk associated with norgestimate.
04.08.01 Ethosuximide 

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • No restriction stated
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
15.02 Ethyl Chloride Cryogesic® Spray

econdary care notes

  • NMUH:
    • Non-formulary
  • RFL:
    • No restriction stated
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
07.06 Etilefrine 

Provider notes

  • NMUH:
    • For treatment of priapism in patients with sickle cell disease
    • Etilefrine 25mg Tablets, available from ‘special-order’ manufacturers or specialist importing companies
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
10.01.01 Etodolac 

Provider notes

  • NMUH:
    • Restricted to use by Rheumatology Consultants only
  • RFL:
    • Restricted to use by Rheumatology only
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Restricted to Rheumatology only
10.01.01 Etodolac modified release  

Provider notes

  • NMUH:
    • Restricted to use by Rheumatology Consultants only
  • RFL:
    • Restricted to use by Rheumatology only
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Restricted to Rheumatology only
15.01.01 Etomidate Etomidate-Lipuro®

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
15.01.01 Etomidate Hypnomidate®

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • No restriction stated
07.03.02.02 Etonogestrel 68mg subdermal implant Nexplanon®

Second-choice parenteral progestogen-only contraceptive (JFC July 2019)

Provider notes

  • NMUH:
    • Restricted to Consultants in GU Medicine ONLY.
    • Check for MHRA Drug Safety Updates
  • RFL:
    • No restriction stated
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • As above
08.01.04 Etoposide 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
    • This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system)
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
10.01.01 Etoricoxib 

Provider notes

  • NMUH:
    • Non-formulary
    • Check MHRA Drug Safety Updates 
  • RFL:
    • Restricted to use by Rheumatology only
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
05.03.01 Etravirine 

Provider notes

  • NMUH:
    • To be prescribed as per BHIVA Guidelines by the HIV team only
  • RFL:
    • HIV medicine only
  • RNOH:
    • Non-formulary  
  • UCLH:
  • WH:
    • Non-formulary
13.02.01 Eucerin ® Intensive cream/lotion Urea 10%

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • No restriction stated
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
08.01.05 Everolimus Votubia®

DO NOT CONFUSE Afinitor®, Votubia® AND Certican® AS THEY ARE LICENSED FOR DIFFERENT INDICATIONS.

Approved for:

  • renal angiomyoplipomas who are at risk of complications but who do not require immediate surgery, and is reserved for patients with multiple AMLs in one or both kidneys and one or more lesions of >3cm in diameter. Restricted to renal consultants in renal genetics specialist clinic only (JFC July 2013)
  • refractory focal onset seizures associated with tuberous sclerosis complex (TSC) in line with NHS England Commissioning Policy (JFC June 2019)

 

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Approved for renal angiomyoplipomas (see above and NHSE Commissioning Policy)
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
08.01.05 Everolimus Afinitor®

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

DO NOT CONFUSE Afinitor®, Votubia® AND Certican® AS THEY ARE LICENSED FOR DIFFERENT INDICATIONS

See NICE TA for eligibility criteria

Provider notes

  • NMUH:
    • This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when in line with NICE recommendations and/or Local Trust Guidelines.
    • TA432, 449 and 498 do not apply at NMUH as services not offered.
    • See links below
  • RFL:
    • As per NICE guidance (see below)
    • This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system).  Additionally for in-patients this drug must be prescribed on an in-patient prescription chart (paper or electronic)
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
02.12 Evolocumab 

Provider notes

  • NMUH:
    • This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines.
    • To be prescribed on the recommendation of Consultant Cardiologists and Endocrinologists ONLY
    • See links below
  • RFL:
    • As per NICE guidance
    • Restricted to Lipid Clinic
    • Prescriptions are supplied monthly for first 4 months then 3 monthly.  Homecare service also available
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • Non-formulary
08.03.04.01 Exemestane 

Provider notes

  • NMUH:
    • This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines
  • RFL:
    • No restriction stated
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • Exemestane is indicated for 3rd line treatment (after tamoxifen and anastrazole) in post-menopausal women with metastatic breast cancer
02.12 Ezetimibe 

Primary hypercholesterolaemia where a statin is contraindicated, not tolerated (consider referral to lipid specialist) or as an adjunct where high-intensity statins have failed to sufficiently reduce cholesterol levels

Provider notes

  • NMUH:
    • This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines.
    • See links below
  • RFL:
    • See indication above and NICE TA
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • The use of ezetimibe is reserved as a 3rd line agent where treatment with simvastatin, and then atorvastatin has failed, and for patients for whom the use of a statin is contraindicated, or who are statin intolerant, in accordance with the NICE guidance.
02.11 Factor IX 

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Available from the haemophilia centre
    • Alphanine®, Alprolix® (eftrenonacog alfa), Benefix® (nonacog alfa), Idelvion® (albutrepenonacog alfa), Refixia® (nonacog beta pegol)
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
02.11 Factor VIIa, recombinant Novo 7®

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Available from the haemophilia centre
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • Non-formulary
02.11 Factor VIII 

Provider notes

  • NMUH:
    • PbR (Payment by Results) excluded drug
  • RFL:
    • Available from the Haemophilia centre
    • Advate® (octocog alfa), Elocta® (efmoroctocog alfa), Fanhdi®, Fibrogammin®, Helixate Nexgen® (octocog alfa), Kogenate® (octocog alfa), Novoeight®, Optivate®, Refacto AF® (moroctocog alfa)
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
02.11 Factor VIII + von Willebrand factor 

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Available through the haemophilia centre
    • Voncento®, Wilate®, Haemate P®
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
02.11 Factor VIII Inhibitor Bypassing Fraction 

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Available through the haemophilia centre
    • Feiba®
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
02.11 Factor VIII, recombinant Susoctocog alfa; Obizur®

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Approved for acquired haemophilia A in line with NHSE clinical commissioning policy 170061P (RFL only; JFC November 2018)
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
02.11 Factor X Coagadex®

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Available from the haemphilia centre
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
02.11 Factor XI Hemoleven®

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Available from the Haemphilia centre
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
02.11 Factor XIII Fraction, Dried 

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Available from the haemophilia centre
  • RNOH:
    • Non-formulary
  • UCLH:
    • Non-formulary
  • WH:
    • Non-formulary
05.03.02.01 Famciclovir 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • For Microbiology use only
10.01.04 Febuxostat 

Provider notes

  • NMUH:
    • This medicine has a positive NICE TA and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines.
    • Restricted to Consultant Rheumatologists or under the direction of a Consultant Rheumatologist.
    • See links below
  • RFL:
    • Restricted to Consultant Rheumatologists in line with NICE TA
  • RNOH:
    • See link below
  • UCLH:
  • WH:
    • As per NICE TA
10.03.02 Felbinac 3% gel 

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Restricted to the Rheumatology team ONLY
    • Available over the counter without a prescription
02.06.02 Felodipine 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • Non-formulary
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • Non-formulary
14.04 Fendrix® Hepatitis B vaccine Single Component

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • No restriction stated
  • RNOH:
    • Non-formulary
  • UCLH:
    • Non-formulary
  • WH:
    • Non-formulary
02.12 Fenofibrate 

Provider notes

  • NMUH:
    • Lipantil stocked
  • RFL:
    • Restricted to Lipid Clinic
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • 160mg tablets only
15.01.04.03 Fentanyl 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • Restricted Only on the recommendation of the Pain Team for patients intolerant to or with contraindications to morphine and oxycodone
  • UCLH:
  • WH:
    • No restriction stated
04.07.02 Fentanyl buccal tablets Effentora®

Provider notes

  • NMUH:
    • Non-formulary 
  • RFL:
    • Approved for the pallative care and pain management team only
  • RNOH:
    • Only on the recommendation of the Pain Team for inpatients intolerant to or with contraindications to morphine and oxycodone. Not to be prescribed on discharge.
  • UCLH:
  • WH:
    • Non-formulary
04.07.02 Fentanyl patch 

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • No restriction stated
21.01 Fentanyl patch 

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Fentanyl patch for acute post-operative pain in primary knee replacement surgery
30 patient evaluation at RNOH site only. Evaluation to be reviewed at JFC (April 2015)

04.07.02 Fentanyl sublingual tablets Abstral®

Approved for the treatment of breakthrough, chronic, cancer pain in palliative patients taking opioid agonists, who are unable to obtain relief from, or are intolerant to, oral morphine and oxycodone immediate release. Pain or Palliative Care recommendation only (JFC September 2018).

Provider notes

  • NMUH:
    • Restricted to haematology and palliative care teams only
  • RFL:
    • Approved for the palliative care and pain management team only
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • As above
09.01.01.02 Ferric Carboxymaltose Ferinject®

See local guidance for iron replacement

Approved for:


  1. Iron deficient anaemia in Obstetrics (January 2017)
  2. Iron deficient anaemia in adult outpatients only, not in patients in first trimester of pregnancy or for patient on haemodialysis (March 2017)

Provider notes

  • NMUH:
    • To be used for day case patients and out patients ONLY
    • See link below for parenteral irons prescribing guideline.
    • Ferinject must be prescribed on the specific Daycase Ferinject prescription form; see link below
    • Note: Parenteral iron is contraindicated in the first trimester of pregnancy. For dose of Ferinject in patients with haemodialysis dependent chronic kidney disease, refer to the summary of prouct characteristics.
    • Check MHRA Drug Safety updates
  • RFL:
    • Approved for use in private patients at RFL
    • Approved for use in renal and liver patients at RFH
  • RNOH:
    • For the optimisation of pre-operative anaemia in patients aged 14 to 17 years.
  • UCLH:
    • Restricted to outpatients / daycase / facilitate inpatient discharge
  • WH:
    • Parenteral iron should only be considered if oral therapy has failed due to lack of patient co-operation, severe gastrointestinal side effects, continuing severe blood loss or malabsorption. Provided oral therapy is taken reliably and is absorbed, then the haemoglobin response is not significantly faster with the parenteral route.
17 Ferric subsulphate solution  Monsels

Approved as a haemostatic agent in colposcopy (JFC January 2019)

Provider notes

  • NMUH:
    • As above
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    •  As above
09.01.01.01 Ferrous fumarate 

Provider notes

  • NMUH:
    • No restriction stated (not Galfer)
  • RFL:
    • Non-formulary
  • RNOH:
    • Oral syrup available as 140 mg/5mL
  • UCLH:
  • WH:
    • Oral syrup available as 140 mg/5mL (ONLY formulation available)
09.01.01.01 Ferrous fumarate + Folic acid Pregaday®

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
09.01.01.01 Ferrous gluconate 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • Ferrous gluconate contains a lower content of elemental iron and therefore may be better tolerated than ferrous sulphate.
09.01.01.01 Ferrous sulphate 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • First choice for iron-deficiency anaemia
  • UCLH:
  • WH:
    • No restriction stated
09.01.01.01 Ferrous sulphate modified release Ferrograd®

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
03.04.01 Fexofenadine 

Additionally approved for the treatment of chronic spontaneous urticaria at a 'high dose' for patients who do not respond to 'high dose' cetirizine (JFC November 2018).  Notes: initiate at 180mg daily and increase according to response to a maximum of 360mg twice-daily (720mg daily).

Provider notes

  • NMUH:
    • As per indication stated above
  • RFL:
    • No restriction stated
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • As above
17.01 Fibrin Sealant Evicel®

Approved for Dura matter closure (July 2015)


Provider notes

  • RNOH:
    • Restricted for soft tissue sarcoma surgery, primary bone tumour surgery, complex revision hip and knee surgery and dura mater closure
  • RFL:
    • Renal / Urology surgery
17.01 Fibrin Sealant Tisseel® Ready to Use

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • For use in Vascular / Opthalmology surgery
  • RNOH:
  • UCLH:
  • WH:
  • MEH approvals:
    • Approved for conjunctival surgery in preference to sutures for pterygium surgery (January 2013)
05.01.07 Fidaxomicin 

Consultant microbiologist approval only for multiple recurrent Clostridium difficile infections (at least three). Fidaxomicin could also be used in patients in extremis when all other drugs had failed (October 2012)

Provider notes

  • NMUH:
    • Microbiology approval only
  • RFL:
    • Consultant microbiologist approval only  
  • RNOH:
    • Microbiology approval only
  • UCLH:
  • WH:
    • Microbiology approval only
09.01.06 Filgrastim 

Provider notes

  • NMUH:
    • Zarzio® is the preferred brand
    • Check MHRA Drugs Safety Alerts
    • See link below
  • RFL:
    • Accofil® is the preferred brand (from June 2019)
  • RNOH:
    • Requires HAEMATOLOGIST approval
    • Store in a refrigerator
  • UCLH:
  • WH:
    • No restriction stated
06.04.02 Finasteride 

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Provider notes

  • NMUH:
    • Restricted to Urology use only
  • RFL:
    • No restriction stated
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • Finasteride should be initiated by urology only for the treatment of patients with BPH in whom alpha-blockers have failed.
08.02.04 Fingolimod 

Provider notes

  • NMUH:
    • This medicine has a positive NICE Technology Appraisal but is not listed in the Trust Medicines Formulary as the service is not offered at NMUH.
    • Check MHRA Drug Safety Updates
  • RFL:
    • As per NICE TA
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
02.03.02 Flecainide 

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • No restriction stated
04.07.03 Flecainide 

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Specialist use only
21.01 Florbetapir F 18 injection 

Amyvid (florbetapir) for Alzheimer's disease
10 patient evaluation at RFL site only. Evaluation to be reviewed at JFC (JFC September 2014 and February 2015)

17.01 Flowable haemostatic agent with thrombin Surgiflo®

Approved for complex spinal surgeries. Individual Trusts to decide to choose between Surgilfo and Floseal (choice largely based on acquisition cost and surgeon familiarity) (July 2016)

17.01 Flowable haemostatic agent with thrombin Floseal®

Approved for complex spinal surgeries. Individual Trusts to decide to choose between Surgilfo and Floseal (choice largely based on acquisition cost and surgeon familiarity) (July 2016)

Provider notes

  • RFL:
    • Renal / Urology surgery
13.04 Flucinolone Acetonide 0.0025% - Topical Synalar 1 in 10 Dilution®

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • No restriction stated
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • Non-formulary
05.01.01.02 Flucloxacillin 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • No restriction stated
05.02 Fluconazole 

Provider notes

  • NMUH:
    • Infusion restricted to Microbiology Consultants use only
  • RFL:
    • No restriction stated
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • Restricted antifungal. Microbiology approval only
05.02 Flucytosine infusion 

Provider notes

  • NMUH:
    • Restricted to Microbiology Consultants use only
  • RFL:
    • Microbiology / ID approval required 
  • RNOH:
    • Non-formulary  
  • UCLH:
  • WH:
    • Microbiology approval only
05.02 Flucytosine tablets 

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • 500mg tablets
08.01.03 Fludarabine 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system).  Additionally for in-patients this drug must be prescribed on an in-patient prescription chart (paper or electronic)
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
06.03.01 Fludrocortisone 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • No restriction stated
13.04 Fludroxycortide - topical Haelan®

Provider notes

  • NMUH:
    • Haelan tape is FORMULARY, for use on keloid scars only.
    • Haelan cream and Haelan ointment are NON-FORMULARY.
  • RFL:
    • Restricted to Dermatologists only
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Tape only
15.01.07 Flumazenil 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • Flumazenil is used to reverse the sedative effects of benzodiazepines in anaesthetic, intensive care and diagnostic procedures. It should not be used for routine benzodiazepine reversal. It has a shorter half-life than diazepam and midazolam and care is required to avoid the risk of resedation.
12.01.01 Flumetasone 0.02% + Clioquinol 1% ear drops Locorten-Vioform®

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
13.04 Fluocinolone acetonide 0.00625% - Topical Synalar 1 in 4 Dilution®

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • cream and ointment
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
13.04 Fluocinolone acetonide 0.025% - Topical Synalar®

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Cream, ointment and gel available
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Gel 0.025% (Synalar) 30g ONLY
13.04 Fluocinolone acetonide 0.025% + Clioquinol 3%- Topical Synalar C®

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • Cream and Ointment available
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
11.04.01 Fluocinolone acetonide intravitreal implant Iluvien®

See NICE TA for eligibility criteria

Provider notes

  • NMUH:
    • This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines. 
    • To be prescribed by Consultant Ophthalmologists ONLY for the treatment of Macular Oedema Secondary to Retinal Vein Occlusion as per NICE guidance.
    • See links below
  • RFL:
    • Diabetic macular oedema, Specialist use in line with NICE TA
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • For Diabetic macular oedema after an inadequate response to prior therapy (Nov 2013 TA301)
13.04 Fluocinonide 0.05% - Topical Metosyn®

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • cream and ointment available
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
11.08.02 Fluorescein eye drops - unit dose 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • 1% fluorescein sodium is not kept at RFH
    • Diagnostic examinations
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • 2% only
11.99.99.99 FluorEscein injection 

Provider notes

  • NMUH:
    • 20% available
  • RFL:
    • 10% & 20% available
    • Ophthalmic angiography, e.g. examination of fundus and iris vasculature, sclera and episclera 
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
11.08.02 Fluorescein paper strips 1mg 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
09.05.03 Fluorides En-De-Kay® Tablet

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • For Islington Community Only - direct ward delivery
09.05.03 Fluorides En-De-Kay® Oral Drops

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • For Islington community only
09.05.03 Fluorides Duraphat® Toothpaste

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • 0.619% toothpaste available for Simmons House and Islington community clinics only 
17 Fluorocholine-18F 

Provider notes

  • RFL:
    • PETC/CT imaging for staging of prostate cancer (RFL only, September 2013)
11.04.01 Fluorometholone 0.1% eye drops FML®

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • For mild inflammation
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
13.08.01 Fluorouracil 0.5% + Salicylic acid 10% solution Actikerall®

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Restricted to dermatology
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
13.08.01 Fluorouracil 5% cream Efudix®

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • Restricted to Dermatology only
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
08.01.03 Fluorouracil injection 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
    • This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system)
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
04.03.03 Fluoxetine 

Provider notes

  • NMUH:
    • See links below
  • RFL:
    • No restriction stated
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • Caps 20mg. Liquid 20mg/5ml. Only
  • CIFT:
    • Approved for
      • Depression
      • Generalized Anxiety Disorder (GAD) and panic disorder - 1st/2nd line
      • Social Anxiety Disorder (SAD) - 1st/2nd line
  • BEHMT:
    • Approved for
      • Depression
      • Obsessive-compulsive disorder
      • Bulimia nervosa
04.02.02 Flupentixol decanoate depot injection Depixol® Conc.

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • Restricted for initiation until after a discussion with liaison psychiatry team
  • RNOH:
    • Non-formulary  
  • UCLH:
  • WH:
    • Restricted for initiation by a Consultant Psychiatrist only
04.02.02 Flupentixol decanoate depot injection Depixol® Low Volume

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • Restricted for initiation until after a discussion with liaison psychiatry team
  • RNOH:
    • Non-formulary  
  • UCLH:
  • WH:
    • Restricted for initiation by a Consultant Psychiatrist only
04.02.02 Flupentixol decanoate depot injection Depixol®

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • Restricted for initiation until after a discussion with liaison psychiatry team
  • RNOH:
    • Non-formulary  
  • UCLH:
  • WH:
    • Restricted for initiation by a Consultant Psychiatrist only
04.02.01 Flupentixol tab 

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • Restricted for initiation until after a discussion with liaison psychiatry team
  • RNOH:
    • No restriction stated  
  • UCLH:
  • WH:
    • Depot injection only
04.03.04 Flupentixol tab 

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Restricted for initiation until after a discussion with liaison psychiatry team
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
  • CIFT:
    • Approved for depression
  • BEHMT approvals:
    • Approved for depression
04.02.02 Fluphenazine decanoate depot injection Modecate®

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Restricted for initiation until after a discussion with liaison psychiatry team
  • RNOH:
    • Non-formulary  
  • UCLH:
  • WH:
    • Restricted for initiation by a Consultant Psychiatrist only
04.02.02 Fluphenazine decanoate depot injection Modecate Concentrate®

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Restricted for initiation until after a discussion with liaison psychiatry team
  • RNOH:
    • Non-formulary  
  • UCLH:
  • WH:
    • Restricted for initiation by a Consultant Psychiatrist only
08.03.04.02 Flutamide 

Provider notes

  • NMUH:
    • Restricted to Consultant Oncologist and Urologist use only
  • RFL:
    • No restriction stated
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
03.02 Fluticasone furoate + Umeclidinium + Vilanterol inhaler (DPI) Trelegy®

Approved for COPD when ICS + LAMA + LABA inhalation therapy is indicated, as per NICE guidance (JFC September 2019)

Provider notes

  • NMUH:
    • As per recommendations above
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
    • Non-formulary
  • WH:
    • As above
03.02 Fluticasone furoate + Vilanterol inhaler (DPI) Relvar Ellipta®

Approved for:

  • COPD (JFC February 2017)
  • Asthma (JFC May 2017)
  • Adolescent asthma; age 12-19 (JFC May 2019)

Provider notes

  • NMUH:
    • See links below
  • RFL:
    • No restriction stated
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • As above
12.02.01 Fluticasone furoate 27.5mcg/spray nasal spray 

Provider notes

  • NMUH:
    • Restricted for use in paediatric patients ONLY
  • RFL:
    • No restriction stated
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
01.10 Fluticasone inhaler (DPI) 

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Approved as first-line choice (before budesonide nasules) for eosinophilic oesophagitis in adults. Fluticasone Accuhaler (dry powder inhaler) '250' should be sucked 1-2 doses twice daily and down titrate dose for maintenance dosing (JFC February 2018)

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
    • Non-formulary
  • WH:
    • As above
03.02 Fluticasone inhaler (pMDI + DPI) Flixotide®

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Provider notes

  • NMUH:
    • Restricted to Paediatric Consultants use only.
  • RFL:
    • pMDI and Accuhaler available
  • RNOH:
    • For continuation of therapy
  • UCLH:
  • WH:
    • Turbohalers, Accu-halers and Autohalers are reserved for unable to tolerate an MDI with a spacing device.
    • 50 micrograms, 125 micrograms, 250 micrograms/metered inhalation CFC-Free (Flixotide Evohaler) & Accu- haler 500 micrograms/ metered inhalation ONLY
13.04 Fluticasone propionate - Topical Cutivate®

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Restricted to paediatrics only.
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
03.02 Fluticasone propionate + Formoterol inhaler (pMDI) Flutiform®

Approved for asthma requiring a combined ICS/LABA (May 2013)

  • NMUH:
    • See links below
  • RFL:
    • No restriction stated
  • RNOH:
    • Restricted
  • UCLH:
  • WH:
    • Non-formulary
03.02 Fluticasone propionate + Salmeterol inhaler (DPI) AirFluSal Forspiro®

Provider notes

  • NMUH:
    • See link below
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
    • Non-formulary
  • WH:
    • Non-formulary
03.02 Fluticasone propionate + Salmeterol inhaler (pMDI + DPI) Sirdupla®, Seretide®

Provider notes

  • NMUH:
    • See links below
    • Seretide 125 & 250 Evohalers and are NON-FORMULARY, except in paediatric patients.
    • Seretide 500 is non-formulary. AirFlusal Fospiro 50/500 should be used instead. See link below for further information.
  • RFL:
    • No restriction stated
  • RNOH:
    • Restricted
  • UCLH:
  • WH:
    • Approved for prescribing by Respiratory Team only. All pharmacists must ensure inpatients have been reviewed by Respiratory Nurse Specialist before supplying prior to prescribing.
12.02.01 Fluticasone propionate 400mcg/unit nasal drops 

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • No restriction stated
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
12.02.01 Fluticasone propionate 50mcg/spray nasal spray 

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • No restriction stated
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • No restriction stated
12.04 Fluticasone propionate nasules / nasal spray 

Approved for Oral lichen planus after failure of betamethasone (JFC June 2017)

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
    • Non-formulary
  • WH:
    • Indicated for oral linchen planus (OLP) only
04.03.03 Fluvoxamine maleate 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • BCF: No restriction stated
    • RFH: Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
  • CIFT:
    • Non-formulary
  • BEHMT
    • Non-formulary
09.01.02 Folic Acid 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
    • When used in combination with oral methotrexate various regimens are used from once-weekly, twice-weekly to daily use (except on day of methotrexate)
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • Folic acid is indicated in confirmed folate deficiency due to dietary lack, gastrointestinal disease, pregnancy, chronic haemolytic states, myeloproliferative disorders, haemodialysis, and parenteral nutrition, intensive care of the very sick patient or in premature infants. Folic acid can be used to correct serious haematological changes caused by dihydrofolate reductase inhibitors (DFRIs), after the DFRI has been discontinued. Examples of DFRIs include trimethoprim and co-trimoxazole.
    • Before treating megaloblastic anaemia with folic acid alone, vitamin B12 deficiency MUST be excluded. Folic acid may relieve the haematological features of vitamin B12 deficiency and allow neuropathy to develop undetected. If treatment must be started immediately, both folic acid and hydroxocobalamin should be given.
08.01.05 Folinic acid + fluorouracil + irinotecan (FOLFIRI) 

Approved for:

  • 2nd / 3rd line treatment of inoperable gasto-oesophageal adenocarcinoma (May 2015)
  • 2nd line for high grade neuroendocrine tumour (March 2016)

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • See above
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
08.01.05 Folinic acid + fluorouracil + oxaliplatin + irinotecan (FOLFOXIRI) 

Approved for 1st line treatment of unresectable metastatic colorectal cancer (May 2015)

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • As above
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
08.01.05 Folinic acid + fluorouracil + oxaliplatin + irinotecan (mFOLFIRINOX) 

Approved adjuvant treatment of pancreatic cancer (JFC September 2018)

Provider notes

  • NMUH:
    • aS PER INDICATION ABOVE
  • RFL:
    • As above
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • As above
02.08.01 Fondaparinux 

Provider notes

  • NMUH:
    • Restricted to use for patients with Unstable Angina / NSTEMI.
    • See Trust Guideline on use
  • RFL:
    • Restricted to use for patients with Unstable Angina / NSTEMI
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • Restricted for use in unstable angina and NSTMEI
A2.02.02.03 Foodlink Complete Powder 
  • Sachets - requires a patient  to be able to mix with full-fat milk 
  • Chocolate, strawberry, banana, natural
  • Gluten-free
  • Suitable for vegetarians
  • May not be appropriate in the following patients
    • Patients requiring complete nutrition e.g. reliant entirely on supplements, patients requiring enteral feeding
    • Renal patients (CKD stage 4 and 5)
    • Vegans and patients with lactose intolerance

Provider notes

Non-formulary 

Primary care notes

First-choice product - see Primary Care Guidance

03.01.01.01 Formoterol fumarate inhaler (DPI) Oxis® Turbohaler

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • No restriction stated
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Turbohalers, Accuhalers and Autohalers are reserved for patients unable to tolerate an MDI with spacing device.
A2.02.02.03 Forticreme Complete 

Provider notes

  • NMUH:
    • Stroke, Dysphagia, fluid restrictions, CAPD, HD, Disease related malnutrition, short bowel syndrome, Intractable malabsorption, pre-operative preparation for those who are malnourished, inflammatory bowel disease, total gastrectomy, bowel fistulae, dysphagiaSemi-solid. High in protein. For dysphagia or requiring a soft diet, tolerating low volume of food
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
A2.02.02.03 Fortisip Compact Protein 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
05.03.01 Fosamprenavir 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • HIV medicine only
  • RNOH:
    • Non-formulary  
  • UCLH:
  • WH:
    • No restriction stated
13.10.03 Foscarnet sodium 2% cream 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • Non-formulary
  • RNOH:
  • UCLH:
  • WH:
05.03.02.02 Foscarnet sodium IV 

Provider notes

  • NMUH:
    • Restricted for HIV patients use only.
  • RFL:
    • Restricted to HIV; Transplant patients; Haematology; Oncology
    • Virology approval required for all other indications
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
05.01.07 Fosfomycin intravenous 

Microbiology approval only for treatment of infections, or suspected infections, caused by multi-drug resistant Gram-negative organisms, including ESBLs (JFC August 2016)

Provider notes

  • NMUH:
    • Should only be prescribed following advice from a Consultant Microbiologist
  • RFL:
    • Consultant Microbiology/ID approval only
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • Microbiology approval only
05.01.07 Fosfomycin oral sachets 

Approved for prescribing in primary and secondary care for symptomatic UTI sensitive to fosfomycin, where patients are unable to receive, or the organism is resistant to, first-line antibiotics (July 2015)

Provider notes

  • NMUH:
    • Consultant Microbiology approval only
  • RFL:
    • See Microguide for approved indications
    • Microbiology/ID approval required for all other indications
  • RNOH:
    • Microbiology approval only
  • UCLH:
  • WH:
    • Microbiology approval only
08.03.04.01 Fulvestrant 

Approved as Third-line therapy for locally advanced or metastatic HER2-, ER+ breast cancer in postmenopausal women without symptomatic visceral disease, that has recurred or progressed after a non-steroidal aromatase inhibitor and tamoxifen (JFC February 2016).

Provider notes

  • NMUH:
    • To be prescribed by Oncology Consultants ONLY
    • See indication above
  • RFL:
    • Approved as per above
    • Approved as per NICE TA593 in combination with ribociclib
    • Approved as per NICE TA597 in combination with abemaciclib
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • See indication above
02.02.02 Furosemide 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • No restriction stated
11.03.01 Fusidic Acid 1% gel 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • For Staph aureus eye infections.
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Restricted to Paediatrics and Ophthalmology out-patients
04.07.03 Gabapentin 

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Second choice agent for neuropathic pain after first-line amitriptyline.

 Provider notes

  • NMUH:
    • See link below
  • RFL:
    • No restriction stated
  • RNOH:
    • Second choice agent for neuropathic pain
  • UCLH:
  • WH:
    • Second choice agent for neuropathic pain; also for orthopaedics - post surgery
04.08.01 Gabapentin 

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • Neurology initiation and continuation only
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • Should only be commenced on the recommendation of a Neurologist
    • Neurontin available as 100mg and 300mg capsules
04.11 Galantamine 

Provider notes

  • NMUH:
    • This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines
    • See link below
    • Supply only to be made for CONTINUATION OF THERAPY
  • RFL:
    • Non-formulary
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • No restriction stated
04.11 Galantamine modified release 

Provider notes

  • NMUH:
    • This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines
    • See link below
    • Supply only to be made for CONTINUATION OF THERAPY
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
09.08.01 Galsulfase 

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Restricted to the lysosomal storage disorders unit
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
11.03.03 Ganciclovir 0.15% ophthalmic gel 
  • NMUH:
    • Non-formulary
  • RFL:
    • Restricted to 2nd line for Herpes simplex keratitis
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
11.03.03 Ganciclovir intravitreal injection 

 Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Specialist use only for CMV retinitis 
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • This is an unlicensed special and restricted to Ophthalmology
05.03.02.02 Ganciclovir IV 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • Restricted to HIV; Transplants; Other immunosuppressed patients
    • Virology approval required for all other indications
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Check with Microbiology
05.03.02.02 Ganciclovir oral 

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Check with Microbiology
14.04 Gardasil® Human papilloma virus vaccine

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Red (hospital only prescribing) for PHE HPV vaccination programme for men who have sex with men (MSM)

Grey for PHE HPV vaccination programme for adolescents in school year 8 (age 12-13 years)

Approved for HPV vaccination for MSM (men who have sex with men) in line with Public Health England national immunisation schedule. Restricted to GUM and HIV clinics (JFC September 2018). 

Provider notes

  • NMUH:
    • Restricted to GUM and HIV clinics in line with PHE recommendations
  • RFL:
    • No restriction stated
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
21.01 Gardasil® Human papillomavirus vaccine

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Recalcitrant warts
5 patient evaluation at RFL site only (JFC March 2013)

01.01.02 Gastrocote® 

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
01.01.02 Gaviscon Advance® suspension 

Provider notes

  • NMUH:
    • Gaviscon Advance Tablets are non-formulary and will not be stocked
    • Gaviscon Advance suspension is formulary
  • RFL:
    • Non-formulary
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • Suspension only available
01.01.02 Gaviscon Infant® 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • No restriction stated
08.01.05 Gefitinib 

Provider notes

  • NMUH:
    • This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines.
    • To be prescribed by the Oncology Team ONLY.
    • See links below
  • RFL:
    • Approved for non-small cell lung cancer in line with NICE
    • This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system).  Additionally for in-patients this drug must be prescribed on an in-patient prescription chart (paper or electronic)
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Restricted to the treatment of NSCLC with EGFR mutation.
09.02.02.02 Gelatin intravenous infusion Gelaspan®

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • BCF: No restriction stated
    • RFH: Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
09.02.02.02 Gelatin intravenous infusion Geloplasma®

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
09.02.02.02 Gelatin intravenous infusion Gelofusine®

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • BCF: Non-formulary
    • RFH: No restriction stated
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
09.02.02.02 Gelatin intravenous infusion Volplex®

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
08.01.03 Gemcitabine 

See NICE TA for eligibility criteria

Provider notes

  • NMUH:
    • This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines.
    • See links below
    • TA389 NOT APPLICABLE TO TRUST AS SERVICE IS NOT PROVIDED
  • RFL:
    • No restriction stated
    • This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system)
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
11.03.01 Gentamicin 0.3% drops Ophthalmic

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • Approved for bacterial keratitis.
    • Gentamicin 0.3% eye drops (preservative free) and Gentamicin 0.3% eye drops available.
    • Renal use - see PD antibiotic policies
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • No restriction stated
12.01.01 Gentamicin 0.3% drops Ear

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • No restriction stated
11.03.01 Gentamicin Forte 1.5% eye drops 

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Gentamicin Forte 1.5 % Eye Drops 10 ml Bottle and Gentamicin Forte WITHOUT PRESERVATIVE available 
    • These are unlicensed specials and restricted to Ophthalmology for the treatment of bacterial keratitis.
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Gentamicin Forte 1.5 % Eye Drops 10 ml Bottle and Gentamicin Forte WITHOUT PRESERVATIVE available 
    • These are unlicensed specials and restricted to Ophthalmology.
05.01.04 Gentamicin injection 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • Refer to gentamicin prescribing guidelines in Microguide
  • RNOH:
    • Different brands of gentamicin 80mg in 2mL vials are stocked at RNOH
    • The Amdipharm, Hospira and Sanofi brands are licensed for administration intramuscularly (IM) and intravenously (IV) and will be kept as stock in all ward areas.
    • The Wockhardt brand is licensed for intravenous route (IV) only and will be stocked in Theatres only. This formulation must not be administered intramuscularly.
  • UCLH:
  • WH:
    • No restriction stated
12.03.05 Glandosane® oral spray 

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • No restriction stated
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • Glandosane may be prescribed by an accredited Speech and Language Therapist.
08.02.04 Glatiramer acetate 

Approve for relapsing-remitting multiple sclerosis in line with NHS England Commissioning (JFC Feb 2016).

Brabio® is the preferred brand.

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Restricted to Neurology for MS in line with NICE TA
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • For relapsing-remitting multiple sclerosis, see above
05.03.03.02 Glecaprevir + Pibrentasvir 

Provider notes

  • NMUH:
    • This medicines has a positive NICE TA and will be included in the formulary once NMUH is able to provide this medicine VAT free.
  • RFL:
    • Approved for use by Hepatology for the treatment of Hepatitis C in line with NICE guidance
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
06.01.02.01 Glibenclamide 

Withdrawn from the UK market (November 2019).

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • No restriction stated
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • Glibenclamide can cause profound hypoglycaemia, especially in the elderly
06.01.02.01 Gliclazide 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • Gliclazide has been reported to cause less weight gain than other Sulphonylureas.
    • Tolbutamide and Gliclazide are the drugs of choice in renal impairment.
    • Tolbutamide is short acting. Gliclazide is longer acting and is principally metabolised and inactivated in the liver.
06.01.02.01 Glimepiride 

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • No restriction stated
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Glimepiride is available for supply on consultant signature only, for the treatment of overweight Type II diabetics, or those with compliance problems.
06.01.02.01 Glipizide 

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • No restriction stated
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
06.01.04 Glucagon GlucaGen® HypoKit

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • For use in accordance with the RNOH Hypoglycaemia Emergency Protocol (see link below)
  • UCLH:
  • WH:
    • No restriction stated
A2.07 Glucose 

Provider notes

  • NMUH:
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
06.01.04 Glucose gel 40% GlucoGel®, Glucoboost®, Dextrogel®

Provider notes

  • NMUH:
    • Glucoboost is stocked at NMUH
  • RFL:
    • No restriction stated
  • RNOH:
    • For use in accordance with the RNOH Hypoglycaemia Emergency Protocol (see link below)
  • UCLH:
  • WH:
    • Non-formulary
09.02.02.01 Glucose Intravenous 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • Glucose 5% (100 mL, 250 mL, 500 mL and 1000 mL)
    • Glucose 10% (500 mL)
    • Glucose 20% (500 mL)
    • Glucose 50% (50 mL)
    • Glucose 1% in compound sodium lactate (Hartmann's) (1000 mL)
  • UCLH:
  • WH:
    • No restriction stated
06.01.06 Glucose urine test strip Diastix®

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • No restriction stated
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
13.07 Glutaraldehyde 10% solution Glutarol®

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
01.06.02 Glycerol (Glycerin) 

Provider notes

  • NMUH:
    • See link below
  • RFL:
    • No restriction stated
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • Suppositories 1 g, 2 g, 4 g
11.99.99.99 Glycerol eye drops 

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • This is unlicensed and restricted to Ophthalmology
02.06.01 Glyceryl trinitrate parenteral 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • No restriction stated
01.07.04 Glyceryl Trinitrate rectal ointment 

Provider notes

  • NMUH:
    • Rectogesic brand
  • RFL:
    • Rectogesic brand - restricted to Colorectal team
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Rectogesic brand is first choice for anal fissures (4mg/g)
02.06.01 Glyceryl trinitrate short-acting (tablets and sprays) 

Provider notes

  • NMUH:
    • Nitrolingual Pumpspray and 500mcg sublingual tablets available
  • RFL:
    • Only 500 microgram tablets and 400 microgram spray kept at the RFH.
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • Sublingual tablets 500 micrograms and 400 microgram spray available at WH
02.06.01 Glyceryl trinitrate transdermal 

Provider notes

  • NMUH:
    • Restricted to venous cannulation use only.
  • RFL:
    • No restriction stated
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
07.04.04 Glycine 1.5% Irrigation Solution 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • Available as 3L bags
  • RNOH:
    • Available as 3000 mL bags
  • UCLH:
  • WH:
    • No restriction stated
15.01.03 Glycopyrronium injection 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • No restriction stated
13.12 Glycopyrronium powder Robinul®

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Approved for use in dermatology and Vascular Hyperhidrosis clinic for the treatment of hyperhidrosis
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
13.12 Glycopyrronium solution for iontophoresis 

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Approved for use by Dermatology - paediatric use
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
01.02 Glycopyrronium tablets  

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Unlicensed - 1mg and 2mg tablets available
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
13.12 Glycopyrronium tablets 

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Unlicensed - 1mg and 2mg tablets available
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
01.05.03 Golimumab 

See NCL treatment pathway for place in therapy (note: biosimilar adalimumab and biosimilar infliximab are preferred anti-TNFs; JFC April 2019).

Provider notes

  • NMUH:
    • This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines.
    • Restricted to Consultant Gastroenterologists for NICE approved indications.
    • Check MHRA Drug Safety Update.
    • See links below.
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Restricted to Consultant Gastroenterologists
    • NICE TA329 applies
10.01.03 Golimumab 

Approved for:

  • Rheumatoid arthritis in line with the NCL RA pathway
  • Ankylosing Spondylitis (see NICE TAs)
  • Psoriatic Arthritis (PsA; see NICE TAs)

Provider notes

  • NMUH:
    • This medicine has a positive NICE TA and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines
    • Restricted to Consultant Rheumatologists
    • See links below
    • Check MHRA Drug Safety Updates
  • RFL:
    • Restricted to Rheumatology
    • Approved for use in Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis and non-radiographic axial spondyloarthritis in line with NICE guidance
  • RNOH:
    • Rheumatology Consultants ONLY.
  • UCLH:
  • WH
    • As per NICE TA and above
06.05.01 Gonadorelin 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
06.07.02 Goserelin 

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • Approved to preserve fertility when using cyclophosphamide 
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
06.07.02 Goserelin 

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
06.07.02 Goserelin 

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
08.03.04.02 Goserelin 

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • Preferred product is leuprorelin
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Goserelin is reserved for the treatment of breast cancer only
A5.02.04 Granuflex 

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Hydrocolloid dressing 10 cm * 10 cm (10), 20 cm * 20 cm (5) &amp; Border dressing 10 cm * 13 cm (5), 15 cm * 15 cm (5) only
A5.02.01 GranuGel 

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
03.04.02 Grasses + Rye and Trees Pollen Extract Pollinex®

Approved for grass/tree-pollen seasonal allergic rhinitis requiring treatment with subcutaneous immunotherapy for patients over 6 years old (JFC October 2019).

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • No restriction stated
  • RNOH:
    • Non-formulary
  • UCLH:
    • Approved for:
      • Seasonal allergic rhinitis - treatment when anti-allergy drugs ineffective. Restricted to RLHIM/RNTNE and UCLH paediatric allergy clinics for tree and grass pollen allergies (UMC Oct 2018)
  • WH:
    • As above
05.02 Griseofulvin 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • Non-formulary  
  • UCLH:
  • WH:
    • No restriction stated
13.10.02 Griseofulvin 400mcg/spray Grisol AF®

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
02.05.03 Guanethidine monosulfate 

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Non-formulary
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • Non-formulary
13.05.03 Guselkumab 

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • As per NICE guidance
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
09.08.02 Haem Arginate Normosang®

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • No restriction stated
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
14.07 Haemophilus influenzae type B Combined Vaccine Menitorix®

Approved as Test vaccination to diagnose or exclude antibody deficiency including CVID and SAD (JFC May 2017)

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
    • Test vaccination to diagnose or exclude antibody deficiency including CVID and SAD (UMC March 2017)
  • WH:
    • Non-formulary
01.07.01 Haemorrhoid relief ointment 

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Anusol
  • RNOH:
    • Generic 'Haemorrhoid relief ointment'
  • UCLH:
  • WH:
    • Anusol
04.02.01 Haloperidol 

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • Restricted for initiation until after a discussion with liaison psychiatry team
  • RNOH:
    • No restriction stated  
  • UCLH:
  • WH:
    • No restriction stated
  • CIFT:
    • Approved for mania
  • BEHMT approvals:
    • Non-formulary
04.14 Haloperidol 

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
04.02.02 Haloperidol depot injection Haldol Decanoate®

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • Restricted for initiation until after a discussion with liaison psychiatry team
  • RNOH:
    • Non-formulary  
  • UCLH:
  • WH:
    • Restricted for initiation by a Consultant Psychiatrist only
14.04 Havrix Monodose® Hepatitis A vaccine Single Component

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • No restriction stated
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • Non-formulary
14.04 HBvaxPRO® Hepatitis B vaccine Single Component

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
01.03 Helicobacter Test INFAI 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
02.08.01 Heparin calcium 

Provider notes

  • NMUH:
    • See links below
  • RFL:
    • No restriction stated
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
02.08.01 Heparin sodium  

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

 Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
  • UCLH:
  • WH:
    • No restriction stated
02.08.01 Heparin sodium 

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

 

Provider notes

  • NMUH:
    • See links below
  • RFL:
    • No restriction stated
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • No restriction stated
13.13 Heparinoid 0.3% Hirudoid®

Provider notes

  • NMUH:
    • Cream is formualry and gel is non-formulary
  • RFL:
    • No restriction stated
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
14.05.02 Hepatitis B immunoglobulin for intramuscular use 

Provider notes

  • NMUH:
    • Available from Health Protection Agency
  • RFL:
    • No restriction stated
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Available from Microbiology (Ext 5084)
14.05.02 Hepatitis B immunoglobulin for intravenous use Hepatect® CP

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Restricted to liver and renal transplants
    • See liver transplant protocol for more information
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
14.04 Hepatyrix® Hepatitis A vaccine with typhoid vaccine

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • No restriction stated
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
11.03.01 Hexamidine 0.1% eye drops  

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Restricted approved for use in acanthamoeba keratitis
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
13.10.05 Histoacryl® 

Provider notes

  • NMUH:
    • Restricted for use by Gastroenterology Consultants.
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
11.05 Homatropine 1% eye drops 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
11.05 Homatropine 1% eye drops - preservative free 

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Preservative free Eye-drops Eye-drops 1% (Moorfields’ special)
02.11 Human fibrinogen Riastap®

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Available through the haemophilia centre
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
06.05.01 Human Menopausal Gonadotrophins Menogon®

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
21.01 Hyaluronic acid injection Ostenil Plus®

Hyaluronic acid injection (Ostenil Plus) to prevent surgery
Approved under evaluation at RNOH only (July 2014)

RNOH: Restricted for use in accordance with the evaluation protocol by consultants in the Shoulder and Elbow Unit

10.03.01 Hyaluronidase 

JFC approved for epidurolysis (epidural lysis of adhesions, adhesiolysis) for the treatment of chronic pain in patients presenting with radicular pain (JFC October 2016)

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • Non-formulary
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • No restriction stated
02.05.01 Hydralazine 

Red Hydralazine injection is for hospital prescribing only

Grey Hydralazine tablets have no restriction for primary care

 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • No restriction stated
A5.02.04 Hydrocoll Border 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
13.04 Hydrocortisone - Topical 

 Provider notes

  • NMUH:
    • Hydrocortisone 2.5% Ointment is FORMULARY.
    • Hydrocortisone 2.5% cream is NON-FORMULARY.
    • All other strength are available as both cream and ointment.
  • RFL:
    • 2.5% cream available
    • 0.5% and 1% available in both cream and ointment
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • No restriction stated
06.03.02 Hydrocortisone sodium phosphate Efcortesol®

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
06.03.02 Hydrocortisone sodium succinate Solu-Cortef®

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • No restriction stated
13.04 Hydrocortisone 0.25% + Crotamiton 10% - Topical Eurax-Hydrocortisone®

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • No restriction stated
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
13.04 Hydrocortisone 0.5% + Nystatin + Benzalkonium + Dimeticone - Topical Timodine®

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • Non-formulary
    • Store in a refrigerator
  • UCLH:
  • WH:
    • Non-formulary
13.04 Hydrocortisone 1% + Clotrimazole 1% - Topical Canesten HC®

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • Non-formulary
13.04 Hydrocortisone 1% + Miconazole 2% - Topical Daktacort®

Provider notes

  • NMUH:
    • Datkacort Cream is FORMULARY
    • Daktacort Ointment is NON-FORMULARY
  • RFL:
    • Both cream and ointment available
  • RNOH:
    • Store Daktacort cream in the refrigerator 
  • UCLH:
  • WH:
    • No restriction stated
13.04 Hydrocortisone 1% + Nystatin + Chlorhexidine - Topical Nystaform-HC®

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Cream and ointment
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
13.04 Hydrocortisone 1% + Urea 10% - Topical Alphaderm®

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
10.01.02.02 Hydrocortisone acetate 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • No restriction stated  
  • UCLH:
  • WH:
    • No restriction stated
13.04 Hydrocortisone Acetate 1% + Fusidic Acid 2% - Topical Fucidin H®

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • Non-formulary
01.05.02 Hydrocortisone acetate rectal foam Colifoam®

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
12.03.01 Hydrocortisone buccal tablets 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
13.04 Hydrocortisone butyrate - Topical Locoid®

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • cream, lipocream, ointment and scalp lotion available
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Cream 0.1% 30g, Ointment 0.1% 30g, Lotion 0.1% 30ml ONLY
11.04.01 Hydrocortisone sodium phosphate 3.35 mg/ml drops  Softacort®

Approved for mild non-infectious allergic or inflammatory ocular surface diseases (JFC September 2019)

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
    • Non-formulary
  • WH:
    • As above
06.03.02 Hydrocortisone tablets 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • No restriction stated
13.11.06 Hydrogen peroxide 1% cream Crystacide®

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • No restriction stated
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
12.03.04 Hydrogen peroxide 6% mouthwash BP 

Provider notes

  • NMUH:
    • Check for MHRA Drug Safety Updates
  • RFL:
    • No restriction stated
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • No restriction stated
13.11.06 Hydrogen peroxide solution 

Provider notes

  • NMUH:
    • 3% solution stocked at NMUH
    • Check MHRA drug safety updates
  • RFL:
    • No restriction stated
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • Solution 3% ONLY
13.02.01.01 Hydromol® bath and shower emollient 
  • NOT recommended for dry skin conditions including eczema atopic dermatitis (JFC January 2019)
  • Approved for ichthyosis and epidermolysis bullosa (JFC January 2019)

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Approved for ichthyosis and epidermolysis bullosa
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
13.02.01 Hydromol® cream/ointment 

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • No restriction stated
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Restricted for the use by Consultant Dermatologists ONLY
    • Ointment 125g, 500g available
04.07.02 Hydromorphone injection 

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
    • Relief of severe pain in cancer - intrathecal use for patients on high-dose intrathecal morphine requiring frequent hospital visits for pump refill or unable to tolerate side-effects. Under the National Neuromodulation Registry (UMC Sept 2016)
  • WH:
    • Non-formulary
04.07.02 Hydromorphone modified release Palladone® SR

Provider notes

  • NMUH:
    • Restricted to Consultant Haematologists and Consultant Oncologists use only
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
09.01.02 Hydroxocobalamin 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • No restriction stated
18 Hydroxocobalamin 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
08.01.05 Hydroxycarbamide 

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system).  Additionally for in-patients this drug must be prescribed on an in-patient prescription chart (paper or electronic)
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • No restriction stated
09.01.03 Hydroxycarbamide 

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Provider notes

  • NMUH:
    • Hydroxycarbamide Suspension 50mg/5ml (100 ml) unlicensed preparation is also available
  • RFL:
    • Restricted to Haematology
    • Not prescribed on Chemocare for this indication
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
10.01.03 Hydroxychloroquine 

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • Restricted to Rheumatology Consultants Only
    • See links below
  • UCLH:
  • WH:
    • No restriction stated
13.05.03 Hydroxychloroquine 

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Approved for symptomatic erosive oral lichen planus refractory to topical treatment (corticosteroids or tacrolimus) (JFC June 2018). 

DMARD fact sheet also specifies approval for "Dermatological conditions caused or aggravated by sunlight".

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • No restriction stated
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
03.04.01 Hydroxyzine 

Provider notes

  • NMUH:
    • Check for MHRA Drug Safety Updates
  • RFL:
    • No restriction stated
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • Ucerax brand for syrup only
01.02 Hyoscine butylbromide 

Provider notes

  • NMUH:
    • Check MHRA Drug Safety alerts
  • RFL:
    • No restriction stated
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • Check MHRA drug safety alerts
15.01.03 Hyoscine Hydrobromide 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • No restriction stated
04.06 Hyoscine hydrobromide patches 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • No restriction stated
04.06 Hyoscine hydrobromide tablets 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • No restriction stated
03.07 Hypertonic sodium chloride 3% nebuliser solution MucoClear® 3%

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • No restriction stated
  • RNOH:
    • Restricted for the management of altered respiratory secretions in the spinal injured patient. Requires approval from a member of the Tracheostomy team or an ITU consultant
  • UCLH:
  • WH:
    • Non-formulary
03.07 Hypertonic sodium chloride 7% nebuliser solution Nebusal®

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • No restriction stated
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
11.08.01 Hypromellose 0.3% + Dextran 70 0.1% eye drops Tears naturale®

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Tear deficiency
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
11.08.01 Hypromellose eye drops 

Provider notes

  • NMUH:
    • 0.3% and 1%
  • RFL:
    • 0.3% only
  • RNOH:
    • 0.3%
  • UCLH:
  • WH:
    • 0.3%
11.08.01 Hypromellose eye drops - unit dose 

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Restricted to ophthalmology
06.06.02 Ibandronic Acid 150mg tablets 

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Non-formulary
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • Non-formulary
06.06.02 Ibandronic Acid 50mg tablets 

Approved as second-line adjuvant therapy for post-menopausal (including those for whom it is chemically induced) women with breast cancer to prevent bone recurrence and cancer mortality, for patients without IV access/zolendronic acid toxicity (JFC February 2019).

Provider notes

  • NMUH:
    • 1st line bisphosphonate for the Prevention of skeletal events (pathological fractures, bone complications requiring radiotherapy or surgery) in patients with breast cancer and bone metastases.
  • RFL:
    • See above
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • As above
06.06.02 Ibandronic Acid IV injection 

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Non-formulary
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • Non-formulary
08.01.05 Ibrutinib 

Provider notes

  • NMUH:
    • This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines.
    • See links below
  • RFL:
    • As per NICE guidance
    • This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotheray prescribing system).  Additionally for in-patients this drug must be prescribed on an in-patient prescription chart (paper or electronic)
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • See links below
10.03.02 Ibuprofen 5 % gel 

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Non-formulary
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • Non-formulary
10.01.01 Ibuprofen immediate release 

Provider notes

  • NMUH:
    • See MHRA Drug Safety Update
  • RFL:
    • No restriction stated
  • RNOH:
    • First choice NSAID
  • UCLH:
  • WH:
    • Intravenous injection restricted to Consultant level
07.01.01.01 Ibuprofen IV injection Pedea®
  • NMUH:
    • Refer to SPC
  • RFL:
    • Restricted to neonatal unit
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
03.04.03 Icatibant 

Approved for treatment of hereditary angioedema in line with NHS Commissioning Policies (JFC June 2018)

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • For the treatment of hereditary angioedema in line with NHSE comissioning policies
    • Restricted to Immunology only
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
08.01.02 Idarubicin 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
    • This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system) Additionally for in-patients this drug must be prescribed on an in-patient prescription chart (paper or electronic)
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
02.08 Idarucizumab 

For dabigatran reversal. Restricted to patients with who have life/limb threatening bleeding, uncontrolled bleeding, or require emergency surgery (February 2016)

Provider notes

  • NMUH:
    • See link below
  • RFL:
    • As above
    • Haemophilia recommendation only
  • RNOH:
    • No restriction stated
  • UCLH:
    • Kept in blood transfusion lab and restricted to thrombosis haematology consultants only
  • WH:
    • Non-formulary
08.01.05 Idelalisib tabs 

Idelalisib should not be initiated as a first-line treatment in chronic lymphocytic leukaemia (CLL) patients with 17p deletion or TP53 mutation - see 'Direct Communication' below.

See NICE TA for eligibility criteria

Provider notes

  • NMUH:
    • This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines.
    • See links below
  • RFL:
    • As per NICE guidance
    • This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system).  Additionally for in-patients this drug must be prescribed on an in-patient prescription chart (paper or electronic)
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
09.08.01 Idursulfase 

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Restricted to the lysosomal storage disorders unit
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
08.01.01 Ifosfamide 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system)
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
02.05.01 Iloprost injection  

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Approved for use in pulmonary hypertension, scleroderma and peripheral vascular disease - see local protocols
    • Also approved for use on ITU
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Available on named patient basis only.  Contact pharmacy for further information
02.05.01 Iloprost nebules Ventavis®

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Prior funding approval required
    • Restricted to the treatment of pulmonary hypertension 
  • RNOH:
    • Non-formulary
  • UCLH:
    • Non-formulary
  • WH:
    • Non-formulary
08.01.05 Imatinib tabs 

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Gilvec for GIST only.

Generic for all other indications.

Provider notes

  • NMUH:
    • This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines.
    • To be prescribed by the Haematology Team ONLY.
    • See links below
  • RFL:
    • As per NICE guidance
    • This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system).  Additionally for in-patients this drug must be prescribed on an in-patient prescription chart (paper or electronic)
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • As per NICE TA
09.08.01 Imiglucerase 

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Restricted to the lysosomal storage disorders unit
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
05.01.02.02 Imipenem + Cilastatin 

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Microbiology approval only
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
04.03.01 Imipramine 

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
  • CIFT:
    • Approved for depression
  • BEHMT:
    • Approved for depression
13.07 Imiquimod 3.75% cream Zyclara®

Approve for actinic keratosis (AK) and basal cell carcinoma (BCC) (JFC March 2013)

Provider notes

  • NMUH:
    • Aldara and Zyclara have been approved for actinic keratosis, by JFC, as second line options (following treatment with fluorouracil): Zyclara for surface area >25cm2, Aldara for surface area <25cm2
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
13.07 Imiquimod 5% cream Aldara®

Provider notes

  • NMUH:
    • Restricted to Dermatology and GU Consultants
    • Approved for treatment of Superficial basal cell carcinoma, as a second line option, where fluorouracil treatment is contraindicated or has not been tolerated.
    • Aldara and Zyclara have been approved for actinic keratosis, by JFC, as second-line options (following treatment with fluorouracil): Aldara for surface area <25cm2, Zyclara for surface area >25cm2
  • RFL:
    • Restricted to Dermatology only
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
14.04 Inactivated Influenza Vaccine (Split Virion) 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
A5.03.02 Inadine (Povidone-iodine) 

Provider notes

  • NMUH:
    • 9.5 x 9.5 cm is stocked at NMUH
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
02.02.01 Indapamide 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • No restriction stated
02.02.01 Indapamide modified release 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
11.08.02 Indocyanine green inj 

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • No restriction stated
  • RNOH:
    • Non-formulary
  • UCLH:
    • Non-formulary
  • WH:
    • Non-formulary
10.01.01 Indometacin immediate release caps 

Provider notes

  • NMUH:
    • See link below
  • RFL:
    • Restricted to Neurology
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • No restriction stated
10.01.01 Indometacin modified release caps 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • Restricted to Neurology
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • Restricted to Rheumatology only
07.06 Indometacin suppositories 

Approved for tocolytic therapy during pre-natal repair of myelomeningocele, a serious form of spina bifida (UCLH only; JFC February 2018)

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
    • As tocolytic therapy during pre-natal repair of myelomeningocele (fetal spina bifida) (UMC Dec 2017)
  • WH:
    • Non-formulary
07.04.01 Indoramin 

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Provider notes

  • NMUH:
    • Restricted to Urology use only
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
13.11.01 Industrial Methylated Spirit BP 

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • No restriction stated
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • No restriction stated
14.04 Infanrix Hexa® Diphtheria, tetanus, pertussis, poliomyelitis (inactivated), hepatitis b (rDNA) and Hib

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
  • UCLH:
  • WH:
    • No restriction stated
14.04 Infanrix-IPV+Hib® Diphtheria, Tetanus, Pertussis [Acellular, Component], Poliomyelitis [Inactivated] and Haemophilus T

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • No restriction stated
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • Non-formulary
A2.01.03.02 Infatrini 

Provider notes

  • NMUH:
    • Infatrini (Nutricia Clinical) Liquid (sip or tube feed) per 100mL
    • For ages 0-12 months to increase calorie intake to meet requirements and for growth.
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
01.05.03 Infliximab 

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Remsima is the preferred brand

Provider notes

  • NMUH:
    • This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines
    • Red List Medicine – Hospital Only Prescribing PbR (Payment by Results) excluded drug.
    • Restricted to Consultant Gastroenterologists for NICE approved indications.
    • Check MHRA Drug Safety Update
  • RFL:
    • Restricted to Consultant Gastroenterologists for NICE approved indications
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Restricted to Consultant Gastroenterologists
    • NICE TA163, TA187 and TA329 applies
01.10 Infliximab 

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Remsima is the preferred brand.

Approve for steroid-refractory ipilimumab-induced colitis (August 2016)

04.14 Infliximab 

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Remsima is the brand of choice

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Approved for use in neurosarcoid (Dr Kidd only)
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
10.01.03 Infliximab 

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Remsima is the brand of choice

Approved for:

  • Rheumatoid arthritis in line with the NCL RA pathway
  • Ankylosing Spondylitis (see NICE TAs)
  • Psoriatic Arthritis (PsA; see NICE TAs)

Provider notes

  • NMUH:
    • This medicine has a positive NICE TA and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines.
    • Restricted to Consultant Rheumatologists
    • See links below.
    • Check MHRA Drug Safety Updates.
  • RFL:
    • Approved for use in Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis and non-radiographic axial spondyloarthritis in line with NICE guidance
    • Approved for sarcoid (seek pharmacy advice)
    • Approved for Bechets disease (see pharmacy advice)
  • RNOH:
    • Restricted for Rheumatology Consultants ONLY.
  • UCLH:
  • WH:
    • As per NICE TA and above
13.05.03 Infliximab 

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Remsima is the preferred brand

Provider notes

  • NMUH:
    • This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines.
    • See links below
    • Restricted to Consultant Dermatologists 
    • See MHRA Drug Safety Updates
  • RFL:
    • Approved for treatment of Psoriasis and Hydradenitis Suppurativa (NHSE)
    • Approved for Pyoderma gangrenosum – prior funding approval required
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Restricted
06.01.01.03 Injection Devices Autopen®

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
06.01.01.03 Injection Devices HumaPen® Luxura

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
04.13 Inotersen injection 

See NICE HST for eligibility criteria

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Restricted to the amyloidosis clinic
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
06.01.01.01 Insulin Humulin® S

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
06.01.01.01 Insulin Actrapid®

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • No restriction stated
06.01.01.01 Insulin Aspart  NovoRapid®

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • For use in accordance with RNOH Hyperglycaemia Protocol for Type 1 Diabetes Mellitus (see link below)
  • UCLH:
  • WH:
    • No restriction stated
06.01.01.02 Insulin degludec Tresiba®

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Approved for patients with Type 1 diabetes who had
(i) intermittent adherence to basal insulin leading to recurrent DKA or HbA1c ≥9.5% despite regular intervention from MDT or
(ii) problematic hypoglycaemia and were not eligible for an insulin pump (JFC November 2017)

Provider notes

  • NMUH:
    • To be prescribed as per the indication stated above and Trust guidance (see link below)
  • RFL:
    • See indications above
  • RNOH:
    • Non-formulary
  • UCLH:
    • See indication above
  • WH:
    • As above
06.01.01.02 Insulin Detemir Levemir®

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Initiation as per Diabetes team advice
06.01.01.02 Insulin Glargine 100units/mL Lantus®

For continuation only (new starters to use Abasaglar)

Provider notes

  • NMUH:
    • Check MHRA Safety Alerts
    • See link below
  • RFL:
    • For continuation only (patients newly initiating glargine should use Abasaglar)
    • See link below
  • RNOH:
    • See link below
  • UCLH:
  • WH:
    • As above
06.01.01.02 Insulin Glargine 100units/mL Abasaglar®

Approved for:

  • Type 2 diabetes: First choice analogue basal insulin. See NCL guideline for insulin in Type 2 diabetes guideline
  • Type 1 diabetes


Provider notes

  • NMUH:
    • Check MHRA Safety Alerts
    • See link below for use in Type 2 diabetes
  • RFL:
    • Initiation of therapy under the recommendation of the diabetic team only
    • See link below for use in Type 2 diabetes
  • RNOH:
    • See link below for use in Type 2 diabetes
  • UCLH:
  • WH:
    • Initiation as per Diabetes team advice
06.01.01.01 Insulin Glulisine Apidra®

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • BCF: Not in use
    • RFH: Restricted to endocrinology 
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
06.01.01.01 Insulin Lispro 100 units/mL Humalog®

Provider notes

  • NMUH:
    • Check MHRA Drug Safety Updates 
  • RFL:
    • No restriction stated
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • No restriction stated
08.02.04 Interferon Alfa IntronA®

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Restricted to Consultant Haematologists and Gastroenterologists only
08.02.04 Interferon Alfa Roferon-A®

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Preferred brand for haematology
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
08.02.04 Interferon beta-1a Avonex®

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Restricted to Neurology for MS in line with NICE TA
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
08.02.04 Interferon beta-1a Rebif®

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Restricted to Neurology for MS in line with NICE TA
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
08.02.04 Interferon beta-1b Betaferon®

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Restricted to Neurology for MS in line with NICE TA
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
08.02.04 Interferon gamma-1b Immukin®

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Restricted to immunology use only
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
A5.02.01 Intrasite Gel 

Provider notes

  • NMUH:
    • 8g stocked only
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
07.03.04 Intra-uterine Contraceptive Devices TT 380® Slimline

Provider notes

  • NMUH:
    • Restricted to Consultants in GU Medicine ONLY
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
07.03.04 Intra-uterine Contraceptive Devices Mini TT 380 Slimline®

Provider notes

  • NMUH:
    • Restricted to Consultants in GU Medicine ONLY
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
07.03.04 Intra-uterine Contraceptive Devices Nova-T® 380

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
07.03.04 Intra-uterine Contraceptive Devices T-Safe® 380A QuickLoad

Provider notes

  • NMUH:
    • Restricted to Obs & Gynae and GU Consultants ONLY
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
07.03.02.03 Intra-uterine levonorgestrel system Kyleena®

Approved as first-line intra-uterine device for contraception (February 2019)

Provider notes

  • NMUH:
    • To be used as above
    • Restricted to sexual health clinics
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • As above
07.03.02.03 Intra-uterine levonorgestrel system Levosert®

Approved as first-line intra-uterine device for (JFC March 2018):

  • heavy menstrual bleeding
  • contraception

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • Preferred choice
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • As above
07.03.02.03 Intra-uterine levonorgestrel system Mirena®

Provider notes

  • NMUH:
    • Restricted to Consultants in GU Medicine ONLY
    • Check MHRA Drug Safety Updates
  • RFL:
    • Preferred choice
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
06.02.02 Iodine and Iodide 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • 5% oral solution available
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
08.01.05 Ipilimumab 

See NICE TA for eligibility criteria

Provider notes

  • NMUH:
    • This medicine has a positive NICE Technology Appraisal but is not listed in the Trust Medicines Formulary as the service is not offered at NMUH.
  • RFL:
    • As per NICE TA
    • This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system)
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
12.02.02 Ipratropium bromide 21 mcg/spray [0.03%] nasal spray 

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • No restriction stated
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
03.01.02 Ipratropium inhaler (pMDI) and nebuliser solution 

Provider notes

  • NMUH:
    • See links below
  • RFL:
    • No restriction stated
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • CFC-free inhaler 20 micrograms/metered inhalation ONLY
02.05.05.02 Irbesartan 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • 1st choice for hypertension / diabetes
08.01.05 Irinotecan Hydrochloride 

See NICE TA for eligibility criteria

Provider notes

  • NMUH:
    • To be prescribed by the Oncology team only.
    • See links below
  • RFL:
    • No restriction stated
    • This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system)
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
09.01.01.02 Iron Dextran CosmoFer®

See local guidance for iron replacement

Provider notes

  • NMUH:
    • See link below to access the Trust guidelines on use of parenteral irons for iron deficiency anaemia
    • Check MHRA Drug Safety updates
  • RFL:
    • No restriction stated
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary 
09.01.01.02 Iron Isomaltoside Monofer®

See local guidance for iron replacement

Provider notes

  • NMUH:
    • Check MHRA Drug Safety update
  • RFL:
    • First-choice of fast infusion product (excluding renal)
    • Available to all patient groups at BH and CFH.
    • Restricted to specific patient groups at RFH:
      • For patients who would otherwise require multiple iron infusions, and there is a documented reason why multiple infusions would impact on patient’s quality of life
      • For patients on 2NA in whom a shorter duration iron infusion is indicated, and there is documented reason why a longer infusion would impact on patient’s quality of life
      • For patients in whom there is an URGENT need for IV iron e.g. patients planned for Theatre, or for pregnancy
      • For patients on a cancer pathway to enable cancer treatment to proceed
      • For patients with disabling anaemia who require urgent correction of Hb levels, based on clinical symptoms/clinical need (patient-specific need)
      • For patients who have experienced serious / life-threatening allergies or adverse events to other IV iron products
  • RNOH:
    • For the optimisation of pre-operative anaemia in accordance with local guideline. Oral iron must be used where surgery is not urgent
  • UCLH:
  • WH:
    • Non-formulary
09.01.01.02 Iron Sucrose Venofer®

See local guidance for iron replacement

Provider notes

  • NMUH:
    • See Trust guidelines on use of parenteral irons for iron deficiency anaemia; link below
    • Check MHRA Drug Safety updates
  • RFL:
    • Renal anaemia only - Venofer and Cosmofer are preferred choices
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
04.03.02 Isocarboxazid 

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Restricted for initiation until after a discussion with liaison psychiatry team
  • RNOH:
    • Non-formulary
  • UCLH:
    • Non-formulary
  • WH:
    • Non-formulary
  • BEHMT:
    • Non-formulary
  • CIFT:
    • Non-formulary
15.01.02 Isoflurane 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • No restriction stated
05.01.09 Isoniazid 

Provider notes

  • NMUH:
    • No restriction stated (Isoniazid elixir 50mg/5mL [unlicensed] available for the treatment of tuberculosis in children)
  • RFL:
    • For treatment and prophylaxis of tuberculosis only
    • Microbiology or ID approval required for other indications
  • RNOH:
    • Microbiologist approval only
  • UCLH:
  • WH:
    • No restriction stated
06.01.01.02 Isophane Insulin Insulatard®

Provider notes

  • NMUH:
    • The fomulary choices are vial, 3ml cartridge and Innolet.
  • RFL:
    • No restriction stated
  • RNOH:
    • First line for patients on a feed or patients that are on high doses of steroids, and require insulin. Available in the EDC Fridge
  • UCLH:
  • WH:
    • No restriction stated
06.01.01.02 Isophane Insulin Humulin® I

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • Initiation as per Diabetes team advice
02.07.01 Isoprenaline 

Provider notes

  • NMUH:
    • For refractory bradycardia. Isoprenaline 2.25mg in 2ml injection, available from ‘special-order’ manufacturers or specialist importing companies
  • RFL:
    • Unlicensed product
    • Adhere to local protocols
  • RNOH:
    • Unlicensed product
    • Store in a refrigerator
  • UCLH:
  • WH:
    • Refractory bradycardia
    • Unlicensed product
02.06.01 Isosorbide dinitrate immediate released 

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • No restriction stated
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • No restriction stated
02.06.01 Isosorbide dinitrate parenteral 

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Restricted to cardiac cath lab use only.
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • 0.1% infusion available only
02.06.01 Isosorbide mononitrate 

Provider notes

  • NMUH:
    • 60mg modified release and immediate release 10mg and 20mg tablets available
  • RFL:
    • No restriction stated
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • 60mg modified release and immediate release 10mg and 20mg tablets available
13.06.01 Isotretinoin 0.05% + Erythromycin 2% gel Isotrexin®

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Restricted to Dermatology
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Isotrexin gel is restricted to Dermatology
13.06.01 Isotretinoin 0.05% gel Isotrex®

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • Restricted to Dermatology
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
13.06.02 Isotretinoin capsules 

Provider notes

  • NMUH:
    • Restricted to Dermatology
    • Check MHRA Drug Safety Updates
  • RFL:
    • Restricted to Dermatology
    • Follow prescribing advice and important safety information including pregnancy prevention programme (PPP) for females of childbearing potential.  Maximum 30 days treatment at a time
    • Patients who do not qualify for the pregnancy prevention programme (PPP) may be supplied more than one month at a time
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Isotretinoin capsules are restricted to Dermatology prescribing only and are not available in the community unless by special arrangement, for details see data sheet.
01.06.01 Ispaghula Husk 

Provider notes

  • NMUH:
    • See link below
  • RFL:
    • No restriction stated
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • No restriction stated
05.02 Itraconazole 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • Oral: Restricted to Dermatology; HIV; Haematology. ID/Microbiology approval for all other indications.
    • Intravenous: Microbiology/ID approval
  • RNOH:
    • Microbiology approval only
  • UCLH:
  • WH:
    • For restricted indications as per Trust guidelines or Microbiology advice
02.06.03 Ivabradine 

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

See NICE TA for eligibility criteria 

Secondary care notes

  • NMUH:
    • This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary but may NOT be routinely stocked in pharmacy. This medicine will be ordered if use is as per local Trust Guideline or is approved by the Trust Medicines Management Committee. Contact pharmacy medicines information on ext 2417 for further information.
  • RFL:
    • Restricted to cardiology approval only - as per NICE TA
  • RNOH:
    • Requires CARDIOLOGIST approval
  • UCLH:
  • WH:
    • Available for prescribing to consultant cardiologists only
    • NICE TA267 applies
13.06 Ivermectin 10 mg/g cream 

Approve for papulopustular rosacea. Suitable for primary and secondary care initiation (JFC July 2016)

Provider notes

  • NMUH:
    • To be prescribed by dermatology ONLY for papulopustular rosacea
  • RFL:
    • To be prescribed by dermatology ONLY for papulopustular rosacea
  • RNOH:
    • Non-formulary
  • UCLH:
    • See indication above
  • WH:
    • Non-formulary
05.05.07 Ivermectin tablets 

Provider notes

  • NMUH:
    • 3mg tablets available from 'special order'
  • RFL:
    • No restriction stated
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
08.01.05 Ixazomib 

See NICE TA for eligibility criteria

Provider notes

  • NMUH:
    • This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used  in line with NICE recommendations and/or Local Trust Guidelines.
    • See link below
  • RFL:
    • As per NICE guidance
    • This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system).  Additionally for in-patients this drug must be prescribed on an in-patient prescription chart (paper or electronic)
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
10.01.03 Ixekizumab injection 

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

See NICE TA for eligibility criteria

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • As per NICE guidance for the treatment of Psoriatic Arthritis
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
13.05.03 Ixekizumab injection 

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Provider notes

  • NMUH:
    • This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines.
    • See link below
  • RFL:
    • For Psoriasis in line with NICE guidance
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
A2.01.01.01 Jevity 

Provider notes

  • NMUH:
    • For patients who require a fibre feed, such as those requiring long-term nutrition support.
  • RFL:
    • No restriction stated
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
A2.01.02.01 Jevity 1.5 kcal 

Provider notes

  • NMUH:
    • For patients requiring higher energy intake or fluid restriction or a shorter feeding period who also need a fibre feed.
  • RFL:
    • No restriction stated
  • RNOH:
  • UCLH:
  • WH:
    • Non-formulary
A2.01.02.02 Jevity Plus 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
A2.01.02.02 Jevity Plus HP 

Provider notes

  • NMUH:
    • For patients with high protein requirements who need a fibre feed, including those on long-term nutritional support.
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
A5.02.06 Kaltostat 

Provider notes

  • NMUH:
    • We stock the following in Pharmacy:Kaltostat 7.5x12cm and 5x5cm, Kaltostat Cavity 2g.
    • Kaltostat cavity should only be used when haemostatis is involved. Otherwise Aquacel ribbon (2x45cm) should be used.
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Surgical packing 2 g (5)
10.03.02 Kaolin Poultice 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
15.01.01 Ketamine injection 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • No restriction stated
21.01 Ketamine oral solution  

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Acute pain unresponsive to opiates (inpatient use only; initiation by Pain team consultant or consultant Anaesthetist)
Evaluation for RFL only (approved by DTC in July-17, ratified by JFC in August-17)

07.02.02 Ketoconazole 2% cream 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
13.10.02 Ketoconazole 2% cream 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • Restricted to Dermatology only
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • No restriction stated
13.09 Ketoconazole 2% shampoo 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • Restricted to Dermatology only
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • No restriction stated
06.07 Ketoconazole tablets Ketoconazole HRA®

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Approved as first line in pre-treatment prior to surgery (4-6 weeks prior to surgery) or second line post-surgery in patients with persistent Cushing syndrome (long term treatment)
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
06.01.06 Ketone urine test strips Ketostix®

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • For outpatient use only
15.01.04.02 Ketorolac 

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Restricted to anaesthetics
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Ketorolac tablets are not available
11.08.02 Ketorolac 0.5% eye drops Acular®

Approved for:

  • Treatment of inflammation post cataract surgery in patients unable to tolerate topical corticosteroids
  • Prophylaxis of cystoid macular oedema (CMO) in high-risk patients

Provider notes

  • NMUH:
    • Restricted to Consultant Ophthalmologist use only.
  • RFL:
    • Inflammation in anterior segment.
    • Restricted to Consultant Ophthalmologist use only.
  • RNOH:
  • UCLH:
  • WH:
    • Restricted to ophthalmology
11.04.02 Ketotifen 250mcg/mL eye drops 

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Non-formulary
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • Non-formulary
11.04.02 Ketotifen 250mcg/mL eye drops - preservative free 

Approved for seasonal allergic conjunctivitis who have an allergy to preservatives within either sodium cromoglicate or olopatadine (JFC July 2019)

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • As above
02.04 Labetalol 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • Tablets – no restriction
    • Infusion – following local protocol
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • No restriction stated
04.08.01 Lacosamide  

For patients refractory to standard AEDs (JFC March 2013)

Provider notes

  • NMUH:
    • Restricted for neurology patients with refractory epilepsy to standard antiepileptic drugs
  • RFL:
    • Restricted to neurology
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • Should only be commenced on the recommendation of a Neurologist only for refractory epilepsy (adjunctive Tx of partial-onset seizures in adults and adolescents)
01.06.04 Lactulose 

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Provider notes

  • NMUH:
    • See link below
  • RFL:
    • No restriction stated
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
01.06.04 Lactulose 

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • No restriction stated.
    • May be used at doses up to 30mL QDS
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
05.03.01 Lamivudine 

Provider notes

  • NMUH:
    • Epivir brand only approved for HIV patients
    • Zeffix brand approved for HIV and Hepatitis B patients
  • RFL:
    • 150mg & 300mg approved for HIV patients
    • 100mg approved for Hepatitis B patients
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Epivir brand on formulary
04.02.03 Lamotrigine 

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Provider notes

  • NMUH:
  • RFL:
    • Psychiatry recommendation only
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
  • CIFT:
    • Approved for mania
  • BEHMT:
    • Approved for mania
04.08.01 Lamotrigine 

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Provider notes

  • NMUH:
    • Restricted to Neurology department use only
  • RFL:
    • No restriction stated
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • Tabs 25 mg, 50 mg, 200 mg. Dispersible tabs 5 mg, 25 mg, 100 mg. Only
03.04.03 Lanadelumab injection 

See NICE TA for eligibility criteria

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • For hereditary angioedema in line with NICE TA
    • Restricted to immunology
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
08.03.04.03 Lanreotide Somatuline® LA

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Restricted to endocrine and neuroendocrine team
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Restricted to endocrinology team
08.03.04.03 Lanreotide Somatuline Autogel®

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Restricted to endocrine and neuroendocrine team
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Restricted to endocrinology team
01.03.05 Lansoprazole 

Provider notes

  • NMUH:
    • See links below
    • Check MHRA Drug Safety Alerts
    • The use of orodispersible tablets is restricted to patients with difficulty in swallowing capsules
  • RFL:
    • Orodispersible tablets restricted to patients with feeding tubes/ difficulty in swallowing tablets
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • No restriction stated
09.05.02.02 Lanthanum Fosrenol ®

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Restricted to renal patients only
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
08.01.05 Lapatinib 

Provider notes

  • NMUH:
    • Special Funding Approval required - seek advice from Oncology Pharmacist
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
09.08.01 Laronidase 

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Restricted to the lysosomal storage disorders unit
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
15.02 LAT gel (Lidocaine 4% + Adrenaline 0.1% + Tetracaine 0.5%) 

Approved for second-line management of pain in children requiring sutures/debridement (JFC February 2018)

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
    • No restriction stated
  • WH:
    • Non-formulary
11.06 Latanoprost 0.005% + Timolol 0.5% Xalacom®

Combination therapies to be used when compliance / cost issues arise. See NCL guideline for place in therapy.

Provider notes

  • NMUH:
    • Combination therapies to be used when compliance / cost issues arise
    • See link below
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
11.06 Latanoprost 0.005% eye drops 

See NCL guideline for place in therapy.

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • For ophthalmologists only
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • No restriction stated
11.06 Latanoprost 0.005% eye drops - preservative free 

Restricted to patients with true preservative allergy and/or evidence of epithelial toxicity from preservatives and/or severe dry eyes

Provider notes

  • NMUH:
    • Restricted to patients with true preservative allergy and/or evidence of epithelial toxicity from preservatives and/or severe dry eyes
    • See link below
  • RFL:
    • Restricted to second line use only.
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
05.03.03.02 Ledipasvir + Sofosbuvir 

Provider notes

  • NMUH:
    • This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines.
    • See links below
    • To be prescribed by Consultants Andrew Millar, Dimitra Doufexi and Jonathan Ainsworth ONLY for Hepatitis C.
    • Check MHRA Drug Safety Updates
  • RFL:
    • Approved for use by Hepatology in the treatment of Hepatitis C in line with NICE guidance
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
10.01.03 Leflunomide 

Provider notes

  • NMUH: 
    • Restricted to Rheumatology Consultants ONLY
  • RFL:
    • No restriction stated
  • RNOH:
    • Restricted to Rheumatology Consultants ONLY
    • See links below
  • UCLH:
  • WH:
    • Restricted to Rheumatology Consultants ONLY
08.02.04 Lenalidomide 

Provider notes

  • NMUH:
    • This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines. 
    • All prescriptions must be accompanied by a prescription authorisation form
    • See links below
    • Check MHRA Drug Safety Update
  • RFL:
    • As per NICE TAs
    • This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system). Additionally for in-patients this drug must be prescribed on an in-patients prescription chart (paper or electronic)
    • Patient, prescriber and supplying pharmacy must comply with a pregnancy prevention programme
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
09.01.06 Lenograstim Granocyte®

Provider notes

  • NMUH:
    • Restricted for use in paediatric patients ONLY. For Adult patients, use filgrastim (Zarzio) first line.
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
08.01.05 Lenvatinib caps Kisplyx®

DO NOT CONFUSE Kisplyx® AND Lenvima® AS THEY ARE LICENSED FOR DIFFERENT INDICATIONS

See NICE TA for eligibility criteria

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • As per NICE guidance for renal cell carcinoma
    • This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system).  Additionally for in-patients this drug must be prescribed on an in-patient prescription chart (paper or electronic)
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
08.01.05 Lenvatinib caps Lenvima®

DO NOT CONFUSE Kisplyx® AND Lenvima® AS THEY ARE LICENSED FOR DIFFERENT INDICATIONS

See NICE TA for eligibility criteria

Provider notes

  • NMUH:
    • This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines.
    • See links below
    • TA551 does not apply at NMUH as service is not offered
  • RFL:
    • As per NICE guidance for thyroid cancer and hepatocellular carcinoma
    • This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system).  Additionally for in-patients this drug must be prescribed on an in-patient prescription chart (paper or electronic)
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
06.05.01 Letrozole 

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Approved as a second-line option (off-label) to induce ovulation in women with WHO group II infertility, following failure of treatment with clomifene citrate (JFC January 2018)

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
    • 2nd line (off-label) after the failure of clomifene citrate for ovulation induction in women with WHO Group II anovulation
  • WH:
    • As above
08.03.04.01 Letrozole 

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Provider notes

  • NMUH:
    • Restricted to Oncology department use only
  • RFL:
    • No restriction stated
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • No restriction stated
06.07.02 Leuprorelin 

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Non-formulary
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • Non-formulary
06.07.02 Leuprorelin 

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
06.07.02 Leuprorelin 

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
08.03.04.02 Leuprorelin 

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • Preferred product for use in prostate, maintenance of fertility and breast cancer women.
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
04.08.01 Levetiracetam 

Provider notes

  • NMUH:
    • Restricted to Consultant Neurologists only
    • To be used as second line adjunctive treatment of partial seizures with or without secondary generalisation
  • RFL:
    • No restriction stated
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • Should only be commenced on the recommendation of a Neurologist
    • Tabs 250 mg, 500 mg, 1 g. Oral solution 100 mg/ 1 ml only
    • Intravenous infusion also available
    • The infusion is available in the emergency drugs cupboard
11.06 Levobunolol 0.5% eye drops 

See NCL guideline for place in therapy.

Provider notes

  • NMUH:
    • See link below
    • Check MHRA Drug Safety Update
  • RFL:
    • No restriction stated
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
11.06 Levobunolol 0.5% eye drops - unit dose 

See NCL guideline for place in therapy.

Provider notes

  • NMUH:
    • See link below
    • Check MHRA Drug Safety Update
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Restricted to Ophthalmology
15.02 Levobupivacaine 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • Non-formulary
15.02 Levobupivacaine + Fentanyl 

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • BCF: Levobupivacaine 0.125% + Fentanyl 4mcg/ml in 500ml
    • RFH: Levobupivacaine 0.1% + Fentanyl 0.0002% in 100ml
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • Non-formulary
09.08.01 Levocarnitine 

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Non-formulary for paediatrics (GOSH specialist service)
    • For peritoneal dialysis patients (levocarnitine deficiency)
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
05.01.12 Levofloxacin 

Provider notes

  • NMUH:
    • Restricted to Consultant Microbiologist or Consultant Gastroenterologist recommendation
  • RFL:
    • Follow RFL microbiology guidelines for agreed indications
    • Microbiology approval required for all other indications
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • For restricted indications as per Trust guidelines or Microbiology advice
11.03.01 Levofloxacin 5mg/ml eye drops 
  • NMUH:
    • Non-formulary
  • RFL:
    • Levofloxacin 0.5% eye drops (preservative-free).
    • Restricted to bacterial conjunctivitis, keratitis, post intravitreal injections and corneal abrasions.
  • RNOH:
    • Non-formulary
  • UCLH:
    • Non-formulary
  • WH:
    • Non-formulary
13.03 Levomenthol in aqueous cream 

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • 0.5%, 1% and 2% available
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
04.02.01 Levomepromazine 

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • Restricted for initiation until after a discussion with liaison psychiatry team
  • RNOH:
    • No restriction stated  
  • UCLH:
  • WH:
    • No restriction stated
04.06 Levomepromazine 

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • No restriction stated
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
07.03.05 Levonorgestrel 1.5mg tablet 

Provider notes

  • NMUH:
    • Restricted to Consultants in GU Medicine ONLY
    • Check MHRA drug safety updates
  • RFL:
    • No restriction stated
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
02.14 Levosimendan 

Approved for acutely decompensated severe chronic heart failure who have failed to respond to conventional therapy and failed to respond to or did not tolerate inotropic agents (dobutamine or enoximone) (JFC July 2017)

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
    • Non-formulary
  • WH:
    • As above
06.02.01 Levothyroxine 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
    • Red (hospital only prescribing) for levothyroxine oral solution (Tirosint®) - restricted to ITU only
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • Oral solution 100 mcg/5ml (adults only) and 50 mcg/5ml available
15.02 Lidocaine + Adrenaline injection Xylocaine®

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • For emergency caesarean section
12.03.01 Lidocaine 10% spray Xylocaine®

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
15.02 Lidocaine 10% spray Xylocaine®

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
15.02 Lidocaine 2% + Chlorhexidine 0.25% gel Instillagel®

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • No restriction stated
15.02 Lidocaine 2.5% + Prilocaine 2.5% cream EMLA®

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • No restriction stated
11.07 Lidocaine 4% + Fluorescein 0.25% eye drops - unit dose 

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • For diagnostic or surgical use only. Not to be given for home use
15.02 Lidocaine 4% cream LMX4®

Approved for topical anaesthetic of first-choice prior to venous cannulation or venepuncture for paediatrics (JFC July 2013)

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
15.02 Lidocaine 4% solution Laryngojet®

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • Non-formulary
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • Non-formulary
15.02 Lidocaine 5% + Phenylephrine 0.5% topical solution 

Provider notes

  • NMUH:
    • Formulary for ENT use only
  • RFL:
    • For ENT use only
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
15.02 Lidocaine 5% ointment 

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • No restriction stated
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
04.14 Lidocaine infusion 

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Approved for chronic pain (JFC July 2018)
    • Approved for use in neurology for the treatment of headaches - see local protocol
  • RNOH:
    • Non-formulary
  • UCLH:
    • Approved for
      • Chronic pain (RESTRICTED to Pain Management Centre at Cleveland Street for chronic pain; UMC May 2018)
      • Perioperative pain (RESTRICTED to UCH and Westmoreland Street Operating Theatres in line with guideline only; UMC July 2018)
  • WH:
    • Non-formulary
02.03.02 Lidocaine injection 

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

 Provider notes

  • NMUH:
    • Ampoules are Formulary but infusions are non formulary.
  • RFL:
    • Lidocaine ampoules and infusion available
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
15.01.01 Lidocaine injection 

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • The use of lidocaine (lignocaine) 2% cartridge, bupivacaine 0.0625% infusion andropivacaine is restricted to theatres only.
01.06.07 Linaclotide 

Approved for IBS-C in adults where two optimally dosed laxatives (from different classes) and an antispasmodic fail to relieve symptoms. Initiation should be by a Gastroenterologist and reviewed at 4 weeks. Prescribing should be transferred to GPs for ongoing prescribing if found to be effective (JFC May 2017)

Provider notes

  • NMUH:
    • To be prescribed as per the JFC recommendations
  • RFL:
    • See indication above
  • RNOH 
    • No restriction stated
  • UCLH:
  • WH:
    • For gastro consultants only as per JFC May 2017 guidance
05.01.07 Linezolid 

Provider notes

  • NMUH:
    • Microbiology approval only
  • RFL:
    • Microbiology/ID approval required
  • RNOH:
    • Microbiology approval only
  • UCLH:
  • WH:
    • Microbiology approval only
06.02.01 Liothyronine 

Provider notes

  • NMUH:
    • Liothyronine injection on formulary
    • Liothyronine tablets may be used for indications other than primary hypothyroidism (e.g. thyroid cancer)
  • RFL:
    • IV only on formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
09.01.06 Lipegfilgrastim 

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Alternative to GCSF + district nurse administration at WH only for patients who can receive daily GCSF but cannot self-inject (JFC August 2016)

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • For use by oncology consultants only in patients unable to receive daily GCSF infections or needle phobic patients (D&TC Sept 2016)
13.10.05 LiquiBand® 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • BCF: No restriction stated
    • RFH: Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
13.02.01 Liquid and White Soft Paraffin Ointment 

Provider notes

  • NMUH:
    • Check MHRA Drug Safety Update
  • RFL:
    • No restriction stated
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • No restriction stated
01.06.03 Liquid Paraffin 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
01.06.04 Liquid paraffin + Magnesium hydroxide oral emulsion, BP 

Provider notes

  • NMUH:
    • Restricted to paediatric consultants only
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
11.08.01 Liquid Paraffin and Liquid Paraffin light eye drops Lacrilube®

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • Non-formulary
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • No restriction stated
A2.04.01.02 Liquigen 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
06.01.02.03 Liraglutide Victoza®

Semaglutide is the preferred GLP-1 receptor agonist for type 2 diabetes, when used in line with the NCL Fact sheet (JFC August 2019).

Liraglutide 1.2mg should only be initiated for patients with concurrent gastrointestinal conditions e.g. inflammatory bowel disease (JFC August 2019).

Liraglutide 1.8mg is not recommended (JFC July 2018).

Provider notes

  • NMUH:
    • See links below
  • RFL:
    • Restricted to initiation by endocrinology only for Type 2 diabetes
    • See above for detailed eligibility criteria
  • RNOH:
    • Requires initiation by a Diabetes Specialist
  • UCLH:
  • WH:
    • Initiation restricted to endocrinology
04.04 Lisdexamfetamine 

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
  • CIFT:
    • Approved for adults with ADHD (off-label) - 1st line (joint with methylphenidate)
  • BEHMT:
    • Approved for adults with ADHD (off-label)

 

 

02.05.05.01 Lisinopril 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • No restriction stated
04.02.03 Lithium Carbonate Priadel®

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • Restricted for initiation until after a discussion with liaison psychiatry team
  • RNOH:
    • Restricted for continuation of treatment. Ensure the same brand of lithium is used
  • UCLH:
  • WH:
    • No restriction stated
04.02.03 Lithium Carbonate Camcolit®

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • Restricted for initiation until after a discussion with liaison psychiatry team
  • RNOH:
    • Restricted for continuation of treatment. Ensure the same brand of lithium is used
  • UCLH:
  • WH:
    • 250mg tablets
04.02.03 Lithium Carbonate Liskonum®

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Restricted for initiation until after a discussion with liaison psychiatry team
  • RNOH:
    • Restricted for continuation of treatment. Ensure the same brand of lithium is used
  • UCLH:
  • WH:
    • Non-formulary
04.02.03 Lithium Citrate Li-Liquid®

Provider notes

  • NMUH:
    • Lithium Citrate liquid is formulary for those with feeding tubes or swallowing difficulties
  • RFL:
    • Restricted for initiation until after a discussion with liaison psychiatry team
  • RNOH:
    • Restricted for continuation of treatment. Ensure the same brand of lithium is used
  • UCLH:
  • WH:
    • Non-formulary
04.02.03 Lithium Citrate Priadel® liquid

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Restricted for initiation until after a discussion with liaison psychiatry team
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
11.04.02 Lodoxamide 0.1% eye drops 

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Allergic conjunctivitis
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Restricted to Ophthalmology
04.03.01 Lofepramine 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
  • CIFT:
    • Approved for depression 
  • BEHMT:
    • Approved for depression 
08.01.01 Lomustine 

Provider notes

  • NMUH:
    • Restricted to Consultant Oncologists and Haematologists use only
  • RFL:
    • No restriction stated
    • This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system).  Additionally for in-patients this drug must be prescribed on an in-patients prescription chart (paper or electronic)
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
01.04.02 Loperamide 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • No restriction stated
05.03.01 Lopinavir + Ritonavir 

Provider notes

  • NMUH:
    • Check Drug Safety Update
  • RFL:
    • HIV medicine only
  • RNOH:
    • Non-formulary  
  • UCLH:
  • WH:
    • For TB / HIV clinic only
03.04.01 Loratadine 

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • No restriction stated
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • No restriction stated
04.01.02 Lorazepam 

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

 Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • The injection (4 mg in 1mL) must be stored in a refrigerator
  • UCLH:
  • WH:
    • No restriction stated
  • CIFT:
    • Approved for
      • Anxiolytic
      • Rapid tranquillisation
      • Acute phase of mania and aggression (off-label)
      • Alcohol detoxification (off-label)
  • BEHMT:
    • Approved for 
      • Anxiolytic
      • Rapid tranquillisation
04.08.02 Lorazepam 

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Provider notes

  • NMUH:
    • First line for status in paediatrics.
  • RFL:
    • No restriction stated
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
15.01.04.01 Lorazepam 

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
02.05.05.02 Losartan 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • Alternative (second-line) agent.
    • 25mg and 50mg tablets available only
11.04.01 Loteprednol eye drops Lotemax®

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Restricted to steroid-responder patients requiring topical steroids (2nd line)
  • RNOH:
    • Non-formulary
  • UCLH:
    • Non-formulary
  • WH:
    • Non-formulary
03.01.05 Low range peak flow meter Mini-Wright®
01.06.07 Lubiprostone 

Provider notes

  • NMUH:
    • This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines.
    • See links below
  • RFL:
    • Non-formulary
  • RNOH:
    • Restricted Item Restricted
  • UCLH:
  • WH:
    • NICE TA318 applies
08.01.05 Lutetium (177Lu) oxodotreotide injection 

See NICE TA for eligibility criteria

Provider notes

  • NMUH:
    • Non-formulary
    • This medicine has a positive NICE Technology Appraisal but is not listed in the Trust Medicines Formulary as the service is not offered at NMUH.
  • RFL:
    • As per NICE guidance
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
05.01.03 Lymecycline 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Reserved for Dermatology use only
02.05.01 Macitentan 

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Prior funding approval required
    • Restricted to the treatment of pulmonary hypertension
  • RNOH:
    • Non-formulary
  • UCLH:
    • Non-formulary
  • WH:
    • Non-formulary
01.06.04 Macrogols Laxido®, Movicol®, Movicol liquid®

Provider notes

  • NMUH:
    • See link below
    • Movicol stocked
  • RFL:
    • Movicol sachets
  • RNOH:
    • Laxido
  • UCLH:
  • WH:
    • No restriction stated
01.06.05 Macrogols Klean-Prep®

Provider notes

  • NMUH:
    • For use in renal failure/congestive heart failure only
    • See link below
  • RFL:
    • No restriction stated
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
01.06.05 Macrogols Moviprep®

Approved for bowel evacuation; first-line bowel cleansing agent (Gastroenterology service). 

Provider notes

  • NMUH:
    • See link below
  • RFL:
    • No restriction stated
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
01.06.04 Macrogols paediatric 

Provider notes

  • NMUH:
    • Restricted to Paediatric Consultants only
    • Movicol Paediatric stocked
  • RFL:
    • Movicol Paediatric stocked
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • For Paediatrics Only
09.05.01.03 Magnesium Aspartate Magnaspartate®

Approved for magnesium deficiency (JFC March 2017)

Provider notes

  • NMUH:
    • See link below to access Trust Formulary bulletin on oral Magnesium Aspartate
  • RFL:
    • Non-formulary
  • RNOH:
    • For patients requiring enteral administration i.e. NG/PEG admin or with swallowing difficulties
  • UCLH:
    • Second line to NeoMag®
  • WH:
    • First line treatment for hypomagnesaemia (approved by NCL JCF Mar17). Magnesium glycerophosphate only for patients unable to tolerate magnesium aspartate.
09.05.01.03 Magnesium glycerophosphate 4mmol/tablet 

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • No restriction stated
  • RNOH:
    • The BNF states that to prevent recurrence of hypomagnesaemia in adults, oral magnesium may be given in a dose of 24 mmol Mg2+ daily in divided doses. In children aged 1 month to 12 years, the BNF for children recommends that the initial dose of oral magnesium for hypomagnesaemia is 0.2 mmol/kg Mg2+ three times daily, with the dose adjusted as needed. In children aged 12 to 18 years, it recommends that the initial dose is 4 to 8 mmol Mg2+ three times daily, adjusted as needed.
  • UCLH:
  • WH:
    • First line treatment for hypomagnesemia is magnesium aspartate. Magnesium glycerophosphate should only be used for patients unable to tolerate magnesium aspartate.
01.06.04 Magnesium Hydroxide Mixture BP